<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=us-ascii">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>Epclusa, INN-sofosbuvir/velpatasvir</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Courier;
	panose-1:2 7 4 9 2 2 5 2 4 4;}
@font-face
	{font-family:"Tms Rmn";
	panose-1:2 2 6 3 4 5 5 2 3 4;}
@font-face
	{font-family:Helv;
	panose-1:2 11 6 4 2 2 2 3 2 4;}
@font-face
	{font-family:"New York";
	panose-1:2 4 5 3 6 5 6 2 3 4;}
@font-face
	{font-family:System;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:Batang;
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:PMingLiU;
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:Dotum;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:SimHei;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:MingLiU;
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:Mincho;
	panose-1:2 2 6 9 4 3 5 8 3 5;}
@font-face
	{font-family:Gulim;
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:Century;
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:"Angsana New";
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"Cordia New";
	panose-1:2 11 3 4 2 2 2 2 2 4;}
@font-face
	{font-family:Mangal;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Latha;
	panose-1:2 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sylfaen;
	panose-1:1 10 5 2 5 3 6 3 3 3;}
@font-face
	{font-family:Vrinda;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Raavi;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Shruti;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Sendnya;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:Gautami;
	panose-1:2 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tunga;
	panose-1:0 0 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Estrangelo Edessa";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Palatino Linotype";
	panose-1:2 4 5 2 5 5 5 3 3 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Segoe UI Emoji";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Cambria;
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI Symbol";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:BISansCond;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Black";
	panose-1:2 11 10 4 2 1 2 2 2 4;}
@font-face
	{font-family:"Bahnschrift Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Bahnschrift;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight SemiConde";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiCondensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold SemiConden";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Light Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiLight Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Bahnschrift SemiBold Condensed";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Candara;
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Candara Light";
	panose-1:2 14 5 2 3 3 3 2 2 4;}
@font-face
	{font-family:"Comic Sans MS";
	panose-1:3 15 7 2 3 3 2 2 2 4;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:Constantia;
	panose-1:2 3 6 2 5 3 6 3 3 3;}
@font-face
	{font-family:Corbel;
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"Corbel Light";
	panose-1:2 11 3 3 2 2 4 2 2 4;}
@font-face
	{font-family:Ebrima;
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Franklin Gothic Medium";
	panose-1:2 11 6 3 2 1 2 2 2 4;}
@font-face
	{font-family:Gabriola;
	panose-1:4 4 6 5 5 16 2 2 13 2;}
@font-face
	{font-family:Gadugi;
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:Georgia;
	panose-1:2 4 5 2 5 4 5 2 3 3;}
@font-face
	{font-family:Impact;
	panose-1:2 11 8 6 3 9 2 5 2 4;}
@font-face
	{font-family:"Ink Free";
	panose-1:3 8 4 2 0 5 0 0 0 0;}
@font-face
	{font-family:"Javanese Text";
	panose-1:2 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Leelawadee UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Leelawadee UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Lucida Console";
	panose-1:2 11 6 9 4 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Unicode";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Malgun Gothic";
	panose-1:2 11 5 3 2 0 0 2 0 4;}
@font-face
	{font-family:"\@Malgun Gothic";}
@font-face
	{font-family:"Malgun Gothic Semilight";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Malgun Gothic Semilight";}
@font-face
	{font-family:"Microsoft Himalaya";
	panose-1:1 1 1 0 1 1 1 1 1 1;}
@font-face
	{font-family:"Microsoft JhengHei";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei";}
@font-face
	{font-family:"Microsoft JhengHei UI";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI";}
@font-face
	{font-family:"Microsoft JhengHei Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei Light";}
@font-face
	{font-family:"Microsoft JhengHei UI Light";
	panose-1:2 11 3 4 3 5 4 4 2 4;}
@font-face
	{font-family:"\@Microsoft JhengHei UI Light";}
@font-face
	{font-family:"Microsoft New Tai Lue";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft PhagsPa";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft Sans Serif";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:"Microsoft Tai Le";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Microsoft YaHei";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei";}
@font-face
	{font-family:"Microsoft YaHei UI";
	panose-1:2 11 5 3 2 2 4 2 2 4;}
@font-face
	{font-family:"\@Microsoft YaHei UI";}
@font-face
	{font-family:"Microsoft YaHei Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei Light";}
@font-face
	{font-family:"Microsoft YaHei UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@Microsoft YaHei UI Light";}
@font-face
	{font-family:"Microsoft Yi Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:MingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU-ExtB";}
@font-face
	{font-family:PMingLiU-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@PMingLiU-ExtB";}
@font-face
	{font-family:MingLiU_HKSCS-ExtB;
	panose-1:2 2 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MingLiU_HKSCS-ExtB";}
@font-face
	{font-family:"Mongolian Baiti";
	panose-1:3 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Gothic";
	panose-1:2 11 6 9 7 2 5 8 2 4;}
@font-face
	{font-family:"MS UI Gothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS UI Gothic";}
@font-face
	{font-family:"MS PGothic";
	panose-1:2 11 6 0 7 2 5 8 2 4;}
@font-face
	{font-family:"\@MS PGothic";}
@font-face
	{font-family:"MV Boli";
	panose-1:2 0 5 0 3 2 0 9 0 0;}
@font-face
	{font-family:"Myanmar Text";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Nirmala UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Segoe Print";
	panose-1:2 0 6 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe Script";
	panose-1:3 11 5 4 2 0 0 0 0 3;}
@font-face
	{font-family:"Segoe UI Black";
	panose-1:2 11 10 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Historic";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Light";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semibold";
	panose-1:2 11 7 2 4 2 4 2 2 3;}
@font-face
	{font-family:"Segoe UI Semilight";
	panose-1:2 11 4 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:NSimSun;
	panose-1:2 1 6 9 3 1 1 1 1 1;}
@font-face
	{font-family:"\@NSimSun";}
@font-face
	{font-family:SimSun-ExtB;
	panose-1:2 1 6 9 6 1 1 1 1 1;}
@font-face
	{font-family:"\@SimSun-ExtB";}
@font-face
	{font-family:"Sitka Small";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Text";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Subheading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Heading";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Display";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Sitka Banner";
	panose-1:2 0 5 5 0 0 0 2 0 4;}
@font-face
	{font-family:"Trebuchet MS";
	panose-1:2 11 6 3 2 2 2 2 2 4;}
@font-face
	{font-family:Webdings;
	panose-1:5 3 1 2 1 5 9 6 7 3;}
@font-face
	{font-family:"\@Yu Gothic";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Yu Gothic UI";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI";}
@font-face
	{font-family:"Yu Gothic UI Semibold";
	panose-1:2 11 7 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semibold";}
@font-face
	{font-family:"Yu Gothic Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Light";}
@font-face
	{font-family:"Yu Gothic UI Light";
	panose-1:2 11 3 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Light";}
@font-face
	{font-family:"Yu Gothic Medium";
	panose-1:2 11 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic Medium";}
@font-face
	{font-family:"Yu Gothic UI Semilight";
	panose-1:2 11 4 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Yu Gothic UI Semilight";}
@font-face
	{font-family:"HoloLens MDL2 Assets";
	panose-1:5 10 1 2 1 1 1 1 1 1;}
@font-face
	{font-family:"Agency FB";
	panose-1:2 11 5 3 2 2 2 2 2 4;}
@font-face
	{font-family:Algerian;
	panose-1:4 2 7 5 4 10 2 6 7 2;}
@font-face
	{font-family:"Book Antiqua";
	panose-1:2 4 6 2 5 3 5 3 3 4;}
@font-face
	{font-family:"Arial Narrow";
	panose-1:2 11 6 6 2 2 2 3 2 4;}
@font-face
	{font-family:"Arial Rounded MT Bold";
	panose-1:2 15 7 4 3 5 4 3 2 4;}
@font-face
	{font-family:"Baskerville Old Face";
	panose-1:2 2 6 2 8 5 5 2 3 3;}
@font-face
	{font-family:"Bauhaus 93";
	panose-1:4 3 9 5 2 11 2 2 12 2;}
@font-face
	{font-family:"Bell MT";
	panose-1:2 2 5 3 6 3 5 2 3 3;}
@font-face
	{font-family:"Bernard MT Condensed";
	panose-1:2 5 8 6 6 9 5 2 4 4;}
@font-face
	{font-family:"Bodoni MT";
	panose-1:2 7 6 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Black";
	panose-1:2 7 10 3 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Condensed";
	panose-1:2 7 6 6 8 6 6 2 2 3;}
@font-face
	{font-family:"Bodoni MT Poster Compressed";
	panose-1:2 7 7 6 8 6 1 5 2 4;}
@font-face
	{font-family:"Bookman Old Style";
	panose-1:2 5 6 4 5 5 5 2 2 4;}
@font-face
	{font-family:"Bradley Hand ITC";
	panose-1:3 7 4 2 5 3 2 3 2 3;}
@font-face
	{font-family:"Britannic Bold";
	panose-1:2 11 9 3 6 7 3 2 2 4;}
@font-face
	{font-family:"Berlin Sans FB";
	panose-1:2 14 6 2 2 5 2 2 3 6;}
@font-face
	{font-family:"Berlin Sans FB Demi";
	panose-1:2 14 8 2 2 5 2 2 3 6;}
@font-face
	{font-family:Broadway;
	panose-1:4 4 9 5 8 11 2 2 5 2;}
@font-face
	{font-family:"Brush Script MT";
	panose-1:3 6 8 2 4 4 6 7 3 4;}
@font-face
	{font-family:"Bookshelf Symbol 7";
	panose-1:5 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Californian FB";
	panose-1:2 7 4 3 6 8 11 3 2 4;}
@font-face
	{font-family:"Calisto MT";
	panose-1:2 4 6 3 5 5 5 3 3 4;}
@font-face
	{font-family:Castellar;
	panose-1:2 10 4 2 6 4 6 1 3 1;}
@font-face
	{font-family:"Century Schoolbook";
	panose-1:2 4 6 4 5 5 5 2 3 4;}
@font-face
	{font-family:Centaur;
	panose-1:2 3 5 4 5 2 5 2 3 4;}
@font-face
	{font-family:Chiller;
	panose-1:4 2 4 4 3 16 7 2 6 2;}
@font-face
	{font-family:"Colonna MT";
	panose-1:4 2 8 5 6 2 2 3 2 3;}
@font-face
	{font-family:"Cooper Black";
	panose-1:2 8 9 4 4 3 11 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Bold";
	panose-1:2 14 7 5 2 2 6 2 4 4;}
@font-face
	{font-family:"Copperplate Gothic Light";
	panose-1:2 14 5 7 2 2 6 2 4 4;}
@font-face
	{font-family:"Curlz MT";
	panose-1:4 4 4 4 5 7 2 2 2 2;}
@font-face
	{font-family:Dubai;
	panose-1:2 11 5 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Light";
	panose-1:2 11 3 3 3 4 3 3 2 4;}
@font-face
	{font-family:"Dubai Medium";
	panose-1:2 11 6 3 3 4 3 3 2 4;}
@font-face
	{font-family:Elephant;
	panose-1:2 2 9 4 9 5 5 2 3 3;}
@font-face
	{font-family:"Engravers MT";
	panose-1:2 9 7 7 8 5 5 2 3 4;}
@font-face
	{font-family:"Eras Bold ITC";
	panose-1:2 11 9 7 3 5 4 2 2 4;}
@font-face
	{font-family:"Eras Demi ITC";
	panose-1:2 11 8 5 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Light ITC";
	panose-1:2 11 4 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Eras Medium ITC";
	panose-1:2 11 6 2 3 5 4 2 8 4;}
@font-face
	{font-family:"Felix Titling";
	panose-1:4 6 5 5 6 2 2 2 10 4;}
@font-face
	{font-family:Forte;
	panose-1:3 6 9 2 4 5 2 7 2 3;}
@font-face
	{font-family:"Franklin Gothic Book";
	panose-1:2 11 5 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi";
	panose-1:2 11 7 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Demi Cond";
	panose-1:2 11 7 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Heavy";
	panose-1:2 11 9 3 2 1 2 2 2 4;}
@font-face
	{font-family:"Franklin Gothic Medium Cond";
	panose-1:2 11 6 6 3 4 2 2 2 4;}
@font-face
	{font-family:"Freestyle Script";
	panose-1:3 8 4 2 3 2 5 11 4 4;}
@font-face
	{font-family:"French Script MT";
	panose-1:3 2 4 2 4 6 7 4 6 5;}
@font-face
	{font-family:"Footlight MT Light";
	panose-1:2 4 6 2 6 3 10 2 3 4;}
@font-face
	{font-family:Garamond;
	panose-1:2 2 4 4 3 3 1 1 8 3;}
@font-face
	{font-family:Gigi;
	panose-1:4 4 5 4 6 16 7 2 13 2;}
@font-face
	{font-family:"Gill Sans MT";
	panose-1:2 11 5 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans MT Condensed";
	panose-1:2 11 5 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold Condensed";
	panose-1:2 11 10 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Gill Sans Ultra Bold";
	panose-1:2 11 10 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Gloucester MT Extra Condensed";
	panose-1:2 3 8 8 2 6 1 1 1 1;}
@font-face
	{font-family:"Gill Sans MT Ext Condensed Bold";
	panose-1:2 11 9 2 2 1 4 2 2 3;}
@font-face
	{font-family:"Century Gothic";
	panose-1:2 11 5 2 2 2 2 2 2 4;}
@font-face
	{font-family:"Goudy Old Style";
	panose-1:2 2 5 2 5 3 5 2 3 3;}
@font-face
	{font-family:"Goudy Stout";
	panose-1:2 2 9 4 7 3 11 2 4 1;}
@font-face
	{font-family:"Harlow Solid Italic";
	panose-1:4 3 6 4 2 15 2 2 13 2;}
@font-face
	{font-family:Harrington;
	panose-1:4 4 5 5 5 10 2 2 7 2;}
@font-face
	{font-family:Haettenschweiler;
	panose-1:2 11 7 6 4 9 2 6 2 4;}
@font-face
	{font-family:"High Tower Text";
	panose-1:2 4 5 2 5 5 6 3 3 3;}
@font-face
	{font-family:"Imprint MT Shadow";
	panose-1:4 2 6 5 6 3 3 3 2 2;}
@font-face
	{font-family:"Informal Roman";
	panose-1:3 6 4 2 3 4 6 11 2 4;}
@font-face
	{font-family:"Blackadder ITC";
	panose-1:4 2 5 5 5 16 7 2 13 2;}
@font-face
	{font-family:"Edwardian Script ITC";
	panose-1:3 3 3 2 4 7 7 13 8 4;}
@font-face
	{font-family:"Kristen ITC";
	panose-1:3 5 5 2 4 2 2 3 2 2;}
@font-face
	{font-family:Jokerman;
	panose-1:4 9 6 5 6 13 6 2 7 2;}
@font-face
	{font-family:"Juice ITC";
	panose-1:4 4 4 3 4 10 2 2 2 2;}
@font-face
	{font-family:"Kunstler Script";
	panose-1:3 3 4 2 2 6 7 13 13 6;}
@font-face
	{font-family:"Wide Latin";
	panose-1:2 10 10 7 5 5 5 2 4 4;}
@font-face
	{font-family:"Lucida Bright";
	panose-1:2 4 6 2 5 5 5 2 3 4;}
@font-face
	{font-family:"Lucida Calligraphy";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Fax";
	panose-1:2 6 6 2 5 5 5 2 2 4;}
@font-face
	{font-family:"Lucida Handwriting";
	panose-1:3 1 1 1 1 1 1 1 1 1;}
@font-face
	{font-family:"Lucida Sans";
	panose-1:2 11 6 2 3 5 4 2 2 4;}
@font-face
	{font-family:"Lucida Sans Typewriter";
	panose-1:2 11 5 9 3 5 4 3 2 4;}
@font-face
	{font-family:Magneto;
	panose-1:4 3 8 5 5 8 2 2 13 2;}
@font-face
	{font-family:"Maiandra GD";
	panose-1:2 14 5 2 3 3 8 2 2 4;}
@font-face
	{font-family:"Matura MT Script Capitals";
	panose-1:3 2 8 2 6 6 2 7 2 2;}
@font-face
	{font-family:Mistral;
	panose-1:3 9 7 2 3 4 7 2 4 3;}
@font-face
	{font-family:"Modern No\. 20";
	panose-1:2 7 7 4 7 5 5 2 3 3;}
@font-face
	{font-family:"Monotype Corsiva";
	panose-1:3 1 1 1 1 2 1 1 1 1;}
@font-face
	{font-family:"Niagara Engraved";
	panose-1:4 2 5 2 7 7 3 3 2 2;}
@font-face
	{font-family:"Niagara Solid";
	panose-1:4 2 5 2 7 7 2 2 2 2;}
@font-face
	{font-family:"OCR A Extended";
	panose-1:2 1 5 9 2 1 2 1 3 3;}
@font-face
	{font-family:"Old English Text MT";
	panose-1:3 4 9 2 4 5 8 3 8 6;}
@font-face
	{font-family:Onyx;
	panose-1:4 5 6 2 8 7 2 2 2 3;}
@font-face
	{font-family:"MS Outlook";
	panose-1:5 1 1 0 1 0 0 0 0 0;}
@font-face
	{font-family:"Palace Script MT";
	panose-1:3 3 3 2 2 6 7 12 11 5;}
@font-face
	{font-family:Papyrus;
	panose-1:3 7 5 2 6 5 2 3 2 5;}
@font-face
	{font-family:Parchment;
	panose-1:3 4 6 2 4 7 8 4 8 4;}
@font-face
	{font-family:Perpetua;
	panose-1:2 2 5 2 6 4 1 2 3 3;}
@font-face
	{font-family:"Perpetua Titling MT";
	panose-1:2 2 5 2 6 5 5 2 8 4;}
@font-face
	{font-family:Playbill;
	panose-1:4 5 6 3 10 6 2 2 2 2;}
@font-face
	{font-family:"Poor Richard";
	panose-1:2 8 5 2 5 5 5 2 7 2;}
@font-face
	{font-family:Pristina;
	panose-1:3 6 4 2 4 4 6 8 2 4;}
@font-face
	{font-family:"Rage Italic";
	panose-1:3 7 5 2 4 5 7 7 3 4;}
@font-face
	{font-family:Ravie;
	panose-1:4 4 8 5 5 8 9 2 6 2;}
@font-face
	{font-family:"MS Reference Sans Serif";
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"MS Reference Specialty";
	panose-1:5 0 5 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Rockwell Condensed";
	panose-1:2 6 6 3 5 4 5 2 1 4;}
@font-face
	{font-family:Rockwell;
	panose-1:2 6 6 3 2 2 5 2 4 3;}
@font-face
	{font-family:"Rockwell Extra Bold";
	panose-1:2 6 9 3 4 5 5 2 4 3;}
@font-face
	{font-family:"Script MT Bold";
	panose-1:3 4 6 2 4 6 7 8 9 4;}
@font-face
	{font-family:"Showcard Gothic";
	panose-1:4 2 9 4 2 1 2 2 6 4;}
@font-face
	{font-family:"Snap ITC";
	panose-1:4 4 10 7 6 10 2 2 2 2;}
@font-face
	{font-family:Stencil;
	panose-1:4 4 9 5 13 8 2 2 4 4;}
@font-face
	{font-family:"Tw Cen MT";
	panose-1:2 11 6 2 2 1 4 2 6 3;}
@font-face
	{font-family:"Tw Cen MT Condensed";
	panose-1:2 11 6 6 2 1 4 2 2 3;}
@font-face
	{font-family:"Tw Cen MT Condensed Extra Bold";
	panose-1:2 11 8 3 2 2 2 2 2 4;}
@font-face
	{font-family:"Tempus Sans ITC";
	panose-1:4 2 4 4 3 13 7 2 2 2;}
@font-face
	{font-family:"Viner Hand ITC";
	panose-1:3 7 5 2 3 5 2 2 2 3;}
@font-face
	{font-family:Vivaldi;
	panose-1:3 2 6 2 5 5 6 9 8 4;}
@font-face
	{font-family:"Vladimir Script";
	panose-1:3 5 4 2 4 4 7 7 3 5;}
@font-face
	{font-family:"Wingdings 2";
	panose-1:5 2 1 2 1 5 7 7 7 7;}
@font-face
	{font-family:"Wingdings 3";
	panose-1:5 4 1 2 1 8 7 7 7 7;}
@font-face
	{font-family:AngsanaUPC;}
@font-face
	{font-family:CordiaUPC;}
@font-face
	{font-family:Abadi;}
@font-face
	{font-family:"Abadi Extra Light";}
@font-face
	{font-family:Aharoni;}
@font-face
	{font-family:Aldhabi;}
@font-face
	{font-family:Aparajita;}
@font-face
	{font-family:"Arabic Typesetting";}
@font-face
	{font-family:"Arial Nova";}
@font-face
	{font-family:"Arial Nova Cond";}
@font-face
	{font-family:"Arial Nova Cond Light";}
@font-face
	{font-family:"Arial Nova Light";}
@font-face
	{font-family:"Avenir Next LT Pro";}
@font-face
	{font-family:"Avenir Next LT Pro Light";}
@font-face
	{font-family:BatangChe;}
@font-face
	{font-family:Bembo;}
@font-face
	{font-family:Biome;}
@font-face
	{font-family:"Biome Light";}
@font-face
	{font-family:"Browallia New";}
@font-face
	{font-family:BrowalliaUPC;}
@font-face
	{font-family:Cavolini;}
@font-face
	{font-family:Dante;}
@font-face
	{font-family:DaunPenh;}
@font-face
	{font-family:David;}
@font-face
	{font-family:Daytona;}
@font-face
	{font-family:"Daytona Condensed";}
@font-face
	{font-family:"Daytona Condensed Light";}
@font-face
	{font-family:"Daytona Light";}
@font-face
	{font-family:"DengXian Light";}
@font-face
	{font-family:DilleniaUPC;}
@font-face
	{font-family:DokChampa;}
@font-face
	{font-family:DotumChe;}
@font-face
	{font-family:"Elephant Pro";}
@font-face
	{font-family:EucrosiaUPC;}
@font-face
	{font-family:Euphemia;}
@font-face
	{font-family:FangSong;}
@font-face
	{font-family:FrankRuehl;}
@font-face
	{font-family:FreesiaUPC;}
@font-face
	{font-family:"Georgia Pro";}
@font-face
	{font-family:"Georgia Pro Black";}
@font-face
	{font-family:"Georgia Pro Cond";}
@font-face
	{font-family:"Georgia Pro Cond Black";}
@font-face
	{font-family:"Georgia Pro Cond Light";}
@font-face
	{font-family:"Georgia Pro Cond Semibold";}
@font-face
	{font-family:"Georgia Pro Light";}
@font-face
	{font-family:"Georgia Pro Semibold";}
@font-face
	{font-family:"Gill Sans Nova";}
@font-face
	{font-family:"Gill Sans Nova Cond";}
@font-face
	{font-family:"Gill Sans Nova Cond Lt";}
@font-face
	{font-family:"Gill Sans Nova Cond Ultra Bold";}
@font-face
	{font-family:"Gill Sans Nova Cond XBd";}
@font-face
	{font-family:"Gill Sans Nova Light";}
@font-face
	{font-family:"Gill Sans Nova Ultra Bold";}
@font-face
	{font-family:Gisha;}
@font-face
	{font-family:Grotesque;}
@font-face
	{font-family:"Grotesque Light";}
@font-face
	{font-family:GulimChe;}
@font-face
	{font-family:Gungsuh;}
@font-face
	{font-family:GungsuhChe;}
@font-face
	{font-family:"Hadassah Friedlaender";}
@font-face
	{font-family:HGGothicE;}
@font-face
	{font-family:HGMaruGothicMPRO;}
@font-face
	{font-family:HGMinchoE;}
@font-face
	{font-family:HGPGothicE;}
@font-face
	{font-family:HGPMinchoE;}
@font-face
	{font-family:HGPSoeiKakugothicUB;}
@font-face
	{font-family:HGSGothicE;}
@font-face
	{font-family:HGSMinchoE;}
@font-face
	{font-family:HGSoeiKakugothicUB;}
@font-face
	{font-family:HGSSoeiKakugothicUB;}
@font-face
	{font-family:IrisUPC;}
@font-face
	{font-family:"Iskoola Pota";}
@font-face
	{font-family:JasmineUPC;}
@font-face
	{font-family:KaiTi;}
@font-face
	{font-family:Kalinga;}
@font-face
	{font-family:Kartika;}
@font-face
	{font-family:"Khmer UI";}
@font-face
	{font-family:Kigelia;}
@font-face
	{font-family:"Kigelia Arabic";}
@font-face
	{font-family:"Kigelia Arabic Light";}
@font-face
	{font-family:"Kigelia Light";}
@font-face
	{font-family:KodchiangUPC;}
@font-face
	{font-family:Kokila;}
@font-face
	{font-family:"Lao UI";}
@font-face
	{font-family:Leelawadee;}
@font-face
	{font-family:"Levenim MT";}
@font-face
	{font-family:LilyUPC;}
@font-face
	{font-family:"Mangal Pro";}
@font-face
	{font-family:Meiryo;}
@font-face
	{font-family:"Meiryo UI";}
@font-face
	{font-family:"Microsoft GothicNeo";}
@font-face
	{font-family:"Microsoft GothicNeo Light";}
@font-face
	{font-family:"Microsoft Uighur";}
@font-face
	{font-family:MingLiU_HKSCS;}
@font-face
	{font-family:Miriam;}
@font-face
	{font-family:"Miriam Fixed";}
@font-face
	{font-family:"Modern Love";}
@font-face
	{font-family:"Modern Love Caps";}
@font-face
	{font-family:"Modern Love Grunge";}
@font-face
	{font-family:MoolBoran;}
@font-face
	{font-family:"MS PMincho";}
@font-face
	{font-family:"MT Extra";}
@font-face
	{font-family:Narkisim;}
@font-face
	{font-family:"Neue Haas Grotesk Text Pro";}
@font-face
	{font-family:"News Gothic MT";}
@font-face
	{font-family:Nyala;}
@font-face
	{font-family:OCRB;}
@font-face
	{font-family:"Plantagenet Cherokee";}
@font-face
	{font-family:Posterama;}
@font-face
	{font-family:"Quire Sans";}
@font-face
	{font-family:"Quire Sans Light";}
@font-face
	{font-family:"Quire Sans Pro Light";}
@font-face
	{font-family:"Rockwell Light";}
@font-face
	{font-family:"Rockwell Nova";}
@font-face
	{font-family:"Rockwell Nova Cond";}
@font-face
	{font-family:"Rockwell Nova Cond Light";}
@font-face
	{font-family:"Rockwell Nova Extra Bold";}
@font-face
	{font-family:"Rockwell Nova Light";}
@font-face
	{font-family:Rod;}
@font-face
	{font-family:"Sabon Next LT";}
@font-face
	{font-family:"Sagona Book";}
@font-face
	{font-family:"Sagona ExtraLight";}
@font-face
	{font-family:"Sakkal Majalla";}
@font-face
	{font-family:"Sanskrit Text";}
@font-face
	{font-family:Selawik;}
@font-face
	{font-family:"Selawik Light";}
@font-face
	{font-family:"Selawik Semibold";}
@font-face
	{font-family:"Shonar Bangla";}
@font-face
	{font-family:"Simplified Arabic";}
@font-face
	{font-family:"Simplified Arabic Fixed";}
@font-face
	{font-family:"Sitka Banner Semibold";}
@font-face
	{font-family:"Sitka Display Semibold";}
@font-face
	{font-family:"Sitka Heading Semibold";}
@font-face
	{font-family:"Sitka Small Semibold";}
@font-face
	{font-family:"Sitka Subheading Semibold";}
@font-face
	{font-family:"Sitka Text Semibold";}
@font-face
	{font-family:"Source Sans Pro";}
@font-face
	{font-family:"Source Sans Pro Black";}
@font-face
	{font-family:"Source Sans Pro ExtraLight";}
@font-face
	{font-family:"Source Sans Pro Light";}
@font-face
	{font-family:"Source Sans Pro SemiBold";}
@font-face
	{font-family:"Speak Pro";}
@font-face
	{font-family:"Speak Pro Light";}
@font-face
	{font-family:STCaiyun;}
@font-face
	{font-family:STFangsong;}
@font-face
	{font-family:STHupo;}
@font-face
	{font-family:STKaiti;}
@font-face
	{font-family:STXihei;}
@font-face
	{font-family:STXingkai;}
@font-face
	{font-family:STXinwei;}
@font-face
	{font-family:STZhongsong;}
@font-face
	{font-family:"TH SarabunPSK";}
@font-face
	{font-family:"The Hand";}
@font-face
	{font-family:"The Hand Black";}
@font-face
	{font-family:"The Hand Extrablack";}
@font-face
	{font-family:"The Hand Light";}
@font-face
	{font-family:"The Serif Hand";}
@font-face
	{font-family:"The Serif Hand Black";}
@font-face
	{font-family:"The Serif Hand Extrablack";}
@font-face
	{font-family:"The Serif Hand Light";}
@font-face
	{font-family:"Tisa Offc Serif Pro";}
@font-face
	{font-family:"Tisa Offc Serif Pro Thin";}
@font-face
	{font-family:"Trade Gothic Next";}
@font-face
	{font-family:"Trade Gothic Next Cond";}
@font-face
	{font-family:"Trade Gothic Next Cond Hv";}
@font-face
	{font-family:"Trade Gothic Next Heavy";}
@font-face
	{font-family:"Trade Gothic Next Light";}
@font-face
	{font-family:"Traditional Arabic";}
@font-face
	{font-family:"UD Digi Kyokasho N-B";}
@font-face
	{font-family:"UD Digi Kyokasho N-R";}
@font-face
	{font-family:"UD Digi Kyokasho NK-B";}
@font-face
	{font-family:"UD Digi Kyokasho NK-R";}
@font-face
	{font-family:"UD Digi Kyokasho NP-B";}
@font-face
	{font-family:"UD Digi Kyokasho NP-R";}
@font-face
	{font-family:Univers;}
@font-face
	{font-family:"Univers Condensed";}
@font-face
	{font-family:"Univers Condensed Light";}
@font-face
	{font-family:"Univers Light";}
@font-face
	{font-family:"Urdu Typesetting";}
@font-face
	{font-family:Utsaah;}
@font-face
	{font-family:Vani;}
@font-face
	{font-family:"Verdana Pro";}
@font-face
	{font-family:"Verdana Pro Black";}
@font-face
	{font-family:"Verdana Pro Cond";}
@font-face
	{font-family:"Verdana Pro Cond Black";}
@font-face
	{font-family:"Verdana Pro Cond Light";}
@font-face
	{font-family:"Verdana Pro Cond SemiBold";}
@font-face
	{font-family:"Verdana Pro Light";}
@font-face
	{font-family:"Verdana Pro SemiBold";}
@font-face
	{font-family:Vijaya;}
@font-face
	{font-family:"Walbaum Display";}
@font-face
	{font-family:"Walbaum Display Heavy";}
@font-face
	{font-family:"Walbaum Display Light";}
@font-face
	{font-family:"Walbaum Display SemiBold";}
@font-face
	{font-family:"Walbaum Heading";}
@font-face
	{font-family:"Walbaum Text";}
@font-face
	{font-family:"Yu Mincho";}
@font-face
	{font-family:"Yu Mincho Demibold";}
@font-face
	{font-family:"Yu Mincho Light";}
@font-face
	{font-family:"TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRoman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:TimesNewRomanPSMT;}
@font-face
	{font-family:"Times New Roman Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:PraxisCom-Regular;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Bold";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:EUAlbertina;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 5 4 5 2 3 4;}
@font-face
	{font-family:"\@TimesNewRoman\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial\,Italic";
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:"\@Batang";
	panose-1:2 3 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@BatangChe";}
@font-face
	{font-family:"\@Gungsuh";}
@font-face
	{font-family:"\@GungsuhChe";}
@font-face
	{font-family:"\@DengXian Light";}
@font-face
	{font-family:"\@Gulim";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@GulimChe";}
@font-face
	{font-family:"\@Dotum";
	panose-1:2 11 6 0 0 1 1 1 1 1;}
@font-face
	{font-family:"\@DotumChe";}
@font-face
	{font-family:"\@Meiryo";}
@font-face
	{font-family:"\@Meiryo UI";}
@font-face
	{font-family:"\@MingLiU";
	panose-1:2 1 6 9 0 1 1 1 1 1;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 1 6 1 0 1 1 1 1 1;}
@font-face
	{font-family:"\@MingLiU_HKSCS";}
@font-face
	{font-family:"\@MS PMincho";}
@font-face
	{font-family:"\@STXingkai";}
@font-face
	{font-family:"\@STZhongsong";}
@font-face
	{font-family:"\@Yu Mincho";}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Times-Roman;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:CourierNewPSMT;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"SAS Monospace";}
@font-face
	{font-family:"Bookshelf Symbol 3";}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:17.85pt;
	text-indent:-17.85pt;
	font-size:13.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
h2
	{mso-style-link:"Heading 2 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Helvetica",sans-serif;
	font-weight:bold;
	font-style:italic;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:4.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h4
	{mso-style-link:"Heading 4 Char";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h5
	{mso-style-link:"Heading 5 Char";
	margin:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h6
	{mso-style-link:"Heading 6 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Heading 7 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-link:"Heading 8 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-link:"Heading 9 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:99.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-name:"Comment Text\,Annotationtext";
	mso-style-link:"Comment Text Char\,Annotationtext Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{mso-style-name:"Caption\,Char";
	mso-style-link:"Caption Char\,Char Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
span.MsoCommentReference
	{mso-style-name:"Comment Reference\,Annotationmark\,Kommentarzeichen";}
span.MsoEndnoteReference
	{vertical-align:super;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnote Text Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{mso-style-link:"Macro Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:32.15pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:46.3pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-28.5pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:84.0pt;
	text-indent:-28.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:60.45pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-link:"Title Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:16.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{mso-style-link:"Closing Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{mso-style-link:"Signature Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char1";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Body Text Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{mso-style-link:"Message Header Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-indent:-56.7pt;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{mso-style-link:"Subtitle Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Arial",sans-serif;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{mso-style-link:"Salutation Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{mso-style-link:"Date Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{mso-style-link:"Body Text First Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:10.5pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:green;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{mso-style-link:"Body Text First Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	text-indent:10.5pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{mso-style-link:"Note Heading Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{mso-style-link:"Body Text 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{mso-style-link:"Body Text 3 Char";
	margin:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{mso-style-link:"Body Text Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{mso-style-link:"Body Text Indent 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:1.0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:#606420;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Document Map Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.2pt;
	text-indent:-14.2pt;
	background:navy;
	font-size:11.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Plain Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{mso-style-link:"E-mail Signature Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p
	{margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
address
	{mso-style-link:"HTML Address Char";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
pre
	{mso-style-link:"HTML Preformatted Char";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MemoHeaderStyle, li.MemoHeaderStyle, div.MemoHeaderStyle
	{mso-style-name:MemoHeaderStyle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.9pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-variant:small-caps;
	font-weight:bold;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:11.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAgency
	{mso-style-name:"Table heading rows \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.CommentTextChar
	{mso-style-name:"Comment Text Char\,Annotationtext Char";
	mso-style-link:"Comment Text\,Annotationtext";
	font-family:"Times New Roman",serif;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Helvetica",sans-serif;
	font-weight:bold;
	font-style:italic;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	mso-style-link:"Heading 5";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-link:"Heading 6";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-link:"Heading 7";
	font-family:"Times New Roman",serif;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-link:"Heading 8";
	font-family:"Times New Roman",serif;
	font-style:italic;}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-link:"Heading 9";
	font-family:"Arial",sans-serif;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;
	font-family:"Arial",sans-serif;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;
	font-family:"Arial",sans-serif;}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	mso-style-link:"Endnote Text";
	font-family:"Times New Roman",serif;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	mso-style-link:"Document Map";
	font-family:"Tahoma",sans-serif;
	background:navy;}
span.BodyText3Char
	{mso-style-name:"Body Text 3 Char";
	mso-style-link:"Body Text 3";
	font-family:"Times New Roman",serif;
	font-weight:bold;
	font-style:italic;}
p.TOCHeadings, li.TOCHeadings, div.TOCHeadings
	{mso-style-name:"TOC Headings";
	margin-top:19.85pt;
	margin-right:0in;
	margin-bottom:11.35pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.BodyTextIndent4, li.BodyTextIndent4, div.BodyTextIndent4
	{mso-style-name:"Body Text Indent 4";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:74.6pt;
	text-indent:-.25in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Tahoma",sans-serif;}
p.Bulletstext, li.Bulletstext, div.Bulletstext
	{mso-style-name:"Bullets text";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:17.85pt;
	text-indent:-17.85pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Text1, li.Text1, div.Text1
	{mso-style-name:"Text 1";
	mso-style-link:"Text 1 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.TitleA, li.TitleA, div.TitleA
	{mso-style-name:"Title A";
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TitleB, li.TitleB, div.TitleB
	{mso-style-name:"Title B";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.35pt;
	text-indent:-28.35pt;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Text1Char
	{mso-style-name:"Text 1 Char";
	mso-style-link:"Text 1";
	font-family:"Times New Roman",serif;}
p.TableCenter, li.TableCenter, div.TableCenter
	{mso-style-name:"Table Center";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.TableLeft, li.TableLeft, div.TableLeft
	{mso-style-name:"Table Left";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.TableFixedWidth, li.TableFixedWidth, div.TableFixedWidth
	{mso-style-name:"Table Fixed Width";
	margin:0in;
	font-size:10.0pt;
	font-family:"Courier New";}
p.TableFootnoteSymbol, li.TableFootnoteSymbol, div.TableFootnoteSymbol
	{mso-style-name:"Table Footnote Symbol";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:.25in;
	text-indent:-.25in;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;}
p.TableFootnoteLetter, li.TableFootnoteLetter, div.TableFootnoteLetter
	{mso-style-name:"Table Footnote Letter";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:28.0pt;
	text-indent:-28.0pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;}
p.TableEndofTextTitle, li.TableEndofTextTitle, div.TableEndofTextTitle
	{mso-style-name:"Table End of Text Title";
	margin:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TableTitleContinued, li.TableTitleContinued, div.TableTitleContinued
	{mso-style-name:"Table Title Continued";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.FigureEndofTextTitle, li.FigureEndofTextTitle, div.FigureEndofTextTitle
	{mso-style-name:"Figure End of Text Title";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.ListLetter2, li.ListLetter2, div.ListLetter2
	{mso-style-name:"List Letter 2";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.0pt;
	text-indent:-28.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.ListLetter3, li.ListLetter3, div.ListLetter3
	{mso-style-name:"List Letter 3";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:84.0pt;
	text-indent:-28.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.EMEAstyle1, li.EMEAstyle1, div.EMEAstyle1
	{mso-style-name:"EMEA style 1";
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.EMEAstyle2, li.EMEAstyle2, div.EMEAstyle2
	{mso-style-name:"EMEA style 2";
	margin-top:0in;
	margin-right:70.8pt;
	margin-bottom:0in;
	margin-left:85.05pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.EMEAStyle20, li.EMEAStyle20, div.EMEAStyle20
	{mso-style-name:"EMEA Style 2";
	margin-top:0in;
	margin-right:70.8pt;
	margin-bottom:0in;
	margin-left:85.05pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.BodyText2Char
	{mso-style-name:"Body Text 2 Char";
	mso-style-link:"Body Text 2";
	font-family:"Times New Roman",serif;}
span.BodyTextChar1
	{mso-style-name:"Body Text Char1";
	mso-style-link:"Body Text";
	font-family:"Times New Roman",serif;
	color:green;
	font-style:italic;}
span.BodyTextFirstIndentChar
	{mso-style-name:"Body Text First Indent Char";
	mso-style-link:"Body Text First Indent";
	font-family:"Times New Roman",serif;
	color:green;
	font-style:normal;}
span.BodyTextIndentChar
	{mso-style-name:"Body Text Indent Char";
	mso-style-link:"Body Text Indent";
	font-family:"Times New Roman",serif;}
span.BodyTextFirstIndent2Char
	{mso-style-name:"Body Text First Indent 2 Char";
	mso-style-link:"Body Text First Indent 2";
	font-family:"Times New Roman",serif;}
span.BodyTextIndent2Char
	{mso-style-name:"Body Text Indent 2 Char";
	mso-style-link:"Body Text Indent 2";
	font-family:"Times New Roman",serif;}
span.BodyTextIndent3Char
	{mso-style-name:"Body Text Indent 3 Char";
	mso-style-link:"Body Text Indent 3";
	font-family:"Times New Roman",serif;}
span.ClosingChar
	{mso-style-name:"Closing Char";
	mso-style-link:Closing;
	font-family:"Times New Roman",serif;}
span.DateChar
	{mso-style-name:"Date Char";
	mso-style-link:Date;
	font-family:"Times New Roman",serif;}
span.E-mailSignatureChar
	{mso-style-name:"E-mail Signature Char";
	mso-style-link:"E-mail Signature";
	font-family:"Times New Roman",serif;}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";
	font-family:"Times New Roman",serif;}
span.HTMLAddressChar
	{mso-style-name:"HTML Address Char";
	mso-style-link:"HTML Address";
	font-family:"Times New Roman",serif;
	font-style:italic;}
span.HTMLPreformattedChar
	{mso-style-name:"HTML Preformatted Char";
	mso-style-link:"HTML Preformatted";
	font-family:"Courier New";}
span.MacroTextChar
	{mso-style-name:"Macro Text Char";
	mso-style-link:"Macro Text";
	font-family:"Courier New";}
span.MessageHeaderChar
	{mso-style-name:"Message Header Char";
	mso-style-link:"Message Header";
	font-family:"Arial",sans-serif;
	background:#CCCCCC;}
span.NoteHeadingChar
	{mso-style-name:"Note Heading Char";
	mso-style-link:"Note Heading";
	font-family:"Times New Roman",serif;}
span.PlainTextChar
	{mso-style-name:"Plain Text Char";
	mso-style-link:"Plain Text";
	font-family:"Courier New";}
span.SalutationChar
	{mso-style-name:"Salutation Char";
	mso-style-link:Salutation;
	font-family:"Times New Roman",serif;}
span.SignatureChar
	{mso-style-name:"Signature Char";
	mso-style-link:Signature;
	font-family:"Times New Roman",serif;}
span.SubtitleChar
	{mso-style-name:"Subtitle Char";
	mso-style-link:Subtitle;
	font-family:"Arial",sans-serif;}
span.TitleChar
	{mso-style-name:"Title Char";
	mso-style-link:Title;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.bodytextindent40, li.bodytextindent40, div.bodytextindent40
	{mso-style-name:bodytextindent4;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.TableHeading, li.TableHeading, div.TableHeading
	{mso-style-name:"Table Heading";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.CaptionChar
	{mso-style-name:"Caption Char\,Char Char";
	mso-style-link:"Caption\,Char";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.EMEASubscript
	{mso-style-name:"EMEA Subscript";
	vertical-align:sub;}
p.TableCentre, li.TableCentre, div.TableCentre
	{mso-style-name:"Table Centre";
	margin:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.Table-Text, li.Table-Text, div.Table-Text
	{mso-style-name:Table-Text;
	mso-style-link:"Table-Text Char";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
span.Table-TextChar
	{mso-style-name:"Table-Text Char";
	mso-style-link:Table-Text;
	font-family:"Arial",sans-serif;}
p.Table-Footer, li.Table-Footer, div.Table-Footer
	{mso-style-name:Table-Footer;
	mso-style-link:"Table-Footer Char";
	margin:0in;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;}
span.Table-FooterChar
	{mso-style-name:"Table-Footer Char";
	mso-style-link:Table-Footer;
	font-family:"Times New Roman",serif;}
span.CharChar1
	{mso-style-name:"Char Char1";}
p.EMAStyle2, li.EMAStyle2, div.EMAStyle2
	{mso-style-name:"EMA Style 2";
	margin-top:0in;
	margin-right:70.8pt;
	margin-bottom:0in;
	margin-left:85.05pt;
	text-indent:-28.35pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:black;
	font-weight:bold;}
span.AnnotationtextCharChar
	{mso-style-name:"Annotationtext Char Char";}
p.Tablecentredbold, li.Tablecentredbold, div.Tablecentredbold
	{mso-style-name:"Table centred bold";
	margin:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TableleftCAPS, li.TableleftCAPS, div.TableleftCAPS
	{mso-style-name:"Table left CAPS";
	margin:0in;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman Bold",serif;
	text-transform:uppercase;
	font-weight:bold;
	font-style:italic;}
p.TableleftIT, li.TableleftIT, div.TableleftIT
	{mso-style-name:"Table left IT";
	margin:0in;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
span.CommentTextChar1
	{mso-style-name:"Comment Text Char1";}
span.refgroup
	{mso-style-name:ref_group;}
span.refreference
	{mso-style-name:ref_reference;}
span.textbluebold
	{mso-style-name:textbluebold;}
p.TableHeaderCenter, li.TableHeaderCenter, div.TableHeaderCenter
	{mso-style-name:"Table Header Center";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:10.0pt;
	font-family:"Times New Roman Bold",serif;
	color:black;
	font-weight:bold;}
p.TableCellCenter, li.TableCellCenter, div.TableCellCenter
	{mso-style-name:"Table Cell Center";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.RefAgency, li.RefAgency, div.RefAgency
	{mso-style-name:"Ref\. \(Agency\)";
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Verdana",sans-serif;}
span.PIHeading2Char
	{mso-style-name:"PI Heading 2 Char";
	mso-style-link:"PI Heading 2";
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.PIHeading2, li.PIHeading2, div.PIHeading2
	{mso-style-name:"PI Heading 2";
	mso-style-link:"PI Heading 2 Char";
	margin-top:.25in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
p.Style1, li.Style1, div.Style1
	{mso-style-name:Style1;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:30.0pt;
	text-indent:-30.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.msoIns
	{mso-style-name:"";
	text-decoration:underline;
	color:teal;}
span.msoDel
	{mso-style-name:"";
	text-decoration:line-through;
	color:red;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink="#606420" style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX I</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>SUMMARY OF PRODUCT CHARACTERISTICS</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB><img width=21 height=17 id="Picture 1"
src="Epclusa-h-4210-e_files/image001.gif" alt="BT_1000x858px"></span><span
lang=EN-GB>This medicinal product is subject to additional monitoring. &nbsp;This
will allow quick identification of new safety information. &nbsp;Healthcare
professionals are asked to report any suspected adverse reactions. &nbsp;See
section&nbsp;4.8 for how to report adverse reactions.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF </span></b><b><span lang=EN-GB>THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Epclusa</span><span
lang=EN-GB> 400&nbsp;mg/100&nbsp;mg film&#8209;coated tablets.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QUALITATIVE
AND QUANTITATIVE COMPOSITION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each film&#8209;coated
tablet contains 400&nbsp;mg sofosbuvir and 100&nbsp;mg velpatasvir</span><span
lang=EN-GB>.</span></p>

<p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For the full list
of excipients, see section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Film&#8209;coated
tablet.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pink, diamond&#8209;shaped,
film&#8209;coated tablet of dimensions 20&nbsp;mm&nbsp;x&nbsp;10&nbsp;mm,
debossed on one side with &#8220;GSI&#8221; and &#8220;7916&#8221; on the other
side.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB style='text-transform:uppercase'>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></b><b><span
lang=EN-GB>CLINICAL PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic
indications</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Epclusa</span><span
lang=EN-GB> </span><span lang=EN-GB>is indicated for the treatment of chronic
hepatitis&nbsp;C virus (HCV) infection in adults </span><span lang=EN-GB>(see
sections&nbsp;4.2,&nbsp;4.4 and&nbsp;5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>4.2&nbsp;&nbsp;&nbsp;&nbsp; Posology and method of administration</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Epclusa
treatment should be initiated and monitored by a physician experienced in the
management of patients with HCV infection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Posology</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The recommended
dose of Epclusa is one tablet, taken orally, once daily with or without food
(see section&nbsp;5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoCaption style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB style='font-size:11.0pt'>Table&nbsp;1: Recommended treatment and duration
for all HCV genotypes</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width=253 valign=top style='width:189.7pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Patient population<sup>a</sup></span></b></p>
   </td>
   <td width=366 valign=top style='width:274.65pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Treatment and duration</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=253 style='width:189.7pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Patients without cirrhosis and patients
  with compensated cirrhosis</span></p>
  </td>
  <td width=366 style='width:274.65pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Epclusa</span><span lang=EN-GB
  style='font-size:10.0pt'> for </span><span lang=EN-GB style='font-size:10.0pt'>12&nbsp;weeks</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Addition of ribavirin may be considered
  for genotype&nbsp;3 infected patients with compensated cirrhosis (see section&nbsp;5.1.)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=253 style='width:189.7pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Patients with decompensated cirrhosis</span></p>
  </td>
  <td width=366 style='width:274.65pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Epclusa </span><span lang=EN-GB
  style='font-size:10.0pt'>+ ribavirin for </span><span lang=EN-GB
  style='font-size:10.0pt'>12&nbsp;weeks</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
normal'><span lang=EN-GB style='font-size:9.0pt'>a&nbsp;&nbsp;&nbsp;&nbsp; Includes
patients co&#8209;infected with human immunodeficiency virus (HIV) and patients
with recurrent HCV post-liver transplant (see section&nbsp;4.4.).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>When used in
combination with ribavirin, refer also to the Summary of Product
Characteristics of the medicinal product containing ribavirin.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The following dosing is recommended where ribavirin is divided in
two daily doses and given with food:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Table&nbsp;2: Guidance for ribavirin dosing when administered with Epclusa
to patients with decompensated cirrhosis</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width=225 valign=top style='width:168.45pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Patient</span></b></p>
   </td>
   <td width=389 valign=top style='width:292.1pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Ribavirin Dose</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=225 valign=top style='width:168.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Child&#8209;Pugh&#8209;Turcotte (CPT) </span><span
  lang=EN-GB style='font-size:10.0pt'>Class&nbsp;B cirrhosis pre-transplant</span></p>
  </td>
  <td width=389 valign=top style='width:292.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>1,000&nbsp;mg per day for patients
  &lt;&nbsp;75&nbsp;kg and 1,200&nbsp;mg for those weighing
  &#8805;&nbsp;75&nbsp;kg</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=225 valign=top style='width:168.45pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>CPT Class&nbsp;C cirrhosis pre-transplant</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>CPT Class&nbsp;B or C post-transplant</span></p>
  </td>
  <td width=389 valign=top style='width:292.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Starting dose of 600&nbsp;mg, which can be titrated
  up to a maximum of 1,000/1,200&nbsp;mg (1,000&nbsp;mg for patients weighing
  &lt;&nbsp;75&nbsp;kg and 1,200&nbsp;mg for patients weighing
  &#8805;&nbsp;75&nbsp;kg) if well tolerated.&nbsp; If the starting dose is not
  well tolerated, the dose should be reduced as clinically indicated based on
  haemoglobin levels</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If ribavirin is
used in genotype&nbsp;3 infected patients with compensated cirrhosis (pre- or
post-transplant) the recommended dose of ribavirin is 1,000/1,200</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>mg (</span><span lang=EN-GB>1,000&nbsp;mg
for patients weighing &lt;&nbsp;75&nbsp;kg and 1,200&nbsp;mg for patients
weighing &#8805;&nbsp;75&nbsp;kg</span><span lang=EN-GB>).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For ribavirin
dose modifications, refer to the Summary of Product Characteristics of the
medicinal product containing ribavirin.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Patients should
be instructed that if vomiting occurs within 3&nbsp;hours of dosing an
additional tablet of Epclusa should be taken.&nbsp; If vomiting occurs more
than 3&nbsp;hours after dosing, no further dose of Epclusa is needed (see
section&nbsp;5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If a dose of Epclusa
is missed and it is within 18&nbsp;hours of the normal time, patients should be
instructed to take the tablet as soon as possible and then patients should take
the next dose at the usual time.&nbsp; If it is after 18&nbsp;hours then
patients should be instructed to wait and take the next dose of Epclusa at the
usual time.&nbsp; Patients should be instructed not to take a double dose of Epclusa.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Patients who have previously failed therapy with an NS5A-containing
regimen</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Epclusa +
ribavirin for 24&nbsp;weeks may be considered (see section&nbsp;4.4).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No dose
adjustment is warranted for elderly patients (see section&nbsp;5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Renal impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No dose
adjustment of </span><span lang=EN-GB>Epclusa</span><span lang=EN-GB> is
required for patients with mild or moderate renal impairment. &nbsp;The safety
and efficacy of Epclusa has not been assessed in patients with severe renal impairment
(estimated glomerular filtration rate
[eGFR]&nbsp;&lt;&nbsp;30&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>) or end stage
renal disease (ESRD) requiring haemodialysis (see section&nbsp;5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Hepatic impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No dose
adjustment of </span><span lang=EN-GB>Epclusa</span><span lang=EN-GB> </span><span
lang=EN-GB>is required for patients with mild, moderate, or severe hepatic
impairment (CPT Class&nbsp;A, B, or C) (see section&nbsp;5.2). &nbsp;Safety and
efficacy of </span><span lang=EN-GB>Epclusa</span><span lang=EN-GB> have been assessed
in patients with CPT Class&nbsp;B cirrhosis, but not in patients with CPT Class&nbsp;C
cirrhosis (see sections&nbsp;4.4,&nbsp;4.8 and&nbsp;5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Paediatric population</span></i></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The safety and efficacy of Epclusa in children and adolescents aged less
than 18&nbsp;years have not yet been established. &nbsp;No data are available.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Method of administration</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>For oral use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Patients should be instructed to swallow the tablet whole with or
without food (see section&nbsp;5.2). &nbsp;Due to the bitter taste, it is
recommended that the film&#8209;coated tablet is not chewed or crushed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.3&nbsp;&nbsp;&nbsp;&nbsp; Contraindications</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Hypersensitivity
to the active substances or to any of the excipients listed in section&nbsp;6.1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Use with potent P&#8209;gp and potent CYP inducers</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
products that are potent P&#8209;glycoprotein (P&#8209;gp) or potent cytochrome
P450 (CYP) inducers (rifampicin, rifabutin, St.&nbsp;John&#8217;s wort
[Hypericum perforatum], carbamazepine, phenobarbital and phenytoin).&nbsp; Co&#8209;administration
will significantly decrease sofosbuvir or velpatasvir plasma concentrations and
could result in loss of efficacy of Epclusa (see section&nbsp;4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.4&nbsp;&nbsp;&nbsp;&nbsp; Special
warnings and precautions for use</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Epclusa</span><span
lang=EN-GB> should not be administered concurrently with other medicinal
products containing sofosbuvir.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Severe bradycardia and heart block</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cases of severe
bradycardia and heart block have been observed when sofosbuvir-containing
regimens are used in combination with amiodarone with or without other medicinal
products that lower heart rate.&nbsp; The mechanism is not established.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The concomitant
use of amiodarone was limited through the clinical development of sofosbuvir.&nbsp;
Cases are potentially life threatening, therefore amiodarone should only be
used in patients on Epclusa when other alternative anti-arrhythmic treatments
are not tolerated or are contraindicated.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Should
concomitant use of amiodarone be considered necessary, it is recommended that
patients are closely monitored when initiating Epclusa.&nbsp; Patients who are
identified as being at high risk of bradyarrhythmia should be continuously
monitored for 48&nbsp;hours in an appropriate clinical setting.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Due to the long
half-life of amiodarone, appropriate monitoring should also be carried out for
patients who have discontinued amiodarone within the past few months and are to
be initiated on Epclusa.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>All patients
receiving Epclusa in combination with amiodarone with or without other medicinal
products that lower heart rate should also be warned of the symptoms of
bradycardia and heart block and should be advised to seek medical advice
urgently should they experience them.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Patients who have previously failed therapy with an NS5A-containing
regimen</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There are no
clinical data to support the efficacy of sofosbuvir/velpatasvir for the
treatment of patients who have failed treatment with a regimen containing
another NS5A inhibitor.&nbsp; However, on the basis of NS5A resistance
associated variants (RAVs) typically seen in patients who have failed therapy
with other NS5A inhibitor containing regimens, the <i>in&nbsp;vitro</i>
pharmacology of velpatasvir, and the outcomes of sofosbuvir/velpatasvir
treatment in NS5A-na&iuml;ve patients with baseline NS5A RAVs enrolled into the
ASTRAL-studies, treatment with Epclusa + RBV for 24&nbsp;weeks can be
considered for patients who have failed therapy on an NS5A-containing regimen
and who are deemed at high risk for clinical disease progression and who do not
have alternative treatment options.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Renal impairment</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No dose
adjustment of Epclusa is required for patients with mild or moderate renal
impairment.&nbsp; </span><span lang=EN-GB>The safety of </span><span
lang=EN-GB>Epclusa</span><span lang=EN-GB> has not been assessed in patients
with severe renal impairment (eGFR&nbsp;&lt;&nbsp;30&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>)
or ESRD requiring haemodialysis.&nbsp; When </span><span lang=EN-GB>Epclusa</span><span
lang=EN-GB> is used in combination with ribavirin refer also to the Summary of
Product Characteristics for ribavirin for patients with creatinine clearance
&lt;&nbsp;50&nbsp;mL/min (see section&nbsp;5.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Use with moderate P&#8209;gp inducers or moderate CYP inducers</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
products that are moderate P&#8209;gp or moderate CYP inducers (e.g. oxcarbazepine,
modafinil or efavirenz) may decrease sofosbuvir or velpatasvir plasma
concentrations leading to reduced therapeutic effect of Epclusa. &nbsp;Co-administration
of such medicinal products with Epclusa is not recommended (see
section&nbsp;4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Use with certain HIV antiretroviral regimens</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Epclusa has been
shown to increase tenofovir exposure, especially when used together with an HIV
regimen containing tenofovir disoproxil fumarate and a pharmacokinetic enhancer
(ritonavir or cobicistat).&nbsp; The safety of tenofovir disoproxil fumarate in
the setting of Epclusa and a pharmacokinetic enhancer has not been
established.&nbsp; The potential risks and benefits associated with co&#8209;administration
of Epclusa with the fixed-dose combination tablet containing
elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate or
tenofovir disoproxil fumarate given in conjunction with a boosted HIV protease
inhibitor (e.g. atazanavir or darunavir) should be considered, particularly in
patients at increased risk of renal dysfunction. &nbsp;Patients receiving Epclusa
concomitantly with elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil
fumarate or with tenofovir disoproxil fumarate and a boosted HIV protease
inhibitor should be monitored for tenofovir&#8209;associated adverse reactions.
&nbsp;Refer to tenofovir disoproxil fumarate, emtricitabine/tenofovir
disoproxil fumarate, or elvitegravir/cobicistat/emtricitabine/tenofovir
disoproxil fumarate Summary of Product Characteristics for recommendations on
renal monitoring.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><u><span lang=EN-GB>Use in
diabetic patients </span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Diabetics may
experience improved glucose control, potentially resulting in symptomatic
hypoglycaemia, after initiating HCV direct-acting antiviral treatment. Glucose
levels of diabetic patients initiating direct-acting antiviral therapy should
be closely monitored, particularly within the first 3 months, and their
diabetic medication modified when necessary. The physician in charge of the
diabetic care of the patient should be informed when direct-acting antiviral
therapy is initiated.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB><span style='text-decoration:none'>&nbsp;</span></span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>HCV/HBV (hepatitis&nbsp;B virus) co&#8209;infection</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cases of
hepatitis B&nbsp;virus (HBV) reactivation, some of them fatal, have been
reported during or after treatment with direct-acting antiviral agents. &nbsp;HBV
screening should be performed in all patients before initiation of treatment. &nbsp;HBV/HCV
co-infected patients are at risk of HBV reactivation, and should therefore be
monitored and managed according to current clinical guidelines.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>CPT Class&nbsp;C cirrhosis</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Safety and
efficacy of Epclusa has not been assessed in patients with CPT Class&nbsp;C
cirrhosis (see sections&nbsp;4.8 and&nbsp;5.1).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Liver transplant patients</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The safety and
efficacy of Epclusa in the treatment of HCV infection in patients who are post&#8209;liver
transplant have not been assessed.&nbsp; Treatment with Epclusa in accordance
with the recommended posology (see section&nbsp;4.2) should be guided by an
assessment of the potential benefits and risks for the individual patient.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.5&nbsp;&nbsp;&nbsp;&nbsp; Interaction
with other medicinal products and other forms of interaction</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>As</span><span lang=EN-GB> Epclusa </span><span lang=EN-GB>contains
sofosbuvir and velpatasvir, any interactions that have been identified with
these active substances individually may occur with </span><span lang=EN-GB>Epclusa</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Potential for Epclusa to affect other medicinal products</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Velpatasvir is an inhibitor of drug transporter P&#8209;gp, breast
cancer resistance protein (BCRP), organic anion&#8209;transporting polypeptide
(OATP)&nbsp;1B1 and OATP1B3. &nbsp;Co&#8209;administration of Epclusa with
medicinal products that are substrates of these transporters may increase the
exposure of such medicinal products. &nbsp;See Table&nbsp;3 for examples of
interactions with sensitive substrates of P&#8209;gp (digoxin), BCRP
(rosuvastatin), and OATP (pravastatin).</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Potential for other medicinal products to affect Epclusa</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sofosbuvir and
velpatasvir are substrates of drug transporters P&#8209;gp and BCRP.&nbsp; Velpatasvir
is also a substrate of drug transporter OATP1B.&nbsp; <i>In&nbsp;vitro,</i>
slow metabolic turnover of velpatasvir by CYP2B6, CYP2C8 and CYP3A4 was
observed. &nbsp;Medicinal products that are potent inducers of P&#8209;gp or potent
inducers of CYP2B6, CYP2C8, or CYP3A4 (e.g. rifampicin, rifabutin, St.&nbsp;John&#8217;s
wort, carbamazepine, phenobarbital and phenytoin) may decrease plasma
concentrations of sofosbuvir or velpatasvir leading to reduced therapeutic
effect of sofosbuvir/velpatasvir.&nbsp; The use of such medicinal products with
Epclusa is contraindicated (see section&nbsp;4.3).&nbsp; Medicinal products
that are moderate P&#8209;gp&nbsp;inducers or moderate CYP inducers (e.g.
oxcarbazepine, modafinil or efavirenz) may decrease sofosbuvir or velpatasvir
plasma concentration leading to reduced therapeutic effect of Epclusa.&nbsp; Co&#8209;administration
with such medicinal products is not recommended with Epclusa (see
section&nbsp;4.4).&nbsp; Co&#8209;administration with medicinal products that
inhibit P&#8209;gp or BCRP may increase sofosbuvir or velpatasvir plasma
concentrations.&nbsp; Medicinal products that inhibit OATP, CYP2B6, CYP2C8, or
CYP3A4 may increase plasma concentration of velpatasvir. &nbsp;Clinically
significant medicinal product interactions with Epclusa mediated by P&#8209;gp,
BCRP, OATP, or CYP450 inhibitors are not expected; Epclusa may be co&#8209;administered
with P&#8209;gp, BCRP, OATP and CYP&nbsp;inhibitors.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Patients treated with vitamin&nbsp;K antagonists</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>As liver
function may change during treatment with Epclusa, a close monitoring of
International Normalised Ratio (INR) values is recommended.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Interactions between Epclusa and other medicinal products</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Table</span><span
lang=EN-GB>&nbsp;</span><span lang=EN-GB>3 provides a listing of established or
potentially clinically significant medicinal product interactions (where 90%
confidence interval [CI] of the geometric least&#8209;squares mean [GLSM] ratio
were within &#8220;&#8596;&#8221;, extended above &#8220;&#8593;&#8221;, or
extended below &#8220;&#8595;&#8221; the predetermined interaction boundaries).&nbsp;
The medicinal product interactions described are based on studies conducted
with either </span><span lang=EN-GB>sofosbuvir/velpatasvir or velpatasvir and
sofosbuvir as individual agents, or are predicted medicinal product
interactions that may occur with sofosbuvir/velpatasvir.&nbsp; The table is not
all&#8209;inclusive.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Table&nbsp;3: Interactions between </span></b><b><span lang=EN-GB>Epclusa</span></b><span
lang=EN-GB> <b>and other medicinal products</b></span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid;height:7.25pt'>
   <td width="27%" rowspan=2 valign=bottom style='width:27.12%;border:solid windowtext 1.0pt;
   padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Medicinal product by therapeutic
   areas/Possible Mechanism of Interaction</span></b></p>
   </td>
   <td width="39%" colspan=4 valign=bottom style='width:39.72%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Effects on medicinal product levels.</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Mean ratio (90% confidence interval)<sup>a,b</sup></span></b></p>
   </td>
   <td width="33%" rowspan=2 valign=bottom style='width:33.16%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Recommendation concerning co&#8209;administration
   with Epclusa</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid;height:7.25pt'>
   <td width="14%" valign=bottom style='width:14.1%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Active</span></b></p>
   </td>
   <td width="8%" valign=bottom style='width:8.54%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>C<sub>max</sub></span></b></p>
   </td>
   <td width="8%" valign=bottom style='width:8.54%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>AUC</span></b></p>
   </td>
   <td width="8%" valign=bottom style='width:8.54%;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>C<sub>min</sub></span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="100%" colspan=6 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><span
  lang=EN-GB style='font-size:10.0pt'>ACID REDUCING AGENTS</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><b><i><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></i></b></p>
  </td>
  <td width="39%" colspan=4 valign=top style='width:39.72%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="33%" valign=top style='width:33.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Velpatasvir solubility decreases as pH
  increases.&nbsp; Medicinal products that increase gastric pH are expected to
  decrease the concentration of velpatasvir.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="100%" colspan=6 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
  lang=EN-GB style='font-size:10.0pt'>Antacids</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>e.g. Aluminium or magnesium hydroxide; calcium
  carbonate</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>(Increase in gastric pH)</span></p>
  </td>
  <td width="39%" colspan=4 valign=top style='width:39.72%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Interaction not studied.</span></p>
  <p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
  style='font-size:10.0pt'>Expected.</span></i></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8596; Sofosbuvir</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8595; Velpatasvir</span></p>
  </td>
  <td width="33%" valign=top style='width:33.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>It is recommended to separate antacid and Epclusa
  administration by 4&nbsp;hours.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="100%" colspan=6 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
  lang=EN-GB style='font-size:10.0pt'>H<sub>2</sub>&#8209;receptor antagonists</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:61.0pt'>
  <td width="27%" rowspan=2 valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:61.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=IT-CH style='font-size:10.0pt'>Famotidine</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=IT-CH style='font-size:10.0pt'>(40&nbsp;mg single dose)/ sofosbuvir/
  velpatasvir (400/ 100&nbsp;mg single dose)<sup>c</sup></span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=IT-CH style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Famotidine dosed simultaneously with Epclusa<sup>d</sup></span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Cimetidine<sup>e</sup></span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Nizatidine<sup>e</sup></span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Ranitidine<sup>e</sup></span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(Increase in gastric pH)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:61.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Sofosbuvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:61.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:61.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:61.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="33%" rowspan=2 valign=top style='width:33.16%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:61.0pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>H<sub>2</sub>&#8209;receptor antagonists
  may be administered simultaneously with or staggered from Epclusa at a dose
  that does not exceed doses comparable to famotidine 40&nbsp;mg twice daily.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:72.55pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:72.55pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Velpatasvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:72.55pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8595;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>0.80 (0.70, 0.91)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:72.55pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8595;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>0.81 (0.71, 0.91)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:72.55pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:57.8pt'>
  <td width="27%" rowspan=2 valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:57.8pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=IT-CH style='font-size:10.0pt'>Famotidine</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=IT-CH style='font-size:10.0pt'>(40&nbsp;mg single dose)/ sofosbuvir/
  velpatasvir (400/ 100&nbsp;mg single dose)<sup>c</sup></span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=IT-CH style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Famotidine dosed 12&nbsp;hours prior to Epclusa<sup>d</sup></span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(Increase in gastric pH)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:57.8pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Sofosbuvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:57.8pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8595;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.77 (0.68, 0.87)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:57.8pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8595;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.80 (0.73, 0.88)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:57.8pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="33%" rowspan=2 valign=top style='width:33.16%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:57.8pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:41.9pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:41.9pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Velpatasvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:41.9pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:41.9pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:41.9pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="100%" colspan=6 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
  lang=EN-GB style='font-size:10.0pt'>Proton pump inhibitors</span></i></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:65.6pt'>
  <td width="27%" rowspan=2 valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:65.6pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Omeprazole</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(20&nbsp;mg once daily)/ sofosbuvir/
  velpatasvir (400/ 100&nbsp;mg single dose fasted)<sup>c</sup></span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Omeprazole dosed simultaneously with Epclusa<sup>d</sup></span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Lansoprazole<sup>e</sup></span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Rabeprazole<sup>e</sup></span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Pantoprazole<sup>e</sup></span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Esomeprazole<sup>e</sup></span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(Increase in gastric pH)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:65.6pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Sofosbuvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:65.6pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8595;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.66 (0.55, 0.78)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:65.6pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8595;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.71 (0.60, 0.83)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:65.6pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="33%" rowspan=2 valign=top style='width:33.16%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:65.6pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Co-administration with proton pump
  inhibitors is not recommended. &nbsp;If it is considered necessary to co&#8209;administer,
  then Epclusa should be administered with food and taken 4&nbsp;hours before
  proton pump inhibitor at max doses comparable to omeprazole 20&nbsp;mg.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:83.8pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:83.8pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Velpatasvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:83.8pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8595;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>0.63 (0.50, 0.78)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:83.8pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8595;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>0.64 (0.52, 0.79)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:83.8pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:70.95pt'>
  <td width="27%" rowspan=2 valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:70.95pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Omeprazole</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(20&nbsp;mg once daily)/ sofosbuvir/
  velpatasvir (400/ 100&nbsp;mg single dose fed)<sup>c</sup></span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Omeprazole dosed 4&nbsp;hours after Epclusa<sup>d</sup></span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(Increase in gastric pH)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:70.95pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Sofosbuvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:70.95pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8595;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.79 (0.68, 0.92)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:70.95pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:70.95pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></b></p>
  </td>
  <td width="33%" rowspan=2 valign=top style='width:33.16%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:70.95pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:20.9pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:20.9pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Velpatasvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:20.9pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8595;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>0.67 (0.58, 0.78)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:20.9pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8595;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>0.74 (0.63, 0.86)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:20.9pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="100%" colspan=6 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><span
  lang=EN-GB style='font-size:10.0pt'>ANTIARRHYTHMICS</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Amiodarone</span></p>
  </td>
  <td width="39%" colspan=4 valign=top style='width:39.72%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Interaction not studied.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Effect on amiodarone, velpatasvir, and sofosbuvir
  concentrations unknown.</span></p>
  </td>
  <td width="33%" valign=top style='width:33.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Use only if no other alternative is available. &nbsp;Close
  monitoring is recommended if this medicinal product is administered with Epclusa
  (see sections&nbsp;4.4 and 4.8).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Digoxin</span></p>
  </td>
  <td width="39%" colspan=4 valign=top style='width:39.72%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Interaction only studied with
  velpatasvir.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
  lang=EN-GB style='font-size:10.0pt'>Expected:</span></i></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596; Sofosbuvir</span></p>
  </td>
  <td width="33%" rowspan=3 valign=top style='width:33.16%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Co&#8209;administration of Epclusa with
  digoxin may increase the concentration of digoxin. &nbsp;Caution is warranted
  and therapeutic concentration monitoring of digoxin is recommended when co&#8209;administered
  with Epclusa.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:51.8pt'>
  <td width="27%" rowspan=2 valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:51.8pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=IT-CH style='font-size:10.0pt'>Digoxin (0.25&nbsp;mg single dose)<sup>f</sup>/
  velpatasvir (100&nbsp;mg single dose)</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=IT-CH style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(Inhibition of P&#8209;gp)</span></p>
  </td>
  <td width="39%" colspan=4 valign=top style='width:39.72%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:51.8pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Effect on velpatasvir exposure not
  studied</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
  lang=EN-GB style='font-size:10.0pt'>Expected:</span></i></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596; Velpatasvir</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:51.8pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:51.8pt'>
  <p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
  style='font-size:10.0pt'>Observed:</span></i></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Digoxin</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:51.8pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>1.9 (1.7, 2.1)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:51.8pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>1.3 (1.1, 1.6)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:51.8pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="100%" colspan=6 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><span
  lang=EN-GB style='font-size:10.0pt'>ANTICOAGULANTS</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Dabigatran etexilate</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>(Inhibition of P&#8209;gp)</span></p>
  </td>
  <td width="39%" colspan=4 valign=top style='width:39.72%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Interaction not studied.</span></p>
  <p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
  style='font-size:10.0pt'>Expected:</span></i></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8593; Dabigatran</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8596; Sofosbuvir</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8596; Velpatasvir</span></p>
  </td>
  <td width="33%" valign=top style='width:33.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Clinical monitoring, looking for signs of bleeding
  and anaemia, is recommended when dabigatran etexilate is co-administered with
  Epclusa.&nbsp; A coagulation test helps to identify patients with an
  increased bleeding risk due to increased dabigatran exposure.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Vitamin&nbsp;K antagonists</span></p>
  </td>
  <td width="39%" colspan=4 valign=top style='width:39.72%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Interaction not studied</span></p>
  </td>
  <td width="33%" valign=top style='width:33.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Close monitoring of INR is recommended with all
  vitamin&nbsp;K antagonists.&nbsp; This is due to liver function changes
  during treatment with Epclusa.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="100%" colspan=6 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><span
  lang=EN-GB style='font-size:10.0pt'>ANTICONVULSANTS</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Carbamazepine</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Phenytoin</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Phenobarbital</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>(Induction of P&#8209;gp </span><span lang=EN-GB
  style='font-size:10.0pt'>and CYPs</span><span lang=EN-GB style='font-size:
  10.0pt'>)</span></p>
  </td>
  <td width="39%" colspan=4 valign=top style='width:39.72%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Interaction not studied.</span></p>
  <p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
  style='font-size:10.0pt'>Expected:</span></i></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8595; Sofosbuvir</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8595; Velpatasvir</span></p>
  </td>
  <td width="33%" valign=top style='width:33.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='margin-left:-.45pt;line-height:normal'><span
  lang=EN-GB style='font-size:10.0pt'>Epclusa</span><span lang=EN-GB
  style='font-size:10.0pt'> is contraindicated with carbamazepine,
  phenobarbital and phenytoin, potent P&#8209;gp and CYP&nbsp;inducers (see
  section&nbsp;4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:75.75pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:75.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Oxcarbazepine</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>(Induction of P&#8209;gp and CYPs)</span></p>
  </td>
  <td width="39%" colspan=4 valign=top style='width:39.72%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:75.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Interaction not studied.</span></p>
  <p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
  style='font-size:10.0pt'>Expected:</span></i></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8595; Sofosbuvir</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8595; Velpatasvir</span></p>
  </td>
  <td width="33%" valign=top style='width:33.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:75.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Co&#8209;administration of Epclusa with
  oxcarbazepine is expected to decrease the concentration of sofosbuvir and
  velpatasvir, leading to reduced therapeutic effect of Epclusa.&nbsp; Co&#8209;administration
  is not recommended (see section&nbsp;4.4).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="100%" colspan=6 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><span
  lang=EN-GB style='font-size:10.0pt'>ANTIFUNGALS</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Ketoconazole</span></p>
  </td>
  <td width="39%" colspan=4 valign=top style='width:39.72%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Interaction only studied with velpatasvir</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
  lang=EN-GB style='font-size:10.0pt'>Expected:</span></i></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596; Sofosbuvir</span></p>
  </td>
  <td width="33%" rowspan=3 valign=top style='width:33.16%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>No dose adjustment of Epclusa or
  ketoconazole is required.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:25.7pt'>
  <td width="27%" rowspan=2 valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:25.7pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Ketoconazole (200&nbsp;mg twice daily)/
  velpatasvir (100&nbsp;mg single dose)<sup>d</sup></span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(Inhibition of P&#8209;gp and CYPs)</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Itraconazole<sup>e</sup></span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Voriconazole<sup>e</sup></span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Posaconazole<sup>e</sup></span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Isavuconazole<sup>e</sup></span></p>
  </td>
  <td width="39%" colspan=4 valign=top style='width:39.72%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:25.7pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Effect on ketoconazole exposure not
  studied.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
  lang=EN-GB style='font-size:10.0pt'>Expected:</span></i></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596; Ketoconazole</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:25.65pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:25.65pt'>
  <p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
  style='font-size:10.0pt'>Observed:</span></i></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Velpatasvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:25.65pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>1.3 (1.0, 1.6)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:25.65pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>1.7 (1.4, 2.2)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:25.65pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="100%" colspan=6 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><span
  lang=EN-GB style='font-size:10.0pt'>ANTIMYCOBACTERIALS</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:45.05pt'>
  <td width="27%" rowspan=2 valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:45.05pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Rifampicin (600&nbsp;mg once daily)/
  sofosbuvir (400&nbsp;mg single dose)<sup>d</sup></span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(Induction of P&#8209;gp and CYPs)</span></p>
  </td>
  <td width="39%" colspan=4 valign=top style='width:39.72%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:45.05pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Effect on rifampicin exposure not
  studied.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
  lang=EN-GB style='font-size:10.0pt'>Expected:</span></i></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596; Rifampicin</span></p>
  </td>
  <td width="33%" rowspan=4 valign=top style='width:33.16%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:45.05pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Epclusa</span><span lang=EN-GB
  style='font-size:10.0pt'> is contraindicated with rifampicin, a potent P&#8209;gp
  and CYP inducer (see section&nbsp;4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:45.05pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:45.05pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
  lang=EN-GB style='font-size:10.0pt'>Observed:</span></i></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Sofosbuvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:45.05pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8595;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.23 (0.19, 0.29)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:45.05pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8595;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.28 (0.24, 0.32)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:45.05pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:38.7pt'>
  <td width="27%" rowspan=2 valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:38.7pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Rifampicin (600&nbsp;mg once daily)/
  velpatasvir (100&nbsp;mg single dose)</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(Induction of P&#8209;gp and CYPs)</span></p>
  </td>
  <td width="39%" colspan=4 valign=top style='width:39.72%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:38.7pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Effect on rifampicin exposure not
  studied.</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
  lang=EN-GB style='font-size:10.0pt'>Expected:</span></i></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596; Rifampicin</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:58.15pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:58.15pt'>
  <p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
  style='font-size:10.0pt'>Observed:</span></i></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Velpatasvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:58.15pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8595;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>0.29 (0.23, 0.37)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:58.15pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8595;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>0.18 (0.15, 0.22)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:58.15pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Rifabutin</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Rifapentine</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>(Induction of P&#8209;gp and CYPs)</span></p>
  </td>
  <td width="39%" colspan=4 valign=top style='width:39.72%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Interaction not studied.</span></p>
  <p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
  style='font-size:10.0pt'>Expected:</span></i></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8595; Sofosbuvir</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8595; Velpatasvir</span></p>
  </td>
  <td width="33%" valign=top style='width:33.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Epclusa</span><span lang=EN-GB style='font-size:
  10.0pt'> is contraindicated with rifabutin, a potent P&#8209;gp and CYP
  inducer (see section&nbsp;4.3).</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Co&#8209;administration of Epclusa with rifapentine
  is expected to decrease the concentration of sofosbuvir and velpatasvir,
  leading to reduced therapeutic effect of Epclusa.&nbsp; Co&#8209;administration
  is not recommended (see section&nbsp;4.4).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="100%" colspan=6 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><span
  lang=EN-GB style='font-size:10.0pt'>HIV ANTIVIRAL AGENTS: REVERSE
  TRANSCRIPTASE INHIBITORS</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Tenofovir disoproxil fumarate</span></p>
  </td>
  <td width="72%" colspan=5 valign=top style='width:72.88%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Epclusa</span><span lang=EN-GB style='font-size:
  10.0pt'> has been shown to increase tenofovir exposure (P&#8209;gp-inhibition).&nbsp;
  The increase in tenofovir exposure (AUC and C<sub>max</sub>) was around 40&#8209;80%
  during co-treatment with Epclusa and tenofovir disoproxil
  fumarate/emtricitabine as part of various HIV regimens.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Patients receiving tenofovir disoproxil fumarate and
  Epclusa concomitantly should be monitored for adverse reactions associated
  with tenofovir disoproxil fumarate. &nbsp;Refer to the tenofovir disoproxil
  fumarate-containing product&#8217;s Summary of Product Characteristics for
  recommendations on renal monitoring (see section&nbsp;4.4).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="27%" rowspan=3 valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Efavirenz/ emtricitabine/ tenofovir
  disoproxil fumarate</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(600/ 200/ 300&nbsp;mg once daily)/
  sofosbuvir/ velpatasvir (400/ 100&nbsp;mg once daily)<sup>c, d</sup></span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Efavirenz</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="33%" rowspan=3 valign=top style='width:33.16%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Co&#8209;administration of Epclusa with
  efavirenz/ emtricitabine/ tenofovir disoproxil fumarate is expected to
  decrease the concentration of velpatasvir.&nbsp; Co&#8209;administration of Epclusa
  with efavirenz&#8209;containing regimens is not recommended (see
  section&nbsp;4.4).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Sofosbuvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>1.4 (1.1, 1.7)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Velpatasvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8595;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>0.53 (0.43, 0.64)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8595;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>0.47 (0.39, 0.57)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8595;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>0.43 (0.36, 0.52)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="27%" rowspan=3 valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Emtricitabine/ <b>rilpivirine</b>/
  tenofovir disoproxil fumarate</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(200/ 25/ 300&nbsp;mg once daily)/
  sofosbuvir/ velpatasvir (400/ 100&nbsp;mg once daily)<sup>c, d</sup></span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Rilpivirine</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="33%" rowspan=3 valign=top style='width:33.16%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>No dose adjustment of Epclusa or
  emtricitabine/ rilpivirine/ tenofovir disoproxil fumarate is required.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Sofosbuvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Velpatasvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8596;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="100%" colspan=6 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=Default style='page-break-after:avoid'><b><i><span lang=EN-GB
  style='font-size:10.0pt;color:windowtext'>HIV ANTIVIRAL AGENTS: HIV PROTEASE
  INHIBITORS</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="27%" rowspan=4 valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>Atazanavir</span></b><span lang=EN-GB
  style='font-size:10.0pt'> boosted with ritonavir (300/ 100&nbsp;mg once
  daily)&nbsp;+&nbsp;emtricitabine/ tenofovir disoproxil fumarate (200/
  300&nbsp;mg once daily)/ sofosbuvir/ velpatasvir (400/ 100&nbsp;mg once
  daily)<sup>c, d</sup></span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Atazanavir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>1.4 (1.2, 1.6)</span></p>
  </td>
  <td width="33%" rowspan=4 valign=top style='width:33.16%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>No dose adjustment of Epclusa, atazanavir
  (ritonavir boosted) or emtricitabine/ tenofovir disoproxil fumarate is
  required.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Ritonavir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>1.3 (1.5, 1.4)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:20.65pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:20.65pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Sofosbuvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:20.65pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:20.65pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:20.65pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:37.9pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:37.9pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Velpatasvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:37.9pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>1.6 (1.4, 1.7)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:37.9pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>2.4 (2.2, 2.6)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:37.9pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>4.0 (3.6, 4.5)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="27%" rowspan=4 valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>Darunavir</span></b><span lang=EN-GB
  style='font-size:10.0pt'> boosted with ritonavir (800/ 100&nbsp;mg once
  daily)&nbsp;+&nbsp;emtricitabine/ tenofovir disoproxil fumarate (200/
  300&nbsp;mg once daily)/ sofosbuvir/ velpatasvir (400/ 100&nbsp;mg once
  daily)<sup>c, d</sup></span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Darunavir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="33%" rowspan=4 valign=top style='width:33.16%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>No dose adjustment of Epclusa, darunavir
  (ritonavir boosted) or emtricitabine/ tenofovir disoproxil fumarate is
  required.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Ritonavir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Sofosbuvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8595;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.62 (0.54, 0.71)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8595;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.72 (0.66, 0.80)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Velpatasvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8595;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>0.76 (0.65, 0.89)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8596;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="27%" rowspan=4 valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>Lopinavir</span></b><span lang=EN-GB
  style='font-size:10.0pt'> boosted with ritonavir&nbsp;(4x200&nbsp;mg/
  50&nbsp;mg once daily)&nbsp;+&nbsp;emtricitabine/ tenofovir disoproxil
  fumarate (200/ 300&nbsp;mg once daily)/ sofosbuvir/ velpatasvir (400/
  100&nbsp;mg once daily)<sup>c, d</sup></span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Lopinavir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="33%" rowspan=4 valign=top style='width:33.16%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>No dose adjustment of Epclusa, lopinavir
  (ritonavir boosted) or emtricitabine/ tenofovir disoproxil fumarate is
  required.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Ritonavir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Sofosbuvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8595;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.59 (0.49 0.71)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8595;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.7 (0.6, 0.8)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Velpatasvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8595;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>0.70 (0.59, 0.83)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>1.6 (1.4, 1.9)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="100%" colspan=6 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><span
  lang=EN-GB style='font-size:10.0pt'>HIV ANTIVIRAL AGENTS: INTEGRASE
  INHIBITORS</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="27%" rowspan=3 valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>Raltegravir </span></b><span lang=EN-GB
  style='font-size:10.0pt'>(400&nbsp;mg twice daily)<sup>g</sup>
  +&nbsp;emtricitabine/ tenofovir disoproxil fumarate (200/ 300&nbsp;mg once
  daily)/ sofosbuvir/ velpatasvir (400/ 100&nbsp;mg once daily)<sup>c, d</sup></span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Raltegravir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8595;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.79 (0.42, 1.5)</span></p>
  </td>
  <td width="33%" rowspan=3 valign=top style='width:33.16%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>No dose adjustment of Epclusa,
  raltegravir or emtricitabine/ tenofovir disoproxil fumarate is required.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Sofosbuvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Velpatasvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8596;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="27%" rowspan=5 valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>Elvitegravir</span></b><span lang=EN-GB
  style='font-size:10.0pt'>/ cobicistat/ emtricitabine/ tenofovir alafenamide
  fumarate</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(150/ 150/ 200/ 10&nbsp;mg once daily)/
  sofosbuvir/ velpatasvir (400/ 100&nbsp;mg once daily)<sup>c, d</sup></span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Elvitegravir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="33%" rowspan=5 valign=top style='width:33.16%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>No dose adjustment of Epclusa or
  elvitegravir/ cobicistat/ emtricitabine/ tenofovir alafenamide fumarate is
  required.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Cobicistat</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>2.0 (1.7, 2.5)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Tenofovir alafenamide</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Sofosbuvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>1.4 (1.2, 1.5)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Velpatasvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>1.3 (1.2, 1.5)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>1.5 (1.4, 1.7)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>1.6 (1.4, 1.8)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="27%" rowspan=4 valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>Elvitegravir</span></b><span lang=EN-GB
  style='font-size:10.0pt'>/ cobicistat/ emtricitabine/ tenofovir disoproxil
  fumarate</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(150/ 150/ 200/ 300&nbsp;mg once daily)/
  sofosbuvir/ velpatasvir (400/ 100&nbsp;mg once daily)<sup>c, d</sup></span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Elvitegravir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="33%" rowspan=4 valign=top style='width:33.16%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>No dose adjustment of Epclusa or
  elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil fumarate is
  required.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Cobicistat</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>1.7 (1.5, 1.9)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Sofosbuvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Velpatasvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>1.4 (1.2, 1.5)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:14.8pt'>
  <td width="27%" rowspan=3 valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:14.8pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Dolutegravir (50&nbsp;mg once daily)/
  sofosbuvir/ velpatasvir (400/ 100&nbsp;mg once daily)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:14.8pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Dolutegravir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:14.8pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:14.8pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:14.8pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="33%" rowspan=3 valign=top style='width:33.16%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:14.8pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>No dose adjustment of Epclusa or
  dolutegravir is required.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:17.95pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:17.95pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Sofosbuvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:17.95pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:17.95pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:17.95pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:26.05pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:26.05pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Velpatasvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:26.05pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:26.05pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:26.05pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8596;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="100%" colspan=6 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><span
  lang=EN-GB style='font-size:10.0pt'>HERBAL SUPPLEMENTS</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>St.&nbsp;John&#8217;s wort</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>(Induction of P&#8209;gp and CYPs)</span></p>
  </td>
  <td width="39%" colspan=4 valign=top style='width:39.72%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Interaction not studied.</span></p>
  <p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
  style='font-size:10.0pt'>Expected:</span></i></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8595; Sofosbuvir</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8595; Velpatasvir</span></p>
  </td>
  <td width="33%" valign=top style='width:33.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Epclusa</span><span lang=EN-GB style='font-size:
  10.0pt'> is contraindicated with St.&nbsp;John&#8217;s wort a potent P&#8209;gp
  and CYP inducer (see section&nbsp;4.3).</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="100%" colspan=6 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><span
  lang=EN-GB style='font-size:10.0pt'>HMG&#8209;CoA REDUCTASE INHIBITORS</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Rosuvastatin</span></p>
  </td>
  <td width="39%" colspan=4 valign=top style='width:39.72%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Interaction only studied with velpatasvir</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
  lang=EN-GB style='font-size:10.0pt'>Expected:</span></i></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596; Sofosbuvir</span></p>
  </td>
  <td width="33%" rowspan=3 valign=top style='width:33.16%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Co&#8209;administration of Epclusa with
  rosuvastatin increases the concentration of rosuvastatin, which is associated
  with increased risk of myopathy, including rhabdomyolysis.&nbsp;
  Rosuvastatin, at a dose that does not exceed 10&nbsp;mg, may be administered
  with Epclusa.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt' style='page-break-inside:
  avoid !msorm;height:7.25pt !msorm'>
  <td width="27%" rowspan=2 valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;border:solid windowtext 1.0pt !msorm;
  border-top:none !msorm;padding:0in 5.75pt 0in 5.75pt !msorm;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Rosuvastatin (10&nbsp;mg single dose)/
  velpatasvir (100&nbsp;mg once daily)<sup>d</sup></span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(Inhibition of OATP1B and BCRP)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;border-top:none !msorm;border-left:none !msorm;
  border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
  padding:0in 5.75pt 0in 5.75pt !msorm;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
  lang=EN-GB style='font-size:10.0pt'>Observed:</span></i></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Rosuvastatin</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;border-top:none !msorm;border-left:none !msorm;
  border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
  padding:0in 5.75pt 0in 5.75pt !msorm;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>2.6 (2.3, 2.9)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;border-top:none !msorm;border-left:none !msorm;
  border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
  padding:0in 5.75pt 0in 5.75pt !msorm;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>2.7 (2.5, 2.9)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;border-top:none !msorm;border-left:none !msorm;
  border-bottom:solid windowtext 1.0pt !msorm;border-right:solid windowtext 1.0pt !msorm;
  padding:0in 5.75pt 0in 5.75pt !msorm;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="39%" colspan=4 valign=top style='width:39.72%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Effect on velpatasvir exposure not studied</span></p>
  <p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
  style='font-size:10.0pt'>Expected:</span></i></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8596; Velpatasvir</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Pravastatin</span></p>
  </td>
  <td width="39%" colspan=4 valign=top style='width:39.72%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Interaction only studied with velpatasvir</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
  lang=EN-GB style='font-size:10.0pt'>Expected:</span></i></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596; Sofosbuvir</span></p>
  </td>
  <td width="33%" rowspan=3 valign=top style='width:33.16%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>No dose adjustment of Epclusa or
  pravastatin is required.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="27%" rowspan=2 valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Pravastatin (40&nbsp;mg single dose)/
  velpatasvir (100&nbsp;mg once daily)<sup>d</sup></span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(Inhibition of OATP1B)</span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
  lang=EN-GB style='font-size:10.0pt'>Observed:</span></i></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Pravastatin</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>1.3 (1.1, 1.5)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>1.4 (1.2, 1.5)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="39%" colspan=4 valign=top style='width:39.72%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Effect on velpatasvir exposure not studied</span></p>
  <p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
  style='font-size:10.0pt'>Expected:</span></i></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8596; Velpatasvir</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:91.75pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:91.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Other statins</span></p>
  </td>
  <td width="39%" colspan=4 valign=top style='width:39.72%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:91.75pt'>
  <p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
  style='font-size:10.0pt'>Expected:</span></i></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8593; Statins</span></p>
  </td>
  <td width="33%" valign=top style='width:33.16%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:91.75pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Interactions cannot be excluded with other HMG&#8209;CoA
  reductase inhibitors. &nbsp;When co&#8209;administered with Epclusa, careful
  monitoring for statin adverse reactions should be undertaken and a reduced
  dose of statins should be considered if required.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:11.75pt'>
  <td width="100%" colspan=6 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:11.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><span
  lang=EN-GB style='font-size:10.0pt'>NARCOTIC ANALGESICS</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:22.75pt'>
  <td width="27%" rowspan=3 valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:22.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Methadone</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(Methadone maintenance therapy [30 to
  130&nbsp;mg daily])/ sofosbuvir (400&nbsp;mg once daily)<sup>d</sup></span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:22.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>R&#8209;methadone</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:22.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:22.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:22.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="33%" rowspan=4 valign=top style='width:33.16%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:22.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>No dose adjustment of Epclusa or
  methadone is required.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>S&#8209;methadone</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Sofosbuvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>1.3 (1.0, 1.7)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:34.55pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:34.55pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Methadone</span></p>
  </td>
  <td width="39%" colspan=4 valign=top style='width:39.72%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:34.55pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Interaction only studied with sofosbuvir</span></p>
  <p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
  style='font-size:10.0pt'>Expected:</span></i></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8596; Velpatasvir</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:10.95pt'>
  <td width="100%" colspan=6 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:10.95pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><span
  lang=EN-GB style='font-size:10.0pt'>IMMUNOSUPPRESSANTS</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:22.75pt'>
  <td width="27%" rowspan=2 valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:22.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=IT-CH style='font-size:10.0pt'>Ciclosporin</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=IT-CH style='font-size:10.0pt'>(600&nbsp;mg single dose)/ sofosbuvir
  (400&nbsp;mg single dose)<sup>f</sup></span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:22.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Ciclosporin</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:22.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:22.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:22.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="33%" rowspan=4 valign=top style='width:33.16%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:22.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>No dose adjustment of Epclusa or
  ciclosporin is required.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Sofosbuvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>2.5 (1.9, 3.5)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>4.5 (3.3, 6.3)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:22.75pt'>
  <td width="27%" rowspan=2 valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:22.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=IT-CH style='font-size:10.0pt'>Ciclosporin</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=IT-CH style='font-size:10.0pt'>(600&nbsp;mg single dose)<sup>f</sup>/
  velpatasvir (100&nbsp;mg single dose)<sup>d</sup></span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:22.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Ciclosporin</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:22.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:22.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8595;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.88 (0.78, 1.0)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:22.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Velpatasvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>1.6 (1.2, 2.0)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>2.0 (1.5, 2.7)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:34.55pt'>
  <td width="27%" rowspan=2 valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:34.55pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Tacrolimus</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(5&nbsp;mg single dose)<sup>f</sup>/
  sofosbuvir (400&nbsp;mg single dose)<sup>d</sup></span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:34.55pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Tacrolimus</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:34.55pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8595;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.73 (0.59, 0.90)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:34.55pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>1.1 (0.84, 1.4)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:34.55pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="33%" rowspan=3 valign=top style='width:33.16%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:34.55pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>No dose adjustment of Epclusa or
  tacrolimus is required.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Sofosbuvir</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8595;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.97 (0.65, 1.4)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>1.1 (0.81, 1.6)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:34.55pt'>
  <td width="27%" valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:34.55pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Tacrolimus</span></p>
  </td>
  <td width="39%" colspan=4 valign=top style='width:39.72%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:34.55pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Effect on velpatasvir exposure not studied.</span></p>
  <p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB
  style='font-size:10.0pt'>Expected:</span></i></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>&#8596; Velpatasvir</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:10.95pt'>
  <td width="100%" colspan=6 valign=top style='width:100.0%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:10.95pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><i><span
  lang=EN-GB style='font-size:10.0pt'>ORAL CONTRACEPTIVES</span></i></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:70.25pt'>
  <td width="27%" rowspan=3 valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:70.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Norgestimate/ ethinyl estradiol
  (norgestimate 0.180&nbsp;mg/ 0.215&nbsp;mg/ 0.25&nbsp;mg/ ethinyl estradiol
  0.025&nbsp;mg)/ sofosbuvir (400&nbsp;mg once daily)<sup>d</sup></span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:70.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Norel-gestromin</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:70.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:70.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:70.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="33%" rowspan=6 valign=top style='width:33.16%;border-top:none;
  border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:70.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>No dose adjustment of oral contraceptives
  is required.</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Norgestrel</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>1.2 (0.98, 1.5)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>1.2 (1.0, 1.5)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Ethinyl estradiol</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:22.75pt'>
  <td width="27%" rowspan=3 valign=top style='width:27.12%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.75pt 0in 5.75pt;height:22.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Norgestimate/ ethinyl estradiol
  (norgestimate 0.180&nbsp;mg/ 0.215&nbsp;mg/ 0.25&nbsp;mg/ ethinyl estradiol
  0.025&nbsp;mg)/ velpatasvir (100&nbsp;mg once daily)<sup>d</sup></span></p>
  </td>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:22.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Norel-gestromin</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:22.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:22.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:22.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Norgestrel</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:7.25pt'>
  <td width="14%" valign=top style='width:14.1%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Ethinyl estradiol</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8593;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>1.4 (1.2, 1.7)</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8596;</span></p>
  </td>
  <td width="8%" valign=top style='width:8.54%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.75pt 0in 5.75pt;height:7.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&#8595;</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.83 (0.65, 1.1)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>a&nbsp;&nbsp;&nbsp;&nbsp; Mean
ratio (90%&nbsp;CI) of co&#8209;administered drug pharmacokinetics of study
medicinal products alone or in combination.&nbsp; No effect&nbsp;=&nbsp;1.00.</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>b&nbsp;&nbsp;&nbsp; All
interaction studies conducted in healthy volunteers.</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>c&nbsp;&nbsp;&nbsp;&nbsp; Administered
as Epclusa.</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>d&nbsp;&nbsp;&nbsp; Lack
of pharmacokinetics interaction bounds 70&#8209;143%.</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>e&nbsp;&nbsp;&nbsp;&nbsp; These
are medicinal products within class where similar interactions could be
predicted.</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>f&nbsp;&nbsp;&nbsp;&nbsp; Bioequivalence/Equivalence
boundary 80&#8209;125%.</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
normal'><span lang=EN-GB style='font-size:9.0pt'>g&nbsp;&nbsp;&nbsp; Lack of
pharmacokinetics interaction bounds 50&#8209;200%.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.6&nbsp;&nbsp;&nbsp;&nbsp; </span></b><b><span
lang=EN-GB>Fertility, p</span></b><b><span lang=EN-GB>regnancy and lactation</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Pregnancy</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>There are no or
limited amount of data (less than 300&nbsp;pregnancy outcomes) from the use of
sofosbuvir, velpatasvir or Epclusa in pregnant women.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Sofosbuvir</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Animal studies
do not indicate direct or indirect harmful effects with respect to reproductive
toxicity (see section&nbsp;5.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It has not been
possible to fully estimate exposure margins achieved for sofosbuvir in the rat
relative to the exposure in humans at the recommended clinical dose (see
section&nbsp;5.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Velpatasvir</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Animal studies have
shown a possible link to reproductive toxicity (see section&nbsp;5.3).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>As a precautionary measure, Epclusa use is not recommended during
pregnancy.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Breast&#8209;feeding</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is unknown
whether sofosbuvir, metabolites of sofosbuvir or velpatasvir are excreted in
human milk.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Available
pharmacokinetic data in animals have shown excretion of velpatasvir and
metabolites of sofosbuvir in milk.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='layout-grid-mode:line'>A risk to the newborns/infants cannot
be excluded.&nbsp; Therefore, </span><span lang=EN-GB>Epclusa<span
style='layout-grid-mode:line'> should not be used during breast&#8209;feeding.</span></span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Fertility</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No human data on
the effect of Epclusa on fertility are available.&nbsp; Animal studies do not
indicate harmful effects of sofosbuvir or velpatasvir on fertility.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If ribavirin is
co&#8209;administered with </span><span lang=EN-GB>Epclusa, refer to the
Summary of Product Characterisitics for ribavirin for detailed recommendations
regarding pregnancy, contraception, and breast&#8209;feeding.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.7&nbsp;&nbsp;&nbsp;&nbsp; Effects
on ability to drive and use machines</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Epclusa has no
or negligible influence on the ability to drive and use machines.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.8&nbsp;&nbsp;&nbsp;&nbsp; Undesirable
effects</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><u><span lang=EN-GB>Summary of the safety
profile</span></u></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>The
safety assessment of </span><span lang=EN-GB style='font-size:11.0pt;
color:windowtext'>Epclusa</span><span lang=EN-GB style='font-size:11.0pt;
color:windowtext'> was based on pooled Phase&nbsp;3 clinical study data from patients
with genotype&nbsp;1, 2, 3, 4, 5 or 6 HCV infection (with or without compensated
cirrhosis) including 1,035 patients who received Epclusa for 12&nbsp;weeks.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='layout-grid-mode:line'>The proportion of </span><span lang=EN-GB>patients<span
style='layout-grid-mode:line'> who permanently discontinued treatment due to
adverse events was 0.2% and the proportion of patients who experienced any
severe adverse events was 3.2% for </span>patients<span style='layout-grid-mode:
line'> receiving </span>Epclusa<span style='layout-grid-mode:line'> for
12&nbsp;weeks. &nbsp;In clinical studies, headache, fatigue and nausea were the
most common (incidence &#8805;&nbsp;10%) treatment emergent adverse events
reported in </span>patients<span style='layout-grid-mode:line'> treated with
12&nbsp;weeks of </span>Epclusa<span style='layout-grid-mode:line'>.&nbsp;
These and other adverse events were reported at a similar frequency in placebo
treated patients compared with Epclusa treated patients.</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Patients<span style='layout-grid-mode:line'> with decompensated cirrhosis</span></span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='layout-grid-mode:line'>The safety profile of Epclusa has been evaluated
in one open&#8209;label study in which </span><span lang=EN-GB>patients<span
style='layout-grid-mode:line'> with CPT Class&nbsp;B cirrhosis received </span>Epclusa<span
style='layout-grid-mode:line'> for 12&nbsp;weeks (n&nbsp;=&nbsp;90), </span>Epclusa
<span style='layout-grid-mode:line'>+ RBV for 12&nbsp;weeks (n&nbsp;=&nbsp;87)
or </span>Epclusa<span style='layout-grid-mode:line'> for 24&nbsp;weeks (n&nbsp;=&nbsp;90).
&nbsp;The adverse events observed were consistent with expected clinical
sequelae of decompensated liver disease, or the known toxicity profile of
ribavirin for </span>patients<span style='layout-grid-mode:line'> receiving </span>Epclusa<span
style='layout-grid-mode:line'> in combination with ribavirin.</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='layout-grid-mode:line'>Among the 87&nbsp;</span><span lang=EN-GB>patients<span
style='layout-grid-mode:line'> who were treated with </span>Epclusa <span
style='layout-grid-mode:line'>+ RBV for 12&nbsp;weeks, decreases in haemoglobin
to less than 10&nbsp;g/dL and 8.5&nbsp;g/dL during treatment were experienced
by 23% and 7%&nbsp;</span>patients, respectively.<span style='layout-grid-mode:
line'>&nbsp; Ribavirin was discontinued in 15% of </span>patients<span
style='layout-grid-mode:line'> treated with </span>Epclusa <span
style='layout-grid-mode:line'>+ RBV for 12&nbsp;weeks due to adverse events.</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='layout-grid-mode:line'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Description of selected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Cardiac arrhythmias</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Cases of severe
bradycardia and heart block have been observed when sofosbuvir-containing
regimens are used in combination with amiodarone and/or other medicinal
products that lower heart rate (see sections&nbsp;4.4 and&nbsp;4.5).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal><i><span lang=EN-GB>Skin disorders</span></i></p>

<p class=MsoNormal><span lang=EN-GB>Frequency Not known: Stevens-Johnson
syndrome</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Reporting of suspected adverse reactions</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Reporting
suspected adverse reactions after authorisation of the medicinal product is
important.&nbsp; It allows continued monitoring of the benefit/risk balance of
the medicinal product.&nbsp; Healthcare professionals are asked to report any
suspected adverse reactions via <span style='color:black;background:#BFBFBF'>the
national reporting system listed in </span></span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:black;background:#BFBFBF;text-decoration:none'>Appendix&nbsp;V</span></a></span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.9&nbsp;&nbsp;&nbsp;&nbsp; Overdose</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default style='text-autospace:ideograph-numeric ideograph-other'><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>The highest documented
doses of sofosbuvir and velpatasvir were a single dose of 1,200&nbsp;mg and a
single dose of 500&nbsp;mg, respectively.&nbsp; In these healthy volunteer
studies, there were no untoward effects observed at these dose levels, and
adverse events were similar in frequency and severity to those reported in the
placebo groups.&nbsp; The effects of higher doses/exposures are not known.</span></p>

<p class=Default style='text-autospace:ideograph-numeric ideograph-other'><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No specific
antidote is available for overdose with Epclusa. &nbsp;If overdose occurs the
patient must be monitored for evidence of toxicity. &nbsp;Treatment of overdose
with Epclusa consists of general supportive measures including monitoring of
vital signs, as well as observation of the clinical status of the patient. &nbsp;Haemodialysis
can efficiently remove the predominant circulating metabolite of sofosbuvir, GS&#8209;331007,
with an extraction ratio of 53%.&nbsp; Haemodialysis is unlikely to result in
significant removal of velpatasvir, since velpatasvir is highly bound to plasma
protein.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACOLOGICAL
PROPERTIES</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.1&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic
properties</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Pharmacotherapeutic
group: </span><span lang=EN-GB>Direct acting antiviral</span><span lang=EN-GB>,
ATC code: </span><span lang=EN-GB>J05AP55</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Mechanism of action</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sofosbuvir is a
pan&#8209;genotypic inhibitor of the HCV NS5B RNA&#8209;dependent
RNA&nbsp;polymerase, which is essential for viral replication.&nbsp; Sofosbuvir
is a nucleotide prodrug that undergoes intracellular metabolism to form the
pharmacologically active uridine analogue triphosphate (GS&#8209;461203), which
can be incorporated into HCV&nbsp;RNA by the NS5B&nbsp;polymerase and acts as a
chain terminator.&nbsp; GS&#8209;461203 (the active metabolite of sofosbuvir)
is neither an inhibitor of human DNA and RNA&nbsp;polymerases nor an inhibitor
of mitochondrial RNA&nbsp;polymerase.</span></p>

<p class=Default style='text-autospace:ideograph-numeric ideograph-other'><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default style='text-autospace:ideograph-numeric ideograph-other'><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>Velpatasvir is a HCV
inhibitor targeting the HCV&nbsp;NS5A protein, which is essential for both RNA
replication and the assembly of HCV virions. &nbsp;<i>In&nbsp;vitro</i>
resistance selection and cross-resistance studies indicate velpatasvir targets
NS5A as its mode of action.</span></p>

<p class=Default style='text-autospace:ideograph-numeric ideograph-other'><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Antiviral activity</span></u></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>The 50% effective concentration (EC<sub>50</sub>) values of sofosbuvir
and velpatasvir against full&#8209;length or chimeric replicons encoding NS5B
and NS5A sequences from the laboratory strains are presented in Table&nbsp;4. &nbsp;The
EC<sub>50</sub> values of sofosbuvir and velpatasvir against clinical isolates
are presented in Table&nbsp;5.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>Table&nbsp;4: Activity of sofosbuvir and velpatasvir
against full&#8209;length or chimeric laboratory replicons</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid;height:23.7pt'>
   <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:23.7pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Replicon genotype</span></b></p>
   </td>
   <td width=142 valign=top style='width:106.3pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:23.7pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Sofosbuvir EC<sub>50</sub>, nM<sup>a</sup></span></b></p>
   </td>
   <td width=151 valign=top style='width:113.4pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:23.7pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Velpatasvir EC<sub>50</sub>, nM<sup>a</sup></span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>1a</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>40</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.014</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>1b</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>110</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.016</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>2a</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>50</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.005&#8209;0.016<sup>c</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>2b</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>15<sup>b</sup></span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.002&#8209;0.006<sup>c</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>3a</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>50</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.004</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>4a</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>40</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.009</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>4d</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>NA</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.004</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>5a</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>15<sup>b</sup></span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.021&#8209;0.054<sup>d</sup></span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:3.2pt'>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:3.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>6a</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:3.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>14<sup>b</sup></span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:3.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.006&#8209;0.009</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=102 valign=top style='width:76.3pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>6e</span></p>
  </td>
  <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>NA</span></p>
  </td>
  <td width=151 valign=top style='width:113.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.130<sup>d</sup></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB style='font-size:9.0pt'>NA&nbsp;=&nbsp;Not available</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-size:9.0pt'>a&nbsp;&nbsp;&nbsp;&nbsp; Mean value from multiple
experiments of same laboratory replicon.</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-size:9.0pt'>b&nbsp;&nbsp;&nbsp; Stable chimeric 1b replicons
carrying NS5B genes from genotype&nbsp;2b, 5a or 6a were used for testing.</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-size:9.0pt'>c&nbsp;&nbsp;&nbsp;&nbsp; Data from various strains of
full length NS5A replicons or chimeric NS5A replicons carrying full&#8209;length
NS5A genes that contain L31 or M31 polymorphisms.</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-size:9.0pt'>d&nbsp;&nbsp;&nbsp; Data
from a chimeric NS5A replicon carrying NS5A amino acids 9&#8209;184.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>Table&nbsp;5: Activity of sofosbuvir and velpatasvir against
transient replicons containing NS5A or NS5B from clinical isolates</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid;height:14.3pt'>
   <td width=73 rowspan=2 valign=top style='width:55.05pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:14.3pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Replicon genotype</span></b></p>
   </td>
   <td width=246 colspan=2 valign=top style='width:184.25pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:14.3pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Replicons containing NS5B from clinical
   isolates</span></b></p>
   </td>
   <td width=246 colspan=2 valign=top style='width:184.3pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:14.3pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Replicons containing NS5A from clinical
   isolates</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Number of clinical isolates</span></b></p>
   </td>
   <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Median sofosbuvir EC<sub>50</sub>, nM
   (range)</span></b></p>
   </td>
   <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Number of clinical isolates</span></b></p>
   </td>
   <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Median velpatasvir EC<sub>50</sub>, nM
   (range)</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=73 valign=top style='width:55.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>1a</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>67</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>62 (29&#8209;128)</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>23</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.019 (0.011&#8209;0.078)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=73 valign=top style='width:55.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>1b</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>29</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>102 (45&#8209;170)</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>34</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.012 (0.005&#8209;0.500)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=73 valign=top style='width:55.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>2a</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>15</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>29 (14&#8209;81)</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>8</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.011 (0.006&#8209;0.364)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=73 valign=top style='width:55.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>2b</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>NA</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>NA</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>16</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.002 (0.0003&#8209;0.007)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=73 valign=top style='width:55.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>3a</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>106</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>81 (24&#8209;181)</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>38</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.005 (0.002&#8209;1.871)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=73 valign=top style='width:55.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>4a</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>NA</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>NA</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>5</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.002 (0.001&#8209;0.004)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=73 valign=top style='width:55.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>4d</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>NA</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>NA</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>10</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.007 (0.004&#8209;0.011)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=73 valign=top style='width:55.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>4r</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>NA</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>NA</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>7</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.003 (0.002&#8209;0.006)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=73 valign=top style='width:55.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>5a</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>NA</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>NA</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>42</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.005 (0.001&#8209;0.019)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:3.2pt'>
  <td width=73 valign=top style='width:55.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:3.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>6a</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:3.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>NA</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:3.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>NA</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:3.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>26</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:3.2pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.007 (0.0005&#8209;0.113)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=73 valign=top style='width:55.05pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>6e</span></p>
  </td>
  <td width=123 valign=top style='width:92.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>NA</span></p>
  </td>
  <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>NA</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>15</span></p>
  </td>
  <td width=132 valign=top style='width:99.25pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0.024 (0.005&#8209;0.433))</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB style='font-size:9.0pt'>NA&nbsp;=&nbsp;Not available</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The presence of
40% human serum had no effect on the anti&#8209;HCV activity of sofosbuvir but
reduced the anti&#8209;HCV activity of velpatasvir by 13&#8209;fold against
genotype&nbsp;1a HCV replicons.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Evaluation of
sofosbuvir in combination with velpatasvir showed no antagonistic effect in
reducing HCV&nbsp;RNA levels in replicon cells.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Resistance</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>In cell culture</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>HCV replicons
with reduced susceptibility to sofosbuvir have been selected in cell culture
for multiple genotypes including 1b, 2a, 2b, 3a, 4a, 5a and 6a.&nbsp; Reduced
susceptibility to sofosbuvir was associated with the primary NS5B substitution
S282T in all replicon genotypes examined.&nbsp; Site-directed mutagenesis of
the S282T substitution in replicons of genotype&nbsp;1 to 6 conferred 2&#8209;
to 18&#8209;fold reduced susceptibility to sofosbuvir and reduced the
replication viral capacity by 89% to 99% compared to the corresponding
wild-type.&nbsp; In biochemical assays, the ability of the active triphosphate
of sofosbuvir (GS&#8209;461203) to inhibit recombinant NS5B polymerase from
genotypes&nbsp;1b, 2a, 3a and 4a expressing the S282T substitution was reduced
compared to its ability to inhibit wild-type recombinant NS5B polymerase, as
indicated by a 8.5&#8209; to 24&#8209;fold increase in the 50% inhibitory
concentration (IC<sub>50</sub>).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>In&nbsp;vitro</span></i><span
lang=EN-GB> selection of HCV replicons with reduced susceptibility to
velpatasvir was performed in cell culture for multiple genotypes including 1a,
1b, 2a, 3a, 4a, 5a and 6a.&nbsp; Variants were selected at NS5A resistance
associated positions 24, 28, 30, 31, 32, 58, 92 and 93. &nbsp;The resistance
associated variants (RAVs) selected in 2 or more genotypes were F28S, L31I/V
and Y93H.&nbsp; Site-directed mutagenesis of known NS5A&nbsp;RAVs showed that
substitutions conferring a &gt;&nbsp;100&#8209;fold reduction in velpatasvir
susceptibility are M28G, A92K and Y93H/N/R/W in genotype&nbsp;1a, A92K in
genotype&nbsp;1b, C92T and Y93H/N in genotype&nbsp;2b, Y93H in genotype&nbsp;3,
and L31V and P32A/L/Q/R in genotype&nbsp;6.&nbsp; No individual substitutions
tested in genotypes&nbsp;2a, 4a, or 5a conferred a &gt;&nbsp;100&#8209;fold
reduction in velpatasvir susceptibility. &nbsp;Combinations of these variants
often showed greater reductions in susceptibility to velpatasvir than single
RAVs alone.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>In clinical studies</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Studies in patients without cirrhosis and patients with compensated
cirrhosis</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In a pooled
analysis of patients without cirrhosis or with compensated cirrhosis who
received Epclusa for 12&nbsp;weeks in three Phase&nbsp;3 studies, 12&nbsp;patients
(2 with genotype&nbsp;1 and 10 with genotype&nbsp;3) qualified for resistance
analysis due to virologic failure.&nbsp; One additional patient with genotype&nbsp;3
HCV infection at baseline was reinfected with genotype&nbsp;1a HCV at virologic
failure and was excluded from the virological analysis.&nbsp; No patients with
genotype&nbsp;2, 4, 5, or 6 HCV infection experienced virologic failure.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Of the 2
genotype&nbsp;1 virologic failure patients, one patient had virus with emergent
NS5A&nbsp;RAV Y93N and the other patient had virus with emergent NS5A&nbsp;RAVs
L31I/V and Y93H at virologic failure. &nbsp;Both patients had virus at baseline
harboring NS5A&nbsp;RAVs.&nbsp; No NS5B nucleoside inhibitor (NI) RAVs were
observed at failure in the 2&nbsp;patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Of the 10
genotype&nbsp;3 virologic failure patients, Y93H was observed in all 10&nbsp;patients
at failure (6 had Y93H emerge post-treatment and 4&nbsp;patients had Y93H at
baseline and post-treatment).&nbsp; No NS5B&nbsp;NI&nbsp;RAVs were observed at
failure in the 10&nbsp;patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Studies in patients with decompensated cirrhosis</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In one Phase&nbsp;3
study in patients with decompensated cirrhosis who received Epclusa + RBV for
12&nbsp;weeks, 3&nbsp;patients (1 with genotype&nbsp;1 and 2 with
genotype&nbsp;3) qualified for resistance analysis due to virologic
failure.&nbsp; No patients with genotype&nbsp;2 or 4 HCV infection in the Epclusa
+ RBV 12&nbsp;weeks group experienced virologic failure.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The 1 virologic
failure patient with genotype&nbsp;1 HCV had no NS5A or NS5B&nbsp;RAVs at
failure.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Of the 2 genotype&nbsp;3
virologic failure patients, one had NS5A&nbsp;RAV Y93H emerge at failure.&nbsp;
Another patient had virus with Y93H at baseline and virologic failure and also
developed low levels (&lt;&nbsp;5%) of NS5B&nbsp;NI&nbsp;RAVs N142T and E237G
at failure.&nbsp; Pharmacokinetic data from this patient was consistent with
non-adherence to treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In this study,
2&nbsp;patients treated with Epclusa for 12 or 24&nbsp;weeks without ribavirin
had emergent NS5B S282T at low levels (&lt;&nbsp;5%) along with L159F.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Effect of baseline HCV resistance-associated variants on treatment outcome</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Studies in patients without cirrhosis and patients with compensated
cirrhosis</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Analyses were
conducted to explore the association between pre-existing baseline NS5A&nbsp;RAVs
and treatment outcome for patients without cirrhosis or with compensated
cirrhosis in three Phase&nbsp;3 clinical studies (ASTRAL&#8209;1, ASTRAL&#8209;2
and ASTRAL&#8209;3).&nbsp; Of the 1,035&nbsp;patients treated with
sofosbuvir/velpatasvir in the three Phase&nbsp;3 clinical studies, 1,023&nbsp;patients
were included in the analysis of NS5A&nbsp;RAVs; 7&nbsp;patients were excluded
as they neither achieved sustained virologic response (SVR12) nor had virologic
failure and 5&nbsp;additional patients were excluded as NS5A gene sequencing
failed.&nbsp; In the pooled analysis of the Phase&nbsp;3 studies, 380/1,023
(37%) patients&#8217; virus had baseline NS5A&nbsp;RAVs.&nbsp; Genotype&nbsp;2,
4, and 6 HCV&#8209;infected patients had a higher prevalence of NS5A&nbsp;RAVs
(70%, 63% and 52%, respectively) compared to genotype&nbsp;1 (23%), genotype&nbsp;3
(16%), and genotype&nbsp;5 (18%) HCV&#8209;infected patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Baseline RAVs
had no relevant impact on SVR12 rates in patients infected with genotype&nbsp;1,
2, 4, 5 and 6 HCV, as summarised in Table&nbsp;6. &nbsp;Genotype&nbsp;3
infected patients with the NS5A RAV Y93H at baseline had a lower SVR12 rate
than patients without Y93H after treatment with Epclusa for </span><span
lang=EN-GB>12&nbsp;weeks</span><span lang=EN-GB>, as summarised in Table&nbsp;7.
&nbsp;In the ASTRAL&#8209;3 study, the Y93H RAV was detected at baseline in 9%
of patients treated with Epclusa.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>Table&nbsp;6: SVR12 in patients with or without baseline
NS5A&nbsp;RAVs by HCV genotype (studies ASTRAL&#8209;1, ASTRAL&#8209;2 and
ASTRAL&#8209;3)</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid;height:14.3pt'>
   <td width=121 rowspan=2 valign=top style='width:90.45pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:14.3pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></b></p>
   </td>
   <td width=491 colspan=4 valign=top style='width:368.55pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:14.3pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Epclusa
   12&nbsp;weeks</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Genotype&nbsp;1</span></b></p>
   </td>
   <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Genotype&nbsp;3</span></b></p>
   </td>
   <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Genotypes&nbsp;2, 4, 5 or 6</span></b></p>
   </td>
   <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Total</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=121 style='width:90.45pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>With any baseline NS5A&nbsp;RAVs</span></p>
  </td>
  <td width=113 style='width:85.05pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>97% (73/75)</span></p>
  </td>
  <td width=123 style='width:92.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>88% (38/43)</span></p>
  </td>
  <td width=142 style='width:106.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>100%
  (262/262)</span></p>
  </td>
  <td width=113 style='width:85.05pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>98%
  (373/380)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=121 style='width:90.45pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Without baseline NS5A&nbsp;RAVs</span></p>
  </td>
  <td width=113 style='width:85.05pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEAEnBodyText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB style='font-size:10.0pt'>100% (251/251)</span></p>
  </td>
  <td width=123 style='width:92.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEAEnBodyText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB style='font-size:10.0pt'>97% (225/231)</span></p>
  </td>
  <td width=142 style='width:106.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEAEnBodyText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB style='font-size:10.0pt'>100% (161/161)</span></p>
  </td>
  <td width=113 style='width:85.05pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEAEnBodyText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB style='font-size:10.0pt'>99% (637/643)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Table&nbsp;7: SVR12 in patients with and without baseline Y93H, 1%
Cut-off (Resistance Analysis Population Set) ASTRAL 3</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=608
 style='width:455.7pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid;height:15.1pt'>
   <td width=192 nowrap rowspan=2 valign=bottom style='width:144.25pt;
   border:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt;height:15.1pt'></td>
   <td width=415 nowrap colspan=3 style='width:311.45pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 3.5pt 0in 3.5pt;height:15.1pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Epclusa
   12&nbsp;Weeks</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid;height:30.65pt'>
   <td width=127 nowrap style='width:95.15pt;border-top:none;border-left:none;
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt;height:30.65pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>All Subjects</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;274)</span></b></p>
   </td>
   <td width=142 nowrap style='width:106.35pt;border-top:none;border-left:none;
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt;height:30.65pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Cirrhotic</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;80)</span></b></p>
   </td>
   <td width=147 nowrap style='width:109.95pt;border-top:none;border-left:none;
   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 3.5pt 0in 3.5pt;height:30.65pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Non-Cirrhotic</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;197)</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid;height:15.1pt'>
  <td width=192 nowrap style='width:144.25pt;border-top:none;border-left:solid windowtext 1.0pt;
  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt;
  height:15.1pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Overall</span></p>
  </td>
  <td width=127 nowrap style='width:95.15pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:15.1pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>95.3% (263/274) </span></p>
  </td>
  <td width=142 nowrap style='width:106.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:15.1pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>91.3% (73/80) </span></p>
  </td>
  <td width=147 nowrap style='width:109.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:15.1pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>97.9% (190/194) </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:15.1pt'>
  <td width=192 nowrap style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt;height:15.1pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>95%&nbsp;CI</span></p>
  </td>
  <td width=127 nowrap style='width:95.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:15.1pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>92.9% to 98.0%</span></p>
  </td>
  <td width=142 nowrap style='width:106.35pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:15.1pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>82.8% to 96.4%</span></p>
  </td>
  <td width=147 nowrap style='width:109.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:15.1pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>92.8% to 98.6%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:15.1pt'>
  <td width=192 nowrap style='width:144.25pt;border-top:none;border-left:solid windowtext 1.0pt;
  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt;
  height:15.1pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>SVR with Y93H</span></p>
  </td>
  <td width=127 nowrap style='width:95.15pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:15.1pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>84.0% (21/25) </span></p>
  </td>
  <td width=142 nowrap style='width:106.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:15.1pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>50.0% (2/4) </span></p>
  </td>
  <td width=147 nowrap style='width:109.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:15.1pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>90.5% (19/21) </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:15.1pt'>
  <td width=192 nowrap style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt;height:15.1pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>95%&nbsp;CI</span></p>
  </td>
  <td width=127 nowrap style='width:95.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:15.1pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>63.9% to 95.5%</span></p>
  </td>
  <td width=142 nowrap style='width:106.35pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:15.1pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>6.8% to 93.2%</span></p>
  </td>
  <td width=147 nowrap style='width:109.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:15.1pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>69.6% to 98.8%</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:15.1pt'>
  <td width=192 nowrap style='width:144.25pt;border-top:none;border-left:solid windowtext 1.0pt;
  border-bottom:none;border-right:solid windowtext 1.0pt;padding:0in 3.5pt 0in 3.5pt;
  height:15.1pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>SVR without Y93H</span></p>
  </td>
  <td width=127 nowrap style='width:95.15pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:15.1pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>96.4% (242/249)</span></p>
  </td>
  <td width=142 nowrap style='width:106.35pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:15.1pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>93.4% (71/76) </span></p>
  </td>
  <td width=147 nowrap style='width:109.95pt;border:none;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:15.1pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>98.8% (171/173) </span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:15.1pt'>
  <td width=192 nowrap style='width:144.25pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 3.5pt 0in 3.5pt;height:15.1pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>95%&nbsp;CI</span></p>
  </td>
  <td width=127 nowrap style='width:95.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:15.1pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>94.3% to 98.9%</span></p>
  </td>
  <td width=142 nowrap style='width:106.35pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:15.1pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>85.3% to 97.8%</span></p>
  </td>
  <td width=147 nowrap style='width:109.95pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 3.5pt 0in 3.5pt;height:15.1pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>95.9% to 99.9%</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The NS5B NI RAV
S282T was not detected in the baseline NS5B sequence of any patient in Phase&nbsp;3
studies.&nbsp; SVR12 was achieved in all 77&nbsp;patients who had baseline NS5B&nbsp;NI&nbsp;RAVs
including N142T, L159F, E/N237G, C/M289L/I, L320F/I/V, V321A/I, and
S282G+V321I.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Studies in patients with decompensated cirrhosis (CPT Class&nbsp;B)</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Analyses were
conducted to explore the association between pre-existing baseline NS5A&nbsp;RAVs
and treatment outcome for patients with decompensated cirrhosis in one Phase&nbsp;3
study (ASTRAL&#8209;4).&nbsp; Of the 87&nbsp;patients treated with Epclusa + RBV,
85&nbsp;patients were included in the analysis of NS5A&nbsp;RAVs; 2&nbsp;patients
were excluded as they neither achieved SVR12 nor had virologic failure.&nbsp;
Among the patients who received treatment with Epclusa + RBV for 12&nbsp;weeks,
29% (25/85) of patients had baseline virus with NS5A&nbsp;RAVs: 29% (19/66),
75% (3/4), 15% (2/13), and 50% (1/2) for patients with genotype&nbsp;1, 2, 3
and 4 HCV, respectively.</span></p>

<p class=EMEAEnBodyText align=left style='margin:0in;text-align:left'><span
lang=EN-GB>&nbsp;</span></p>

<p class=EMEAEnBodyText align=left style='margin:0in;text-align:left'><span
lang=EN-GB>SVR12 in patients with or without baseline NS5A&nbsp;RAVs in the Epclusa
+ RBV 12&nbsp;week group for this study is shown in Table&nbsp;8.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><b><span lang=EN-GB>Table&nbsp;8: SVR12 in patients with or without baseline
NS5A&nbsp;RAVs by HCV genotype (study ASTRAL&#8209;4)</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid;height:14.3pt'>
   <td width=121 rowspan=2 valign=top style='width:90.45pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:14.3pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></b></p>
   </td>
   <td width=491 colspan=4 valign=top style='width:368.55pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:14.3pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Epclusa
   + RBV 12&nbsp;weeks</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Genotype&nbsp;1</span></b></p>
   </td>
   <td width=123 valign=top style='width:92.15pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Genotype&nbsp;3</span></b></p>
   </td>
   <td width=142 valign=top style='width:106.3pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Genotypes&nbsp;2 or 4</span></b></p>
   </td>
   <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Total</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=121 style='width:90.45pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>With any baseline NS5A&nbsp;RAVs</span></p>
  </td>
  <td width=113 style='width:85.05pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>100%
  (19/19)</span></p>
  </td>
  <td width=123 style='width:92.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>50% (1/2)</span></p>
  </td>
  <td width=142 style='width:106.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>100% (4/4)</span></p>
  </td>
  <td width=113 style='width:85.05pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEAEnBodyText align=left style='margin:0in;text-align:left;
  page-break-after:avoid'><span lang=EN-GB style='font-size:10.0pt'>96% (24/25)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=121 style='width:90.45pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Without baseline NS5A&nbsp;RAVs</span></p>
  </td>
  <td width=113 style='width:85.05pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEAEnBodyText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB style='font-size:10.0pt'>98% (46/47)</span></p>
  </td>
  <td width=123 style='width:92.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEAEnBodyText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB style='font-size:10.0pt'>91% (10/11)</span></p>
  </td>
  <td width=142 style='width:106.3pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEAEnBodyText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB style='font-size:10.0pt'>100% (2/2)</span></p>
  </td>
  <td width=113 style='width:85.05pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=EMEAEnBodyText align=left style='margin:0in;text-align:left'><span
  lang=EN-GB style='font-size:10.0pt'>98% (58/60)</span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The single
genotype&nbsp;3 patient who had baseline NS5A&nbsp;RAVs and failed to achieve
SVR12 had NS5A substitution Y93H at baseline; pharmacokinetic data from this
patient was consistent with non&#8209;adherence to treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Three patients
in the Epclusa + RBV 12&nbsp;week group had baseline NS5B&nbsp;NI&nbsp;RAVs
(N142T and L159F) and all three patients achieved SVR12.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Cross&#8209;resistance</span></u></p>

<p class=MsoNormal style='line-height:normal'><i><span lang=EN-GB>In&nbsp;vitro</span></i><span
lang=EN-GB> data suggests that the majority of NS5A&nbsp;RAVs that confer
resistance to ledipasvir and daclatasvir remained susceptible to
velpatasvir.&nbsp; Velpatasvir was fully active against the sofosbuvir
resistance-associated substitution S282T in NS5B while all velpatasvir resistance-associated
substitutions in NS5A were fully susceptible to sofosbuvir.&nbsp; Both
sofosbuvir and velpatasvir were fully active against substitutions associated
with resistance to other classes of direct-acting antivirals with different
mechanisms of actions, such as NS5B non&#8209;nucleoside inhibitors and NS3
protease inhibitors.&nbsp; The efficacy of Epclusa has not been assessed in
patients who have previously failed treatment with other regimens that include
an NS5A inhibitor.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Clinical efficacy and safety</span></u></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>The
efficacy of </span><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Epclusa</span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'> was evaluated in three
Phase&nbsp;3 studies in patients with genotype&nbsp;1 to 6 HCV infection with
or without compensated cirrhosis, one Phase&nbsp;3 study in patients with
genotype&nbsp;1 to 6 HCV infection with decompensated cirrhosis, and one
Phase&nbsp;3 study in HCV/HIV&#8209;1 co-infected patients with genotype&nbsp;1
to 6 HCV infection, as summarised in Table&nbsp;9.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Table&nbsp;9: Studies conducted with Epclusa in patients with genotype&nbsp;1,
2, 3, 4, 5 or 6 HCV infection</span></b></p>

<div align=center>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid;height:25.45pt'>
   <td width=90 valign=top style='width:67.25pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:25.45pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Study</span></b></p>
   </td>
   <td width=217 valign=top style='width:163.0pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:25.45pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Population</span></b></p>
   </td>
   <td width=307 valign=top style='width:230.15pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:25.45pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Study arms</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>(Number of patients treated)</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=90 style='width:67.25pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>ASTRAL&#8209;1</span></p>
  </td>
  <td width=217 style='width:163.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Genotype&nbsp;1, 2, 4, 5 and 6</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>TN and TE, without cirrhosis or with
  compensated cirrhosis</span></p>
  </td>
  <td width=307 style='width:230.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Epclusa 12&nbsp;weeks (624)</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Placebo 12&nbsp;weeks (116)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=90 style='width:67.25pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>ASTRAL&#8209;2</span></p>
  </td>
  <td width=217 style='width:163.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Genotype&nbsp;2</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>TN and TE, without cirrhosis or with compensated
  cirrhosis</span></p>
  </td>
  <td width=307 style='width:230.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Epclusa 12&nbsp;weeks (134)</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>SOF+RBV 12&nbsp;weeks (132)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=90 style='width:67.25pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>ASTRAL&#8209;3</span></p>
  </td>
  <td width=217 style='width:163.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>Genotype&nbsp;3</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB
  style='font-size:10.0pt'>TN and TE, without cirrhosis or with compensated
  cirrhosis</span></p>
  </td>
  <td width=307 style='width:230.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Epclusa 12&nbsp;weeks (277)</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>SOF+RBV 24&nbsp;weeks (275)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=90 style='width:67.25pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>ASTRAL&#8209;4</span></p>
  </td>
  <td width=217 style='width:163.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Genotype&nbsp;1, 2, 3, 4, 5 and 6</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>TN and TE, with CPT Class&nbsp;B decompensated
  cirrhosis </span></p>
  </td>
  <td width=307 style='width:230.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Epclusa 12&nbsp;weeks (90)</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Epclusa + RBV 12&nbsp;weeks (87)</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Epclusa 24&nbsp;weeks (90)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=90 style='width:67.25pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>ASTRAL&#8209;5</span></p>
  </td>
  <td width=217 style='width:163.0pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Genotype&nbsp;1, 2, 3, 4, 5 and 6</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>TN and TE, without cirrhosis or with
  compensated cirrhosis, with HCV/HIV&#8209;1 co-infection</span></p>
  </td>
  <td width=307 style='width:230.15pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Epclusa 12&nbsp;weeks (106)</span></p>
  </td>
 </tr>
</table>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='font-size:9.0pt'>TN&nbsp;=&nbsp;treatment-na&iuml;ve patients; TE&nbsp;=&nbsp;treatment-experienced
patients (including those who have failed a peginterferon alfa + ribavirin
based regimen with or without an HCV protease inhibitor)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The ribavirin dose
was weight-based (1,000&nbsp;mg daily administered in two divided doses for
patients &lt;&nbsp;75&nbsp;kg and 1,200&nbsp;mg for those &#8805;&nbsp;75&nbsp;kg)
and administered in two divided doses when used in combination with sofosbuvir
in the ASTRAL&#8209;2 and ASTRAL&#8209;3 studies or in combination with Epclusa
in the ASTRAL&#8209;4 study. &nbsp;Ribavirin dose adjustments were performed
according to the ribavirin prescribing information.&nbsp; Serum HCV&nbsp;RNA
values were measured during the clinical studies using the COBAS
AmpliPrep/COBAS Taqman HCV test (version&nbsp;2.0) with a lower limit of
quantification (LLOQ) of 15&nbsp;IU/mL. &nbsp;Sustained virologic response
(SVR12), defined as HCV&nbsp;RNA less than LLOQ at 12&nbsp;weeks after the
cessation of treatment, was the primary endpoint to determine the HCV cure
rate.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Clinical studies in patients without cirrhosis and patients with compensated
cirrhosis</span></i></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Genotype&nbsp;1, 2, 4, 5 and 6 HCV&#8209;infected adults <b>&#8211;</b>
ASTRAL&#8209;1 (study&nbsp;1138)</span></i></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>ASTRAL&#8209;1
was a randomised, double-blind, placebo-controlled study that evaluated
12&nbsp;weeks of treatment with </span><span lang=EN-GB style='font-size:11.0pt;
color:windowtext'>Epclusa </span><span lang=EN-GB style='font-size:11.0pt;
color:windowtext'>compared with 12&nbsp;weeks of placebo in patients with
genotype&nbsp;1, 2, 4, 5, or 6 HCV infection.&nbsp; Patients with genotype&nbsp;1,
2, 4 or 6 HCV infection were randomised in a 5:1 ratio to treatment with </span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>Epclusa</span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'> for 12&nbsp;weeks or
placebo for 12&nbsp;weeks. &nbsp;Patients with genotype&nbsp;5 HCV infection
were enrolled to the </span><span lang=EN-GB style='font-size:11.0pt;
color:windowtext'>Epclusa </span><span lang=EN-GB style='font-size:11.0pt;
color:windowtext'>group.&nbsp; Randomisation was stratified by HCV genotype (1,
2, 4, 6, and indeterminate) and the presence or absence of cirrhosis.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Demographics
and baseline characteristics were balanced between the Epclusa and placebo
group. &nbsp;Of the 740&nbsp;treated patients, the median age was 56&nbsp;years
(range: 18 to 82); 60% of the patients were male; 79% were White, 9% were
Black; 21% had a baseline body mass index of at least 30&nbsp;kg/m<sup>2</sup>;
the proportions of patients with genotype&nbsp;1, 2, 4, 5, or 6 HCV infection
were 53%, 17%, 19%, 5% and 7%, respectively; 69% had non&#8209;CC IL28B alleles
(CT or TT); 74% had baseline HCV&nbsp;RNA levels of at least 800,000&nbsp;IU/mL;
19% had compensated cirrhosis; and 32% were treatment-experienced.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Table&nbsp;10
presents the SVR12 for the ASTRAL&#8209;1 study by HCV genotypes. &nbsp;No
patients in the placebo group achieved SVR12.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Table&nbsp;10: SVR12 in study ASTRAL&#8209;1 by HCV genotype</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=631
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid;height:27.0pt'>
   <td width=73 rowspan=3 valign=top style='width:54.7pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:27.0pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></b></p>
   </td>
   <td width=558 colspan=8 valign=top style='width:418.5pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:27.0pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Epclusa
   12&nbsp;weeks</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;624)</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid;height:12.75pt'>
   <td width=69 rowspan=2 valign=top style='width:51.5pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Total</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>(all GTs)</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;624)</span></b></p>
   </td>
   <td width=211 colspan=3 valign=top style='width:158.2pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>GT&#8209;1</span></b></p>
   </td>
   <td width=70 rowspan=2 valign=top style='width:52.85pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>GT&#8209;2</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;104)</span></b></p>
   </td>
   <td width=76 rowspan=2 valign=top style='width:56.7pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>GT&#8209;4</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;116)</span></b></p>
   </td>
   <td width=66 rowspan=2 valign=top style='width:49.65pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>GT&#8209;5</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;35)</span></b></p>
   </td>
   <td width=66 rowspan=2 valign=top style='width:49.6pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>GT&#8209;6</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;41)</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid;height:12.75pt'>
   <td width=70 valign=top style='width:52.5pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>GT&#8209;1a</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;210)</span></b></p>
   </td>
   <td width=70 valign=top style='width:52.25pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>GT&#8209;1b</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;118)</span></b></p>
   </td>
   <td width=71 valign=top style='width:53.45pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Total</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;328)</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid;height:24.75pt'>
  <td width=73 style='width:54.7pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:24.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>SVR12</span></p>
  </td>
  <td width=69 style='width:51.5pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:24.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>99%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(618/624)</span></p>
  </td>
  <td width=70 style='width:52.5pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:24.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>98%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(206/210)</span></p>
  </td>
  <td width=70 style='width:52.25pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:24.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>99%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(117/118)</span></p>
  </td>
  <td width=71 style='width:53.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:24.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>98%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(323/328)</span></p>
  </td>
  <td width=70 style='width:52.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:24.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>100%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(104/104)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:24.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>100%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(116/116)</span></p>
  </td>
  <td width=66 style='width:49.65pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:24.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>97%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(34/35)</span></p>
  </td>
  <td width=66 style='width:49.6pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:24.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>100%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(41/41)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:12.75pt'>
  <td width=631 colspan=9 style='width:473.2pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt;height:12.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Outcome for patients without SVR12</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:50.25pt'>
  <td width=73 style='width:54.7pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:50.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>On-treatment virologic failure</span></p>
  </td>
  <td width=69 style='width:51.5pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:50.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/624</span></p>
  </td>
  <td width=70 style='width:52.5pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:50.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/210</span></p>
  </td>
  <td width=70 style='width:52.25pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:50.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/118</span></p>
  </td>
  <td width=71 style='width:53.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:50.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/328</span></p>
  </td>
  <td width=70 style='width:52.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:50.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/104</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:50.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/116</span></p>
  </td>
  <td width=66 style='width:49.65pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:50.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/35</span></p>
  </td>
  <td width=66 style='width:49.6pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:50.25pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/41</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:24.75pt'>
  <td width=73 style='width:54.7pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:24.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Relapse<sup>a</sup></span></p>
  </td>
  <td width=69 style='width:51.5pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:24.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&lt;&nbsp;1%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(2/623)</span></p>
  </td>
  <td width=70 style='width:52.5pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:24.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&lt;&nbsp;1%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(1/209)</span></p>
  </td>
  <td width=70 style='width:52.25pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:24.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>1%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(1/118)</span></p>
  </td>
  <td width=71 style='width:53.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:24.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>1%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(2/327)</span></p>
  </td>
  <td width=70 style='width:52.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:24.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/104</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:24.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/116</span></p>
  </td>
  <td width=66 style='width:49.65pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:24.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/35</span></p>
  </td>
  <td width=66 style='width:49.6pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:24.75pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/41</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid;height:25.5pt'>
  <td width=73 style='width:54.7pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Other<sup>b</sup></span></p>
  </td>
  <td width=69 style='width:51.5pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:25.5pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>1%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(4/624)</span></p>
  </td>
  <td width=70 style='width:52.5pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:25.5pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>1%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(3/210)</span></p>
  </td>
  <td width=70 style='width:52.25pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/118</span></p>
  </td>
  <td width=71 style='width:53.45pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>1%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(3/328)</span></p>
  </td>
  <td width=70 style='width:52.85pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/104</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:25.5pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/116</span></p>
  </td>
  <td width=66 style='width:49.65pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt;height:25.5pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>3%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(1/35)</span></p>
  </td>
  <td width=66 style='width:49.6pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt;
  height:25.5pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/41</span></p>
  </td>
 </tr>
</table>

<p class=Default style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt;color:white'>GT&nbsp;=&nbsp;genotype</span></p>

<p class=Default style='margin-left:14.2pt;text-indent:-14.2pt;page-break-after:
avoid'><span lang=EN-GB style='font-size:9.0pt;color:windowtext'>a&nbsp;&nbsp;&nbsp;&nbsp; The
denominator for relapse is the number of patients with HCV&nbsp;RNA &lt;&nbsp;LLOQ
at their last on-treatment assessment.</span></p>

<p class=Default style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:9.0pt;color:windowtext'>b&nbsp;&nbsp;&nbsp; Other
includes patients who did not achieve SVR12 and did not meet virologic failure
criteria.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Genotype&nbsp;2 HCV&#8209;infected adults <b>&#8211;</b> ASTRAL&#8209;2
(study&nbsp;1139)</span></i></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>ASTRAL&#8209;2
was a randomised, open-label study that evaluated 12&nbsp;weeks of treatment
with Epclusa compared with 12&nbsp;weeks of treatment with SOF+RBV in patients
with genotype&nbsp;2 HCV infection.&nbsp; Patients were randomised in a 1:1
ratio to treatment with Epclusa for 12&nbsp;weeks or SOF+RBV for
12&nbsp;weeks.&nbsp; Randomisation was stratified by the presence or absence of
cirrhosis and prior treatment experience (treatment&#8209;na</span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>&iuml;</span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>ve <i>versus</i> treatment&#8209;experienced).</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Demographics
and baseline characteristics were balanced across the two treatment
groups.&nbsp; Of the 266 treated patients, the median age was 58&nbsp;years
(range: 23 to 81); 59% of the patients were male; 88% were White, 7% were
Black; 33% had a baseline body mass index of at least 30&nbsp;kg/m<sup>2</sup>;
62% had non&#8209;CC IL28B alleles (CT or TT); 80% had baseline HCV&nbsp;RNA
levels of at least 800,000&nbsp;IU/mL; 14% had compensated cirrhosis and 15%
were treatment-experienced.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Table&nbsp;11 presents
the SVR12 for the ASTRAL&#8209;2 study.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Table&nbsp;11: SVR12 in study ASTRAL&#8209;2 (HCV genotype&nbsp;2)</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
   lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
   </td>
   <td width=206 valign=top style='width:2.15in;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Epclusa</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>12&nbsp;weeks</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;134)</span></b></p>
   </td>
   <td width=206 valign=top style='width:2.15in;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>SOF+RBV</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>12&nbsp;weeks</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;132)</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>SVR12</span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>99% (133/134)</span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>94% (124/132)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=3 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Outcome for patients without SVR12</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>On-treatment virologic failure</span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/134</span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/132</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Relapse<sup>a</sup></span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/133</span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>5% (6/132)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Other<sup>b</sup></span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>1% (1/134)</span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>2% (2/132)</span></p>
  </td>
 </tr>
</table>

<p class=Default style='margin-left:14.2pt;text-indent:-14.2pt;page-break-after:
avoid'><span lang=EN-GB style='font-size:9.0pt;color:windowtext'>a&nbsp;&nbsp;&nbsp;&nbsp; The
denominator for relapse is the number of patients with HCV&nbsp;RNA &lt;&nbsp;LLOQ
at their last on-treatment assessment.</span></p>

<p class=Default style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:9.0pt;color:windowtext'>b&nbsp;&nbsp;&nbsp; Other
includes patients who did not achieve SVR12 and did not meet virologic failure
criteria.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Treatment
with </span><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Epclusa</span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'> for 12&nbsp;weeks
demonstrated the statistical superiority (p&nbsp;=&nbsp;0.018) over treatment
with SOF+RBV for 12&nbsp;weeks (treatment difference +5.2%; 95% confidence
interval: +0.2% to +10.3%).</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Genotype&nbsp;3 HCV&#8209;infected adults <b>&#8211;</b> ASTRAL&#8209;3
(study&nbsp;1140)</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ASTRAL&#8209;3
was a randomised, open-label study that evaluated 12&nbsp;weeks of treatment
with Epclusa compared with 24&nbsp;weeks of treatment with SOF+RBV in patients
with genotype&nbsp;3 HCV infection.&nbsp; Patients were randomised in a 1:1
ratio to treatment with Epclusa for 12&nbsp;weeks or SOF+RBV for
24&nbsp;weeks.&nbsp; Randomisation was stratified by the presence or absence of
cirrhosis and prior treatment experience (treatment&#8209;na&iuml;ve <i>versus</i>
treatment&#8209;experienced).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Demographics and
baseline characteristics were balanced across the two treatment groups.&nbsp;
Of the 552 treated patients, the median age was 52&nbsp;years (range: 19 to
76); 62% of the patients were male; 89% were White, 9% were Asian; 1% were
Black; 20% had a baseline body mass index of at least 30&nbsp;kg/m<sup>2</sup>;
61% had non&#8209;CC IL28B alleles (CT or TT); 70% had baseline HCV&nbsp;RNA
levels of at least 800,000&nbsp;IU/mL, 30% had compensated cirrhosis and 26%
were treatment-experienced.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Table&nbsp;12
presents the SVR12 for the ASTRAL&#8209;3 study.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Table&nbsp;12: SVR12 in study ASTRAL&#8209;3 (HCV genotype&nbsp;3)</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
   lang=EN-GB>&nbsp;</span></p>
   </td>
   <td width=206 valign=top style='width:2.15in;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Epclusa</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>12&nbsp;weeks</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;277)</span></b></p>
   </td>
   <td width=206 valign=top style='width:2.15in;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>SOF+RBV</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>24&nbsp;weeks</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;275)</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>SVR12</span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>95% (264/277)</span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>80% (221/275)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=619 colspan=3 valign=top style='width:464.35pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Outcome for patients without SVR12</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>On-treatment virologic failure</span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/277</span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>&lt;&nbsp;1% (1/275)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Relapse<sup>a</sup></span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>4% (11/276)</span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>14% (38/272)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=206 valign=top style='width:154.75pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Other<sup>b</sup></span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>1% (2/277)</span></p>
  </td>
  <td width=206 valign=top style='width:2.15in;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>5% (15/275)</span></p>
  </td>
 </tr>
</table>

<p class=Default style='margin-left:14.2pt;text-indent:-14.2pt;page-break-after:
avoid'><span lang=EN-GB style='font-size:9.0pt;color:windowtext'>a&nbsp;&nbsp;&nbsp;&nbsp; The
denominator for relapse is the number of patients with HCV&nbsp;RNA &lt;&nbsp;LLOQ
at their last on-treatment assessment.</span></p>

<p class=Default style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:9.0pt;color:windowtext'>b&nbsp;&nbsp;&nbsp; Other
includes patients who did not achieve SVR12 and did not meet virologic failure
criteria.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Treatment with Epclusa
for 12&nbsp;weeks demonstrated the statistical superiority (p&nbsp;&lt;&nbsp;0.001)
compared to treatment with SOF+RBV for 24&nbsp;weeks (treatment difference +14.8%;
95% confidence interval: +9.6% to +20.0%).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>SVR12 for
selected subgroups are presented in Table&nbsp;13.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Table&nbsp;13: SVR12 for selected subgroups in study ASTRAL&#8209;3
(HCV genotype&nbsp;3)</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width=124 valign=top style='width:92.85pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
   lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></p>
   </td>
   <td width=248 colspan=2 valign=top style='width:185.7pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Epclusa</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>12&nbsp;weeks</span></b></p>
   </td>
   <td width=248 colspan=2 valign=top style='width:185.8pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>SOF+RBV</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>24&nbsp;weeks<sup>a</sup></span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=124 valign=top style='width:92.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>SVR12</span></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Treatment-na&iuml;ve</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;206)</span></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Treatment-experienced</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;71)</span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Treatment-na&iuml;ve</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;201)</span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Treatment-experienced</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;69)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=124 valign=top style='width:92.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Without cirrhosis</span></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>98% (160/163)</span></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>91% (31/34)</span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>90% (141/156)</span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>71% (22/31)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=124 valign=top style='width:92.85pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>With cirrhosis</span></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>93% (40/43)</span></p>
  </td>
  <td width=124 valign=top style='width:92.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>89% (33/37)</span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>73% (33/45)</span></p>
  </td>
  <td width=124 valign=top style='width:92.9pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>58% (22/38)</span></p>
  </td>
 </tr>
</table>

<p class=Default style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:9.0pt;color:windowtext'>a&nbsp;&nbsp;&nbsp;&nbsp; Five
patients with missing cirrhosis status in the SOF+RBV 24&nbsp;week group were
excluded from this subgroup analysis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Clinical studies in patients with decompensated cirrhosis <b>&#8211;</b>
ASTRAL&#8209;4 (study&nbsp;1137)</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ASTRAL&#8209;4
was a randomised, open-label study in patients with genotype&nbsp;1, 2, 3, 4, 5
or 6 HCV infection and CPT Class&nbsp;B cirrhosis.&nbsp; Patients were randomised
in a 1:1:1 ratio to treatment with Epclusa for 12&nbsp;weeks, Epclusa + RBV for
12&nbsp;weeks or Epclusa for 24&nbsp;weeks.&nbsp; Randomisation was stratified
by HCV genotype (1, 2, 3, 4, 5, 6 and indeterminate).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Demographics and
baseline characteristics were balanced across the treatment groups.&nbsp; Of
the 267 treated patients, the median age was 59&nbsp;years (range: 40 to 73);
70% of the patients were male; 90% were White, 6% were Black; 42% had a
baseline body mass index of at least 30&nbsp;kg/m<sup>2</sup>.&nbsp; The
proportions of patients with genotype&nbsp;1, 2, 3, 4 or 6 HCV were 78%, 4%,
15%, 3%, and &lt;&nbsp;1% (1&nbsp;patient), respectively.&nbsp; No patients
with genotype&nbsp;5 HCV infection were enrolled.&nbsp; 76% of the patients had
non&#8209;CC IL28B alleles (CT or TT); 56% had baseline HCV&nbsp;RNA levels of at
least 800,000&nbsp;IU/mL, 55% were treatment-experienced; 90% and 95% of
patients had CPT Class&nbsp;B cirrhosis and Model for End Stage Liver Disease
(MELD) score &#8804;&nbsp;15 at baseline, respectively.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Table&nbsp;14 presents
the SVR12 for the ASTRAL&#8209;4 study by HCV genotype.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Table&nbsp;14: SVR12 in study ASTRAL&#8209;4 by HCV genotype</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=621
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width=106 valign=top style='width:1.1in;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></b></p>
   </td>
   <td width=157 valign=top style='width:117.6pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Epclusa</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>12&nbsp;weeks</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;90)</span></b></p>
   </td>
   <td width=180 valign=top style='width:134.65pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Epclusa + RBV</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>12&nbsp;weeks</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;87)</span></b></p>
   </td>
   <td width=180 valign=top style='width:134.65pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Epclusa</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>24&nbsp;weeks</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;90)</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=106 valign=top style='width:1.1in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>Overall SVR12</span></b></p>
  </td>
  <td width=157 valign=top style='width:117.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>83% (75/90)</span></p>
  </td>
  <td width=180 valign=top style='width:134.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>94% (82/87)</span></p>
  </td>
  <td width=180 valign=top style='width:134.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>86% (77/90)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=106 valign=top style='width:1.1in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>Genotype&nbsp;1</span></b></p>
  </td>
  <td width=157 valign=top style='width:117.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>88% (60/68)</span></p>
  </td>
  <td width=180 valign=top style='width:134.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>96% (65/68)</span></p>
  </td>
  <td width=180 valign=top style='width:134.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>92% (65/71)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=106 valign=top style='width:1.1in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
  normal;page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Genotype&nbsp;1a</span></b></p>
  </td>
  <td width=157 valign=top style='width:117.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>88% (44/50)</span></p>
  </td>
  <td width=180 valign=top style='width:134.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>94% (51/54)</span></p>
  </td>
  <td width=180 valign=top style='width:134.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>93% (51/55)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=106 valign=top style='width:1.1in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
  normal;page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Genotype&nbsp;1b</span></b></p>
  </td>
  <td width=157 valign=top style='width:117.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>89% (16/18)</span></p>
  </td>
  <td width=180 valign=top style='width:134.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>100% (14/14)</span></p>
  </td>
  <td width=180 valign=top style='width:134.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>88% (14/16)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=106 valign=top style='width:1.1in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>Genotype&nbsp;3</span></b></p>
  </td>
  <td width=157 valign=top style='width:117.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>50% (7/14)</span></p>
  </td>
  <td width=180 valign=top style='width:134.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>85% (11/13)</span></p>
  </td>
  <td width=180 valign=top style='width:134.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>50% (6/12)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=106 valign=top style='width:1.1in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>Genotype&nbsp;2, 4 and 6</span></b></p>
  </td>
  <td width=157 valign=top style='width:117.6pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>100% (8/8)<sup>a</sup></span></p>
  </td>
  <td width=180 valign=top style='width:134.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>100% (6/6)<sup>b</sup></span></p>
  </td>
  <td width=180 valign=top style='width:134.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>86% (6/7)<sup>c</sup></span></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>a&nbsp;&nbsp;&nbsp;&nbsp; n&nbsp;=&nbsp;4
for genotype&nbsp;2 and n&nbsp;=&nbsp;4 for genotype&nbsp;4.</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-size:9.0pt'>b&nbsp;&nbsp;&nbsp; n&nbsp;=&nbsp;4
for genotype&nbsp;2 and n&nbsp;=&nbsp;2 for genotype&nbsp;4.</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
normal'><span lang=EN-GB style='font-size:9.0pt'>c&nbsp;&nbsp;&nbsp;&nbsp; n&nbsp;=&nbsp;4
for genotype&nbsp;2, n&nbsp;=&nbsp;2 for genotype&nbsp;4 and n&nbsp;=&nbsp;1
for genotype&nbsp;6.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Table&nbsp;15
presents the virologic outcome for patients with genotype&nbsp;1 or 3 HCV
infection in the ASTRAL&#8209;4 study.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No patients with
genotype&nbsp;2, 4 or 6 HCV infection experienced virologic failure.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Table&nbsp;15: Virologic outcome for patients with genotype&nbsp;1 and
3 HCV infection in study ASTRAL&#8209;4</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=621
 style='width:466.1pt;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width=106 valign=top style='width:1.1in;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></b></p>
   </td>
   <td width=138 valign=top style='width:103.4pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Epclusa 12&nbsp;weeks</span></b></p>
   </td>
   <td width=208 valign=top style='width:155.95pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Epclusa + RBV 12&nbsp;weeks</span></b></p>
   </td>
   <td width=170 valign=top style='width:127.55pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Epclusa 24&nbsp;weeks</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=621 colspan=4 valign=top style='width:466.1pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>Virologic failure (relapse and on-treatment failure)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=106 valign=top style='width:1.1in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>Genotype&nbsp;1<sup>a</sup></span></b></p>
  </td>
  <td width=138 valign=top style='width:103.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>7% (5/68)</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>1% (1/68)</span></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>4% (3/71)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=106 valign=top style='width:1.1in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
  normal;page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Genotype&nbsp;1a</span></b></p>
  </td>
  <td width=138 valign=top style='width:103.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>6% (3/50) </span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>2% (1/54)</span></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>4% (2/55)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=106 valign=top style='width:1.1in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
  normal;page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Genotype&nbsp;1b</span></b></p>
  </td>
  <td width=138 valign=top style='width:103.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>11% (2/18)</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>0% (0/14)</span></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>6% (1/16)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=106 valign=top style='width:1.1in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>Genotype&nbsp;3</span></b></p>
  </td>
  <td width=138 valign=top style='width:103.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>43% (6/14)</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>15% (2<sup>b</sup>/13)</span></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>42% (5<sup>c</sup>/12)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=106 valign=top style='width:1.1in;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
  lang=EN-GB style='font-size:10.0pt'>Other<sup>d</sup></span></b></p>
  </td>
  <td width=138 valign=top style='width:103.4pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>5% (4/82)</span></p>
  </td>
  <td width=208 valign=top style='width:155.95pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>2% (2/81)</span></p>
  </td>
  <td width=170 valign=top style='width:127.55pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=Table-Text style='margin:0in'><span lang=EN-GB style='font-family:
  "Times New Roman",serif'>5% (4/83)</span></p>
  </td>
 </tr>
</table>

<p class=Default style='margin-left:14.2pt;text-indent:-14.2pt;page-break-after:
avoid'><span lang=EN-GB style='font-size:9.0pt;color:windowtext'>a&nbsp;&nbsp;&nbsp;&nbsp; No
patients with genotype&nbsp;1 HCV had on-treatment virologic failure.</span></p>

<p class=Default style='margin-left:14.2pt;text-indent:-14.2pt;page-break-after:
avoid'><span lang=EN-GB style='font-size:9.0pt;color:windowtext'>b&nbsp;&nbsp;&nbsp; One
patient had on-treatment virologic failure; pharmacokinetic data from this
patient was consistent with non-adherence to treatment.</span></p>

<p class=Default style='margin-left:14.2pt;text-indent:-14.2pt;page-break-after:
avoid'><span lang=EN-GB style='font-size:9.0pt;color:windowtext'>c&nbsp;&nbsp;&nbsp;&nbsp; One
patient had on-treatment virologic failure.</span></p>

<p class=Default style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:9.0pt;color:windowtext'>d&nbsp;&nbsp;&nbsp; Other
includes patients who did not achieve SVR12 and did not meet virologic failure
criteria.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Changes in the
parameters found in the CPT score system in patients achieving SVR12 in ASTRAL&#8209;4
(all 3 regimens) are shown in Table&nbsp;16.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Table&nbsp;16: Changes in CPT score parameters from baseline to week&nbsp;12
and 24 post&#8209;treatment in patients achieving SVR12, ASTRAL&#8209;4</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="100%"
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width=155 valign=top style='width:115.9pt;border-top:windowtext;
   border-left:windowtext;border-bottom:black;border-right:black;border-style:
   solid;border-width:1.0pt;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
   punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
   style='font-size:10.0pt'>&nbsp;</span></p>
   </td>
   <td width=93 valign=top style='width:69.65pt;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
   punctuation-wrap:simple;text-autospace:none'><b><span lang=EN-GB
   style='font-size:10.0pt'>A<span style='letter-spacing:-.05pt'>lb</span><span
   style='letter-spacing:.1pt'>u</span><span style='letter-spacing:-.15pt'>m</span><span
   style='letter-spacing:.1pt'>i</span>n</span></b></p>
   </td>
   <td width=93 valign=top style='width:69.65pt;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
   punctuation-wrap:simple;text-autospace:none'><b><span lang=EN-GB
   style='font-size:10.0pt;letter-spacing:.05pt'>B</span></b><b><span
   lang=EN-GB style='font-size:10.0pt;letter-spacing:-.05pt'>ili</span></b><b><span
   lang=EN-GB style='font-size:10.0pt'>r<span style='letter-spacing:-.05pt'>ubi</span>n</span></b></p>
   </td>
   <td width=93 valign=top style='width:69.65pt;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
   punctuation-wrap:simple;text-autospace:none'><b><span lang=EN-GB
   style='font-size:10.0pt;letter-spacing:-.05pt'>I</span></b><b><span
   lang=EN-GB style='font-size:10.0pt'>NR</span></b></p>
   </td>
   <td width=75 valign=top style='width:56.2pt;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
   punctuation-wrap:simple;text-autospace:none'><b><span lang=EN-GB
   style='font-size:10.0pt'>A<span style='letter-spacing:-.05pt'>s</span>c<span
   style='letter-spacing:-.05pt'>i</span>tes</span></b></p>
   </td>
   <td width=113 valign=top style='width:85.05pt;border-top:solid windowtext 1.0pt;
   border-left:none;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
   punctuation-wrap:simple;text-autospace:none'><b><span lang=EN-GB
   style='font-size:10.0pt;letter-spacing:-.05pt'>En</span></b><b><span
   lang=EN-GB style='font-size:10.0pt'>ce<span style='letter-spacing:.1pt'>p</span><span
   style='letter-spacing:-.05pt'>h</span><span style='letter-spacing:.05pt'>a</span><span
   style='letter-spacing:-.05pt'>l</span><span style='letter-spacing:.05pt'>o</span><span
   style='letter-spacing:-.05pt'>p</span><span style='letter-spacing:.05pt'>a</span>t<span
   style='letter-spacing:-.05pt'>hy</span></span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=621 colspan=6 style='width:466.1pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><b><span lang=EN-GB
  style='font-size:10.0pt;letter-spacing:.1pt'>P</span></b><b><span lang=EN-GB
  style='font-size:10.0pt;letter-spacing:.05pt'>o</span></b><b><span
  lang=EN-GB style='font-size:10.0pt;letter-spacing:-.05pt'>st&#8209;t</span></b><b><span
  lang=EN-GB style='font-size:10.0pt'>rea<span style='letter-spacing:-.05pt'>t</span><span
  style='letter-spacing:-.25pt'>m</span><span style='letter-spacing:.1pt'>e</span><span
  style='letter-spacing:-.1pt'>n</span>t<span style='letter-spacing:-.3pt'> </span><span
  style='letter-spacing:.05pt'>W</span>eek<span style='letter-spacing:-.35pt'>&nbsp;</span><span
  style='letter-spacing:.05pt'>1</span>2<span style='letter-spacing:-.25pt'> </span>(N&nbsp;=&nbsp;<span
  style='letter-spacing:.05pt'>236</span>),<span style='letter-spacing:-.05pt'>
  %</span><span style='letter-spacing:-.3pt'> (</span><span style='letter-spacing:
  -.1pt'>n</span><span style='letter-spacing:-.05pt'>/</span>N)<span
  style='letter-spacing:-.3pt'> </span></span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:115.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>Decrea<span style='letter-spacing:-.05pt'>s</span>ed<span
  style='letter-spacing:-.6pt'> </span><span style='letter-spacing:-.05pt'>s</span>c<span
  style='letter-spacing:.05pt'>o</span>re (I<span style='letter-spacing:-.25pt'>m</span><span
  style='letter-spacing:.05pt'>p</span>r<span style='letter-spacing:.05pt'>o</span><span
  style='letter-spacing:-.1pt'>v</span><span style='letter-spacing:.1pt'>e</span><span
  style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.1pt'>e</span><span
  style='letter-spacing:-.1pt'>n</span><span style='letter-spacing:-.05pt'>t</span>)</span></p>
  </td>
  <td width=93 style='width:69.65pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>34</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>.</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>5</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>%</span><span lang=EN-GB
  style='font-size:9.0pt'> (<span style='letter-spacing:.05pt'>79</span><span
  style='letter-spacing:-.1pt'>/</span><span style='letter-spacing:.05pt'>2</span><span
  style='letter-spacing:-.1pt'>2</span>9)</span></p>
  </td>
  <td width=93 style='width:69.65pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>17</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>.</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>9</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>%</span><span lang=EN-GB
  style='font-size:9.0pt'> (<span style='letter-spacing:.05pt'>41</span><span
  style='letter-spacing:-.1pt'>/</span><span style='letter-spacing:.05pt'>2</span><span
  style='letter-spacing:-.1pt'>2</span>9)</span></p>
  </td>
  <td width=93 style='width:69.65pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>2</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>.</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>2</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>%</span><span lang=EN-GB
  style='font-size:9.0pt'> (<span style='letter-spacing:.05pt'>5</span>/<span
  style='letter-spacing:-.1pt'>2</span><span style='letter-spacing:.05pt'>2</span>9)</span></p>
  </td>
  <td width=75 style='width:56.2pt;border-top:none;border-left:none;border-bottom:
  solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>7</span><span lang=EN-GB
  style='font-size:9.0pt'>.<span style='letter-spacing:.05pt'>9</span><span
  style='letter-spacing:-.1pt'>%</span> (<span style='letter-spacing:.05pt'>18</span><span
  style='letter-spacing:-.1pt'>/</span><span style='letter-spacing:.05pt'>2</span><span
  style='letter-spacing:-.1pt'>2</span>9)</span></p>
  </td>
  <td width=113 style='width:85.05pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>5</span><span lang=EN-GB
  style='font-size:9.0pt'>.<span style='letter-spacing:.05pt'>2</span><span
  style='letter-spacing:-.1pt'>%</span> (<span style='letter-spacing:.05pt'>12</span><span
  style='letter-spacing:-.1pt'>/</span><span style='letter-spacing:.05pt'>2</span><span
  style='letter-spacing:-.1pt'>2</span>9)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:115.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>No<span style='letter-spacing:-.4pt'> </span>c<span
  style='letter-spacing:-.1pt'>h</span>a<span style='letter-spacing:.05pt'>n</span><span
  style='letter-spacing:-.1pt'>ge</span></span></p>
  </td>
  <td width=93 style='width:69.65pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>6</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>0</span><span lang=EN-GB
  style='font-size:9.0pt'>.<span style='letter-spacing:.05pt'>3</span><span
  style='letter-spacing:-.1pt'>%</span> (<span style='letter-spacing:.05pt'>13</span><span
  style='letter-spacing:-.1pt'>8</span>/<span style='letter-spacing:-.1pt'>2</span><span
  style='letter-spacing:.05pt'>2</span>9)</span></p>
  </td>
  <td width=93 style='width:69.65pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>7</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>6</span><span lang=EN-GB
  style='font-size:9.0pt'>.<span style='letter-spacing:.05pt'>4</span><span
  style='letter-spacing:-.1pt'>%</span> (<span style='letter-spacing:.05pt'>17</span><span
  style='letter-spacing:-.1pt'>5</span>/<span style='letter-spacing:-.1pt'>2</span><span
  style='letter-spacing:.05pt'>2</span>9)</span></p>
  </td>
  <td width=93 style='width:69.65pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>9</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>6</span><span lang=EN-GB
  style='font-size:9.0pt'>.<span style='letter-spacing:.05pt'>5</span><span
  style='letter-spacing:-.1pt'>%</span> (<span style='letter-spacing:.05pt'>22</span><span
  style='letter-spacing:-.1pt'>1</span>/<span style='letter-spacing:-.1pt'>2</span><span
  style='letter-spacing:.05pt'>2</span>9)</span></p>
  </td>
  <td width=75 style='width:56.2pt;border-top:none;border-left:none;border-bottom:
  solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>8</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>9</span><span lang=EN-GB
  style='font-size:9.0pt'>.<span style='letter-spacing:.05pt'>1</span><span
  style='letter-spacing:-.1pt'>%</span> (<span style='letter-spacing:.05pt'>20</span><span
  style='letter-spacing:-.1pt'>4</span>/<span style='letter-spacing:-.1pt'>2</span><span
  style='letter-spacing:.05pt'>2</span>9)</span></p>
  </td>
  <td width=113 style='width:85.05pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>9</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>1</span><span lang=EN-GB
  style='font-size:9.0pt'>.<span style='letter-spacing:.05pt'>3</span><span
  style='letter-spacing:-.1pt'>%</span> (<span style='letter-spacing:.05pt'>20</span><span
  style='letter-spacing:-.1pt'>9</span>/<span style='letter-spacing:-.1pt'>2</span><span
  style='letter-spacing:.05pt'>2</span>9)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:115.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>I<span style='letter-spacing:-.1pt'>n</span>crea<span
  style='letter-spacing:-.05pt'>s</span>ed<span style='letter-spacing:-.55pt'> </span><span
  style='letter-spacing:-.05pt'>s</span>c<span style='letter-spacing:.05pt'>o</span>re
  (<span style='letter-spacing:.05pt'>Wo</span>r<span style='letter-spacing:
  -.05pt'>s</span>e<span style='letter-spacing:-.1pt'>n</span><span
  style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:-.1pt'>ng)</span></span></p>
  </td>
  <td width=93 style='width:69.65pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>5</span><span lang=EN-GB
  style='font-size:9.0pt'>.<span style='letter-spacing:.05pt'>2</span><span
  style='letter-spacing:-.1pt'>%</span> (<span style='letter-spacing:.05pt'>12</span><span
  style='letter-spacing:-.1pt'>/</span><span style='letter-spacing:.05pt'>2</span><span
  style='letter-spacing:-.1pt'>2</span>9)</span></p>
  </td>
  <td width=93 style='width:69.65pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>5</span><span lang=EN-GB
  style='font-size:9.0pt'>.<span style='letter-spacing:.05pt'>7</span><span
  style='letter-spacing:-.1pt'>%</span> (<span style='letter-spacing:.05pt'>13</span><span
  style='letter-spacing:-.1pt'>/</span><span style='letter-spacing:.05pt'>2</span><span
  style='letter-spacing:-.1pt'>2</span>9)</span></p>
  </td>
  <td width=93 style='width:69.65pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>1</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>.</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>3</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>%</span><span lang=EN-GB
  style='font-size:9.0pt'> (<span style='letter-spacing:.05pt'>3</span>/<span
  style='letter-spacing:-.1pt'>2</span><span style='letter-spacing:.05pt'>2</span>9)</span></p>
  </td>
  <td width=75 style='width:56.2pt;border-top:none;border-left:none;border-bottom:
  solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>3</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>.</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>1</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>%</span><span lang=EN-GB
  style='font-size:9.0pt'> (<span style='letter-spacing:.05pt'>7</span>/<span
  style='letter-spacing:-.1pt'>2</span><span style='letter-spacing:.05pt'>2</span>9)</span></p>
  </td>
  <td width=113 style='width:85.05pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>3</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>.</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>5</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>%</span><span lang=EN-GB
  style='font-size:9.0pt'> (<span style='letter-spacing:.05pt'>8</span>/<span
  style='letter-spacing:-.1pt'>2</span><span style='letter-spacing:.05pt'>2</span>9)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:115.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>No<span style='letter-spacing:-.55pt'> </span>a<span
  style='letter-spacing:-.05pt'>ss</span>e<span style='letter-spacing:-.05pt'>s</span><span
  style='letter-spacing:.05pt'>s</span><span style='letter-spacing:-.1pt'>m</span><span
  style='letter-spacing:.1pt'>e</span><span style='letter-spacing:-.1pt'>n</span>t</span></p>
  </td>
  <td width=93 style='width:69.65pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;punctuation-wrap:simple;text-autospace:none'><span
  lang=EN-GB style='font-size:9.0pt'>7</span></p>
  </td>
  <td width=93 style='width:69.65pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;punctuation-wrap:simple;text-autospace:none'><span
  lang=EN-GB style='font-size:9.0pt'>7</span></p>
  </td>
  <td width=93 style='width:69.65pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;punctuation-wrap:simple;text-autospace:none'><span
  lang=EN-GB style='font-size:9.0pt'>7</span></p>
  </td>
  <td width=75 style='width:56.2pt;border-top:none;border-left:none;border-bottom:
  solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;punctuation-wrap:simple;text-autospace:none'><span
  lang=EN-GB style='font-size:9.0pt'>7</span></p>
  </td>
  <td width=113 style='width:85.05pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;punctuation-wrap:simple;text-autospace:none'><span
  lang=EN-GB style='font-size:9.0pt'>7</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=621 colspan=6 valign=top style='width:466.1pt;border-top:none;
  border-left:solid windowtext 1.0pt;border-bottom:solid black 1.0pt;
  border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><b><span lang=EN-GB
  style='font-size:10.0pt;letter-spacing:.1pt'>P</span></b><b><span lang=EN-GB
  style='font-size:10.0pt;letter-spacing:.05pt'>o</span></b><b><span
  lang=EN-GB style='font-size:10.0pt;letter-spacing:-.05pt'>st&#8209;t</span></b><b><span
  lang=EN-GB style='font-size:10.0pt'>rea<span style='letter-spacing:-.05pt'>t</span><span
  style='letter-spacing:-.25pt'>m</span><span style='letter-spacing:.1pt'>e</span><span
  style='letter-spacing:-.1pt'>n</span>t<span style='letter-spacing:-.3pt'> </span><span
  style='letter-spacing:.05pt'>W</span>eek<span style='letter-spacing:-.35pt'>&nbsp;</span><span
  style='letter-spacing:.05pt'>2</span>4<span style='letter-spacing:-.25pt'> </span>(N&nbsp;=&nbsp;<span
  style='letter-spacing:.05pt'>236</span>),<span style='letter-spacing:-.3pt'> </span><span
  style='letter-spacing:-.05pt'>%</span> (<span style='letter-spacing:-.1pt'>n</span><span
  style='letter-spacing:-.05pt'>/</span>N)</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:115.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>Decrea<span style='letter-spacing:-.05pt'>s</span>ed<span
  style='letter-spacing:-.6pt'> </span><span style='letter-spacing:-.05pt'>s</span>c<span
  style='letter-spacing:.05pt'>o</span>re (I<span style='letter-spacing:-.25pt'>m</span><span
  style='letter-spacing:.05pt'>p</span>r<span style='letter-spacing:.05pt'>o</span><span
  style='letter-spacing:-.1pt'>v</span><span style='letter-spacing:.1pt'>e</span><span
  style='letter-spacing:-.1pt'>m</span><span style='letter-spacing:.1pt'>e</span><span
  style='letter-spacing:-.1pt'>n</span><span style='letter-spacing:-.05pt'>t</span>)</span></p>
  </td>
  <td width=93 style='width:69.65pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>39</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>.</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>4</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>%</span><span lang=EN-GB
  style='font-size:9.0pt'> (<span style='letter-spacing:.05pt'>84</span><span
  style='letter-spacing:-.1pt'>/</span><span style='letter-spacing:.05pt'>2</span><span
  style='letter-spacing:-.1pt'>1</span>3)</span></p>
  </td>
  <td width=93 style='width:69.65pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>16</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>.</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>4</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>%</span><span lang=EN-GB
  style='font-size:9.0pt'> (<span style='letter-spacing:.05pt'>35</span><span
  style='letter-spacing:-.1pt'>/</span><span style='letter-spacing:.05pt'>2</span><span
  style='letter-spacing:-.1pt'>1</span>3)</span></p>
  </td>
  <td width=93 style='width:69.65pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>2</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>.</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>3</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>%</span><span lang=EN-GB
  style='font-size:9.0pt'> (<span style='letter-spacing:.05pt'>5</span>/<span
  style='letter-spacing:-.1pt'>2</span><span style='letter-spacing:.05pt'>1</span>3)</span></p>
  </td>
  <td width=75 style='width:56.2pt;border-top:none;border-left:none;border-bottom:
  solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>15</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>.</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>0</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>%</span><span lang=EN-GB
  style='font-size:9.0pt'> (<span style='letter-spacing:.05pt'>32</span><span
  style='letter-spacing:-.1pt'>/</span><span style='letter-spacing:.05pt'>2</span><span
  style='letter-spacing:-.1pt'>1</span>3)</span></p>
  </td>
  <td width=113 style='width:85.05pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>9</span><span lang=EN-GB
  style='font-size:9.0pt'>.<span style='letter-spacing:.05pt'>4</span><span
  style='letter-spacing:-.1pt'>% (</span><span style='letter-spacing:.05pt'>20</span><span
  style='letter-spacing:-.1pt'>/</span><span style='letter-spacing:.05pt'>2</span><span
  style='letter-spacing:-.1pt'>1</span>3)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:115.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>No<span style='letter-spacing:-.4pt'> </span>c<span
  style='letter-spacing:-.1pt'>h</span>a<span style='letter-spacing:.05pt'>n</span><span
  style='letter-spacing:-.1pt'>ge</span></span></p>
  </td>
  <td width=93 style='width:69.65pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>5</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>4</span><span lang=EN-GB
  style='font-size:9.0pt'>.<span style='letter-spacing:.05pt'>0</span><span
  style='letter-spacing:-.1pt'>%</span> (<span style='letter-spacing:.05pt'>11</span><span
  style='letter-spacing:-.1pt'>5</span>/<span style='letter-spacing:-.1pt'>2</span><span
  style='letter-spacing:.05pt'>1</span>3)</span></p>
  </td>
  <td width=93 style='width:69.65pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>8</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>0</span><span lang=EN-GB
  style='font-size:9.0pt'>.<span style='letter-spacing:.05pt'>8</span><span
  style='letter-spacing:-.1pt'>%</span> (<span style='letter-spacing:.05pt'>17</span><span
  style='letter-spacing:-.1pt'>2</span>/<span style='letter-spacing:-.1pt'>2</span><span
  style='letter-spacing:.05pt'>1</span>3)</span></p>
  </td>
  <td width=93 style='width:69.65pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>9</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>4</span><span lang=EN-GB
  style='font-size:9.0pt'>.<span style='letter-spacing:.05pt'>8</span><span
  style='letter-spacing:-.1pt'>%</span> (<span style='letter-spacing:.05pt'>20</span><span
  style='letter-spacing:-.1pt'>2</span>/<span style='letter-spacing:-.1pt'>2</span><span
  style='letter-spacing:.05pt'>1</span>3)</span></p>
  </td>
  <td width=75 style='width:56.2pt;border-top:none;border-left:none;border-bottom:
  solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>8</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>1</span><span lang=EN-GB
  style='font-size:9.0pt'>.<span style='letter-spacing:.05pt'>2</span><span
  style='letter-spacing:-.1pt'>%</span> (<span style='letter-spacing:.05pt'>17</span><span
  style='letter-spacing:-.1pt'>3</span>/<span style='letter-spacing:-.1pt'>2</span><span
  style='letter-spacing:.05pt'>1</span>3)</span></p>
  </td>
  <td width=113 style='width:85.05pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>8</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>8</span><span lang=EN-GB
  style='font-size:9.0pt'>.<span style='letter-spacing:.05pt'>3</span><span
  style='letter-spacing:-.1pt'>%</span> (<span style='letter-spacing:.05pt'>18</span><span
  style='letter-spacing:-.1pt'>8</span>/<span style='letter-spacing:-.1pt'>2</span><span
  style='letter-spacing:.05pt'>1</span>3)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:115.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>I<span style='letter-spacing:-.1pt'>n</span>crea<span
  style='letter-spacing:-.05pt'>s</span>ed<span style='letter-spacing:-.55pt'> </span><span
  style='letter-spacing:-.05pt'>s</span>c<span style='letter-spacing:.05pt'>o</span>re
  (<span style='letter-spacing:.05pt'>Wo</span>r<span style='letter-spacing:
  -.05pt'>s</span>e<span style='letter-spacing:-.1pt'>n</span><span
  style='letter-spacing:-.05pt'>i</span><span style='letter-spacing:-.1pt'>ng)</span></span></p>
  </td>
  <td width=93 style='width:69.65pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>6</span><span lang=EN-GB
  style='font-size:9.0pt'>.<span style='letter-spacing:.05pt'>6</span><span
  style='letter-spacing:-.1pt'>%</span> (<span style='letter-spacing:.05pt'>14</span><span
  style='letter-spacing:-.1pt'>/</span><span style='letter-spacing:.05pt'>2</span><span
  style='letter-spacing:-.1pt'>1</span>3)</span></p>
  </td>
  <td width=93 style='width:69.65pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>2</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>.</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>8</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>%</span><span lang=EN-GB
  style='font-size:9.0pt'> (<span style='letter-spacing:.05pt'>6</span>/<span
  style='letter-spacing:-.1pt'>2</span><span style='letter-spacing:.05pt'>1</span>3)</span></p>
  </td>
  <td width=93 style='width:69.65pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>2</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>.</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>8</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>%</span><span lang=EN-GB
  style='font-size:9.0pt'> (<span style='letter-spacing:.05pt'>6</span>/<span
  style='letter-spacing:-.1pt'>2</span><span style='letter-spacing:.05pt'>1</span>3)</span></p>
  </td>
  <td width=75 style='width:56.2pt;border-top:none;border-left:none;border-bottom:
  solid black 1.0pt;border-right:solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>3</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>.</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>8</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>%</span><span lang=EN-GB
  style='font-size:9.0pt'> (<span style='letter-spacing:.05pt'>8</span>/<span
  style='letter-spacing:-.1pt'>2</span><span style='letter-spacing:.05pt'>1</span>3)</span></p>
  </td>
  <td width=113 style='width:85.05pt;border-top:none;border-left:none;
  border-bottom:solid black 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>2</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>.</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:.05pt'>3</span><span lang=EN-GB
  style='font-size:9.0pt;letter-spacing:-.1pt'>%</span><span lang=EN-GB
  style='font-size:9.0pt'> (<span style='letter-spacing:.05pt'>5</span>/<span
  style='letter-spacing:-.1pt'>2</span><span style='letter-spacing:.05pt'>1</span>3)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=155 valign=top style='width:115.9pt;border-top:none;border-left:
  solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:
  solid black 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid;
  punctuation-wrap:simple;text-autospace:none'><span lang=EN-GB
  style='font-size:10.0pt'>No<span style='letter-spacing:-.55pt'> </span>a<span
  style='letter-spacing:-.05pt'>ss</span>e<span style='letter-spacing:-.05pt'>s</span><span
  style='letter-spacing:.05pt'>s</span><span style='letter-spacing:-.1pt'>m</span><span
  style='letter-spacing:.1pt'>e</span><span style='letter-spacing:-.1pt'>n</span>t</span></p>
  </td>
  <td width=93 valign=top style='width:69.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;punctuation-wrap:simple;text-autospace:none'><span
  lang=EN-GB style='font-size:9.0pt;letter-spacing:.05pt'>23</span></p>
  </td>
  <td width=93 valign=top style='width:69.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;punctuation-wrap:simple;text-autospace:none'><span
  lang=EN-GB style='font-size:9.0pt;letter-spacing:.05pt'>23</span></p>
  </td>
  <td width=93 valign=top style='width:69.65pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;punctuation-wrap:simple;text-autospace:none'><span
  lang=EN-GB style='font-size:9.0pt;letter-spacing:.05pt'>23</span></p>
  </td>
  <td width=75 valign=top style='width:56.2pt;border-top:none;border-left:none;
  border-bottom:solid windowtext 1.0pt;border-right:solid black 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;punctuation-wrap:simple;text-autospace:none'><span
  lang=EN-GB style='font-size:9.0pt;letter-spacing:.05pt'>23</span></p>
  </td>
  <td width=113 valign=top style='width:85.05pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal align=center style='text-align:center;line-height:normal;
  page-break-after:avoid;punctuation-wrap:simple;text-autospace:none'><span
  lang=EN-GB style='font-size:9.0pt;letter-spacing:.05pt'>23</span></p>
  </td>
 </tr>
</table>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt;page-break-after:
avoid'><span lang=EN-GB style='font-size:9.0pt;color:windowtext'>Note:&nbsp;&nbsp;&nbsp; Baseline
frequency of ascites was: 20% none, 77% mild/moderate, 3% severe</span></p>

<p class=Default style='margin-left:28.35pt;text-indent:-28.35pt'><span
lang=EN-GB style='font-size:9.0pt;color:windowtext'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Baseline
frequency of encephalopathy was: 38% none, 62% grade&nbsp;1&#8209;2.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Clinical studies in patients with HCV/HIV&#8209;1 Co-infection <b>&#8211;</b>
ASTRAL&#8209;5 (study&nbsp;1202)</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>ASTRAL&#8209;5
evaluated 12&nbsp;weeks of treatment with Epclusa in patients with genotype&nbsp;1,
2, 3, or 4 HCV infection who were co-infected with HIV&#8209;1 (HCV genotype&nbsp;5
and 6 allowed, but no such patients were included).&nbsp; Patients were on a
stable HIV&#8209;1 antiretroviral therapy that included emtricitabine/tenofovir
disoproxil fumarate or abacavir/lamivudine administered with a ritonavir boosted
protease inhibitor (atazanavir, darunavir, or lopinavir), rilpivirine,
raltegravir or emtricitabine/tenofovir disoproxil fumarate /elvitegravir/cobicistat.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Of the 106
treated patients, the median age was 57&nbsp;years (range: 25 to 72); 86% of
the patients were male; 51% were white; 45% were black; 22% had a baseline body
mass index &#8805;&nbsp;30&nbsp;kg/m<sup>2</sup>; 19 patients (18%) had
compensated cirrhosis; and 29% were treatment experienced.&nbsp; The overall
mean CD4+ count was 598&nbsp;cells/&micro;L (range: 183&#8722;1513&nbsp;cells/&micro;L).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Table&nbsp;17
presents the SVR12 for the ASTRAL&#8209;5 study by HCV genotype.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Table&nbsp;17: SVR12 in study ASTRAL&#8209;5 by HCV genotype</span></b></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width=631
 style='border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width=73 rowspan=3 valign=top style='width:54.7pt;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>&nbsp;</span></b></p>
   </td>
   <td width=558 colspan=7 valign=top style='width:418.5pt;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>Epclusa
   12&nbsp;weeks</span></b></p>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;106)</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=95 rowspan=2 valign=top style='width:71.2pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Total</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>(all GTs)</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;106)</span></b></p>
   </td>
   <td width=246 colspan=3 valign=top style='width:184.3pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal align=center style='text-align:center;line-height:normal;
   page-break-after:avoid'><b><span lang=EN-GB style='font-size:10.0pt'>GT&#8209;1</span></b></p>
   </td>
   <td width=76 rowspan=2 valign=top style='width:56.7pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>GT&#8209;2</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;11)</span></b></p>
   </td>
   <td width=76 rowspan=2 valign=top style='width:56.7pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>GT&#8209;3</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;12)</span></b></p>
   </td>
   <td width=66 rowspan=2 valign=top style='width:49.6pt;border-top:none;
   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>GT&#8209;4</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;5)</span></b></p>
   </td>
  </tr>
  <tr style='page-break-inside:avoid'>
   <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>GT&#8209;1a</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;66)</span></b></p>
   </td>
   <td width=85 valign=top style='width:63.8pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>GT&#8209;1b</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;12)</span></b></p>
   </td>
   <td width=76 valign=top style='width:56.7pt;border-top:none;border-left:
   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>Total</span></b></p>
   <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
   lang=EN-GB style='font-size:10.0pt'>(n&nbsp;=&nbsp;78)</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width=73 style='width:54.7pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>SVR12</span></p>
  </td>
  <td width=95 style='width:71.2pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>95%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(101/106)</span></p>
  </td>
  <td width=85 style='width:63.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>95%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(63/66)</span></p>
  </td>
  <td width=85 style='width:63.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>92%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(11/12)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>95%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(74/78)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>100%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(11/11)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>92%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(11/12)</span></p>
  </td>
  <td width=66 style='width:49.6pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>100%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(5/5)</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=631 colspan=8 style='width:473.2pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Outcome for patients without SVR</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=73 style='width:54.7pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>On-treatment virologic failure</span></p>
  </td>
  <td width=95 style='width:71.2pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/106</span></p>
  </td>
  <td width=85 style='width:63.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/66</span></p>
  </td>
  <td width=85 style='width:63.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/12</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/78</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/11</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/12</span></p>
  </td>
  <td width=66 style='width:49.6pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/5</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=73 style='width:54.7pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Relapse<sup>a</sup></span></p>
  </td>
  <td width=95 style='width:71.2pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>2%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(2/103)</span></p>
  </td>
  <td width=85 style='width:63.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>3%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(2/65)</span></p>
  </td>
  <td width=85 style='width:63.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/11</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>3%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(2/76)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/11</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/11</span></p>
  </td>
  <td width=66 style='width:49.6pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/5</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=73 style='width:54.7pt;border:solid windowtext 1.0pt;border-top:
  none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>Other<sup>b</sup></span></p>
  </td>
  <td width=95 style='width:71.2pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>3%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(3/106)</span></p>
  </td>
  <td width=85 style='width:63.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>2%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(1/66)</span></p>
  </td>
  <td width=85 style='width:63.8pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>8%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(1/12)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>3%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(2/78)</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/11</span></p>
  </td>
  <td width=76 style='width:56.7pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>8%</span></p>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>(1/12)</span></p>
  </td>
  <td width=66 style='width:49.6pt;border-top:none;border-left:none;border-bottom:
  solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
  lang=EN-GB style='font-size:10.0pt'>0/5</span></p>
  </td>
 </tr>
</table>

<p class=Default style='page-break-after:avoid'><span lang=EN-GB
style='font-size:9.0pt;color:windowtext'>GT&nbsp;=&nbsp;genotype</span></p>

<p class=Default style='margin-left:14.2pt;text-indent:-14.2pt;page-break-after:
avoid'><span lang=EN-GB style='font-size:9.0pt;color:windowtext'>a&nbsp;&nbsp;&nbsp;&nbsp; The
denominator for relapse is the number of patients with HCV&nbsp;RNA
&lt;&nbsp;LLOQ at their last on-treatment assessment.</span></p>

<p class=Default style='margin-left:14.2pt;text-indent:-14.2pt'><span
lang=EN-GB style='font-size:9.0pt;color:windowtext'>b&nbsp;&nbsp;&nbsp; Other
includes patients who did not achieve SVR12 and did not meet virologic failure
criteria.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>SVR12 was achieved
by 19/19 patients with cirrhosis. &nbsp;No patient had HIV&#8209;1 rebound
during the study, and CD4+ counts were stable during treatment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Paediatric population</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The European
Medicines Agency has deferred the obligation to submit the results of studies
with Epclusa in one or more subsets of the paediatric population in the
treatment of chronic hepatitis&nbsp;C (see section&nbsp;4.2 for information on
paediatric use).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Clinical studies
of Epclusa included 156&nbsp;patients aged&nbsp;65 and over (12% of total number
of patients in the Phase&nbsp;3 clinical studies).&nbsp; The response rates
observed for patients &#8805;&nbsp;65&nbsp;years of age were similar to that of
patients &lt;&nbsp;65&nbsp;years of age, across treatment groups.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.2&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic
properties</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Absorption</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The
pharmacokinetic properties of sofosbuvir, GS&#8209;331007 and velpatasvir have
been evaluated in healthy adult subjects and in patients with chronic
hepatitis&nbsp;C.&nbsp; Following oral administration of Epclusa, sofosbuvir
was absorbed quickly and the peak median plasma concentration was observed
1&nbsp;hour post&#8209;dose.&nbsp; Median peak plasma concentration of GS&#8209;331007
was observed 3&nbsp;hours post&#8209;dose.&nbsp; Velpatasvir median peak
concentrations were observed at 3&nbsp;hours post&#8209;dose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Based on the
population pharmacokinetic analysis in HCV&#8209;infected patients, mean steady&#8209;state
AUC<sub>0&#8209;24</sub> for sofosbuvir (n&nbsp;=&nbsp;982), GS&#8209;331007 (n&nbsp;=&nbsp;1,428)
and velpatasvir (n&nbsp;=&nbsp;1,425) were 1,260, 13,970 and 2,970&nbsp;ng&#8226;h/mL,
respectively.&nbsp; Steady-state C<sub>max</sub> for sofosbuvir, GS&#8209;331007
and velpatasvir were 566, 868 and 259&nbsp;ng/mL, respectively.&nbsp;
Sofosbuvir and GS&#8209;331007 AUC<sub>0&#8209;24</sub> and C<sub>max</sub>
were similar in healthy adult subjects and patients with HCV infection.&nbsp;
Relative to healthy subjects (n&nbsp;=&nbsp;331), velpatasvir AUC<sub>0&#8209;24</sub>
and C<sub>max</sub> were 37% lower and 41% lower, respectively in HCV&#8209;infected
patients.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Effects of food</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Relative to
fasting conditions, the administration of a single dose of Epclusa with a
moderate fat (~600&nbsp;kcal, 30% fat) or high fat (~800&nbsp;kcal, 50% fat)
meal resulted in a 34% and 21% increase in velpatasvir AUC<sub>0&#8209;inf</sub>,
respectively, and a 31% and 5% increase in velpatasvir C<sub>max</sub>, respectively.&nbsp;
The moderate or high fat meal increased sofosbuvir AUC<sub>0&#8209;inf</sub> by
60% and 78%, respectively, but did not substantially affect the sofosbuvir C<sub>max</sub>.
&nbsp;The moderate or high fat meal did not alter GS&#8209;331007 AUC<sub>0&#8209;inf</sub>,
but resulted in a 25% and 37% decrease in its C<sub>max</sub>, respectively. &nbsp;The
response rates in Phase&nbsp;3 studies were similar in HCV&#8209;infected patients
who received Epclusa with food or without food. &nbsp;Epclusa can be
administered without regard to food.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Distribution</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sofosbuvir is
approximately 61&#8209;65% bound to human plasma proteins and the binding is
independent of drug concentration over the range of 1&nbsp;&micro;g/mL to
20&nbsp;&micro;g/mL.&nbsp; Protein binding of GS&#8209;331007 was minimal in
human plasma.&nbsp; After a single 400&nbsp;mg dose of [<sup>14</sup>C]&#8209;sofosbuvir
in healthy subjects, the blood to plasma ratio of [<sup>14</sup>C]&#8209;radioactivity
was approximately 0.7.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Velpatasvir
is &gt;&nbsp;99.5% bound to human plasma proteins and binding is independent of
drug concentration over the range of 0.09</span><span lang=EN-GB
style='font-size:11.0pt;color:windowtext'>&nbsp;&micro;g/mL </span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>to 1.8</span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;&micro;g/mL</span><span
lang=EN-GB style='font-size:11.0pt;color:windowtext'>. &nbsp;After a single 100&nbsp;mg
dose of [<sup>14</sup>C]&#8209;velpatasvir in healthy subjects, the blood to
plasma ratio of [<sup>14</sup>C]&#8209;radioactivity ranged between 0.52 and
0.67.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Biotransformation</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sofosbuvir is
extensively metabolised in the liver to form the pharmacologically active
nucleoside analog triphosphate GS&#8209;461203. &nbsp;The metabolic activation
pathway involves sequential hydrolysis of the carboxyl ester moiety catalysed
by human cathepsin&nbsp;A (CatA) or carboxylesterase&nbsp;1 (CES1) and
phosphoramidate cleavage by histidine triad nucleotide-binding protein&nbsp;1
(HINT1) followed by phosphorylation by the pyrimidine nucleotide biosynthesis pathway.&nbsp;
Dephosphorylation results in the formation of nucleoside metabolite GS&#8209;331007
that cannot be efficiently rephosphorylated and lacks anti-HCV activity <i>in&nbsp;vitro.</i>
&nbsp;Sofosbuvir and GS&#8209;331007 are not substrates or inhibitors of UGT1A1
or CYP3A4, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 enzymes.&nbsp; After
a single 400&nbsp;mg oral dose of [<sup>14</sup>C]-sofosbuvir, GS&#8209;331007
accounted for approximately &gt;&nbsp;90% of total systemic exposure.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Velpatasvir is a
substrate of CYP2B6, CYP2C8, and CYP3A4 with slow turnover. &nbsp;Following a
single dose of 100&nbsp;mg [<sup>14</sup>C]&#8209;velpatasvir, the majority
(&gt;&nbsp;98%) of radioactivity in plasma was parent drug.&nbsp; The
monohydroxylated and desmethylated velpatasvir were the metabolites identified
in human plasma.&nbsp; Unchanged velpatasvir is the major species present in
faeces.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal;page-break-after:
avoid'><u><span lang=EN-GB>Elimination</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Following a
single 400&nbsp;mg oral dose of [<sup>14</sup>C]&#8209;sofosbuvir, mean total
recovery of the [<sup>14</sup>C]&#8209;radioactivity was greater than 92%,
consisting of approximately 80%, 14%, and 2.5% recovered in urine, faeces, and
expired air, respectively.&nbsp; The majority of the sofosbuvir dose recovered
in urine was GS&#8209;331007 (78%) while 3.5% was recovered as
sofosbuvir.&nbsp; These data indicate that renal clearance is the major
elimination pathway for GS&#8209;331007.&nbsp; The median terminal half&#8209;lives
of sofosbuvir and GS&#8209;331007 following administration of Epclusa were 0.5
and 25&nbsp;hours, respectively.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Following a
single 100&nbsp;mg oral dose of [<sup>14</sup>C]&#8209;velpatasvir, mean total
recovery of the [<sup>14</sup>C]&#8209;radioactivity was 95%, consisting of
approximately 94% and 0.4% recovered from the faeces and urine,
respectively.&nbsp; Unchanged velpatasvir was the major species in faeces
accounting for a mean of 77% of the administered dose, followed by
monohydroxylated velpatasvir (5.9%) and desmethylated velpatasvir (3.0%).&nbsp;
These data indicate that biliary excretion of parent drug was a major route of
elimination for velpatasvir. &nbsp;The median terminal half-life of velpatasvir
following administration of Epclusa was approximately 15&nbsp;hours.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Linearity/non-linearity</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Velpatasvir AUC
increases in a nearly dose proportional manner over the dose range of
25&nbsp;mg to 150&nbsp;mg.&nbsp; Sofosbuvir and GS&#8209;331007 AUCs are near
dose&#8209;proportional over the dose range of 200&nbsp;mg to 1,200&nbsp;mg.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><u><span
lang=EN-GB>In&nbsp;vitro</span></u></i><u><span lang=EN-GB> potential for
sofosbuvir/velpatasvir drug-drug interactions</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sofosbuvir and
velpatasvir are substrates of drug transporters P&#8209;gp and BCRP while GS&#8209;331007
is not.&nbsp; Velpatasvir is also a substrate of OATP1B.&nbsp; <i>In&nbsp;vitro,</i>
slow metabolic turnover of velpatasvir by CYP2B6, CYP2C8, and CYP3A4 was
observed.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Velpatasvir is
an inhibitor of drug transporter P&#8209;gp, BCRP, OATP1B1 and OATP1B3 and its
involvement in drug interactions with these transporters is primarily limited
to the process of absorption.&nbsp; At clinically relevant plasma concentration,
velpatasvir is not an inhibitor of hepatic transporters bile salt export pump
(BSEP), sodium taurocholate cotransporter protein (NTCP), OATP2B1, OATP1A2 or organic
cation transporter (OCT)&nbsp;1, renal transporters OCT2, OAT1, OAT3, multidrug
resistance-associated protein&nbsp;2 (MRP2) or multidrug and toxin extrusion
protein (MATE)&nbsp;1, or CYP or uridine glucuronosyltransferase (UGT)&nbsp;1A1
enzymes.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Sofosbuvir and
GS&#8209;331007 are not inhibitors of drug transporters P&#8209;gp, BCRP, MRP2,
BSEP, OATP1B1, OATP1B3 and OCT1. &nbsp;GS&#8209;331007 is not an inhibitor of
OAT1, OCT2, and MATE1.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Pharmacokinetics in special populations</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Race and gender</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>No clinically
relevant pharmacokinetic differences due to race or gender have been identified
for sofosbuvir, GS&#8209;331007 or velpatasvir.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Elderly</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Population
pharmacokinetic analysis in HCV&#8209;infected patients showed that within the
age range (18 to 82&nbsp;years) analysed, age did not have a clinically
relevant effect on the exposure to sofosbuvir, GS&#8209;331007, or velpatasvir.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Renal impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The
pharmacokinetics of sofosbuvir was studied in HCV negative patients with mild
(eGFR &#8805;&nbsp;50 and &lt;&nbsp;80&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>),
moderate (eGFR &#8805;&nbsp;30 and &lt;&nbsp;50&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>),
severe renal impairment (eGFR &lt;&nbsp;30&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>)
and patients with ESRD requiring haemodialysis following a single 400&nbsp;mg
dose of sofosbuvir.&nbsp; Relative to patients with normal renal function (eGFR
&gt;&nbsp;80&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>), the sofosbuvir AUC<sub>0&#8209;inf</sub>
was 61%, 107% and 171% higher in mild, moderate and severe renal impairment,
while the GS&#8209;331007 AUC<sub>0&#8209;inf</sub> was 55%, 88% and 451%
higher, respectively.&nbsp; In patients with ESRD, sofosbuvir AUC<sub>0&#8209;inf</sub>
was 28% higher when sofosbuvir was dosed 1&nbsp;hour before haemodialysis
compared with 60% higher when dosed 1&nbsp;hour after haemodialysis,
respectively.&nbsp; The AUC<sub>0&#8209;inf</sub> of GS&#8209;331007 in
patients with ESRD administered with sofosbuvir 1&nbsp;hour before or
1&nbsp;hour after haemodialysis was at least 10&#8209;fold and 20&#8209;fold
higher, respectively.&nbsp; GS&#8209;331007 is efficiently removed by haemodialysis
with an extraction coefficient of approximately 53%.&nbsp; Following a single
400&nbsp;mg dose of sofosbuvir, a 4&nbsp;hour haemodialysis removed 18% of
administered dose (see section&nbsp;4.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The
pharmacokinetics of velpatasvir was studied with a single dose of 100&nbsp;mg
velpatasvir in HCV negative patients with severe renal impairment (eGFR
&lt;&nbsp;30&nbsp;mL/min by Cockcroft-Gault).&nbsp; Relative to subjects with
normal renal function, velpatasvir AUC<sub>inf</sub> was 50% higher in subjects
with severe renal impairment (see section&nbsp;4.2).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Hepatic impairment</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The
pharmacokinetics of sofosbuvir was studied following 7&#8209;day dosing of
400&nbsp;mg sofosbuvir in HCV&#8209;infected patients with moderate and severe
hepatic impairment (CPT Class&nbsp;B and C).&nbsp; Relative to patients with
normal hepatic function, the sofosbuvir AUC<sub>0&#8209;24</sub> was 126% and
143% higher in moderate and severe hepatic impairment, while the GS&#8209;331007
AUC<sub>0&#8209;24</sub> was 18% and 9% higher, respectively.&nbsp; Population
pharmacokinetics analysis in HCV&#8209;infected patients indicated that
cirrhosis (including decompensated cirrhosis) had no clinically relevant effect
on the exposure to sofosbuvir and GS&#8209;331007.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The
pharmacokinetics of velpatasvir was studied with a single dose of 100&nbsp;mg
velpatasvir in HCV negative patients with moderate and severe hepatic
impairment (CPT Class&nbsp;B and C).&nbsp; Compared to subjects with normal
hepatic function velpatasvir total plasma exposure (AUC<sub>inf</sub>) was
similar in patients with moderate or severe hepatic impairment.&nbsp; Population
pharmacokinetics analysis in HCV&#8209;infected patients indicated that
cirrhosis (including decompensated cirrhosis) had no clinically relevant effect
on the exposure to velpatasvir (see section&nbsp;4.2). </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Body weight</span></i></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Body weight did
not have a clinically significant effect on sofosbuvir or velpatasvir exposure
according to a population pharmacokinetic analysis.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><i><span
lang=EN-GB>Paediatric population</span></i></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>The pharmacokinetics of sofosbuvir, GS&#8209;331007 and velpatasvir
in paediatric patients have not been established </span><span lang=EN-GB>(see
section&nbsp;4.2).</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.3&nbsp;&nbsp;&nbsp;&nbsp; Preclinical
safety data</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Sofosbuvir</span></u></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Exposure
to sofosbuvir in rodent studies could not be detected likely due to high
esterase activity and exposure to the major metabolite GS&#8209;331007 was
instead used to estimate exposure margins.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Sofosbuvir
was not genotoxic in a battery of <i>in&nbsp;vitro</i> or <i>in&nbsp;vivo</i>
assays, including bacterial mutagenicity, chromosome aberration using human
peripheral blood lymphocytes and <i>in&nbsp;vivo</i> mouse micronucleus
assays.&nbsp; No teratogenic effects were observed in the rat and rabbit
developmental toxicity studies with sofosbuvir.&nbsp; Sofosbuvir had no adverse
effects on behaviour, reproduction, or development of the offspring in the rat pre&#8209;
and post&#8209;natal development study.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Sofosbuvir
was not a carcinogen in the 2&#8209;year mouse and rat carcinogenicity studies
at GS&#8209;331007 exposures up to 15 and 9&nbsp;times, respectively, higher
than human exposure.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Velpatasvir</span></u></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Velpatasvir was
not genotoxic in a battery of <i>in&nbsp;vitro</i> or <i>in&nbsp;vivo</i>
assays, including bacterial mutagenicity, chromosome aberration using human
peripheral blood lymphocytes and <i>in&nbsp;vivo</i> rat micronucleus assays.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>Velpatasvir
was not carcinogenic in the 6&#8209;month rasH2 transgenic mouse and 2&#8209;year
rat carcinogenicity studies at exposures at least 50-times and 5-times higher
than human exposure, respectively.</span></p>

<p class=Default><span lang=EN-GB style='font-size:11.0pt;color:windowtext'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Velpatasvir had
no adverse effects on mating and fertility.&nbsp; </span><span lang=EN-GB>No
teratogenic effects were observed in the mouse and rat developmental toxicity
studies with velpatasvir at AUC exposures approximately 31&#8209; and 6&#8209;fold
higher, respectively, than the human exposure at the recommended clinical
dose.&nbsp; However, a possible teratogenic effect was indicated in rabbits
where an increase in total visceral malformations was seen in exposed animals
at AUC exposures up to 0.7 fold the human exposure at recommended clinical
dose.&nbsp; The human relevance of this finding is not known.</span><span
lang=EN-GB>&nbsp; Velpatasvir had no adverse effects on behaviour,
reproduction, or development of the offspring in the rat pre&#8209; and post&#8209;natal
development study at AUC exposures approximately 5&#8209;fold higher than the
human exposure at the recommended clinical dose.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
PARTICULARS</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.1&nbsp;&nbsp;&nbsp;&nbsp; List
of excipients</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Tablet core</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Copovidone</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Microcrystalline cellulose</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Croscarmellose sodium</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Magnesium
stearate</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><u><span
lang=EN-GB>Film&#8209;coating</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Polyvinyl alcohol</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Titanium dioxide</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Polyethylene glycol</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Talc</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Iron oxide red</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.2&nbsp;&nbsp;&nbsp;&nbsp; Incompatibilities</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Not applicable.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.3&nbsp;&nbsp;&nbsp;&nbsp; Shelf
life</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>4&nbsp;years.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.4&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for storage</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicinal
product does not require any special storage conditions.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>6.5&nbsp;&nbsp;&nbsp;&nbsp; Nature and contents of container</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Epclusa tablets
are supplied in high density polyethylene (HDPE) bottle with a polypropylene
child&#8209;resistant closure containing 28&nbsp;film&#8209;coated tablets with
polyester coil.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The following
pack sizes are available: outer cartons containing 1&nbsp;bottle of
28&nbsp;film&#8209;coated tablets.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><a name="OLE_LINK1"><b><span lang=EN-GB>6.6&nbsp;&nbsp;&nbsp;&nbsp; Special
precautions for disposal</span></b></a></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Any unused
medicinal product or waste material should be disposed of in accordance with
local requirements.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION HOLDER</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Gilead Sciences Ireland UC</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Carrigtohill</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>County Cork, T45 DP77</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ireland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/16/1116/001</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Date of first authorisation:
06 July 2016</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; DATE
OF REVISION OF THE TEXT</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this medicinal product is available on the website of the
European Medicines Agency http://www.ema.europa.eu.</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='margin-right:-.1pt;text-align:center;
line-height:normal'><b><span lang=EN-GB>ANNEX II</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURER RESPONSIBLE
FOR BATCH RELEASE</span></b></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR
RESTRICTIONS REGARDING SUPPLY AND USE</span></b></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER CONDITIONS
AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></b></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal'><b><span lang=EN-GB>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR
RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=TitleB><span lang=EN-GB>A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MANUFACTURER
RESPONSIBLE FOR BATCH RELEASE</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><u><span lang=EN-GB>Name and address of the manufacturer responsible for
batch release</span></u></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Gilead Sciences Ireland UC</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>IDA Business &amp; Technology Park</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>Carrigtohill</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>County Cork</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>IRELAND</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR
RESTRICTIONS REGARDING SUPPLY AND USE</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Medicinal
product subject to restricted medical prescription (see Annex&nbsp;I: Summary
of Product Characteristics, section&nbsp;4.2).</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:6.0pt;margin-bottom:0in;
margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:23.4pt;text-indent:-23.4pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Periodic safety update reports</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The requirements
for submission of periodic safety update reports for this medicinal product are
set out in the list of Union reference dates (EURD list) provided for under
Article&nbsp;107c(7) of Directive&nbsp;2001/83/EC and any subsequent updates
published on the European medicines web-portal.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The marketing
authorisation holder shall submit the first periodic safety update report for
this product within 6&nbsp;months following authorisation.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleB><span lang=EN-GB>D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONDITIONS OR
RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid;text-autospace:
none'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:23.4pt;text-indent:-23.4pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Risk Management Plan (RMP)</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The MAH shall
perform the required pharmacovigilance activities and interventions detailed in
the agreed RMP presented in Module&nbsp;1.8.2 of the marketing authorisation
and any agreed subsequent updates of the RMP.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>An updated RMP should be submitted:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><span lang=EN-GB
style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>At the request of the European Medicines Agency;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Whenever the risk management system is modified,
especially as the result of new information being received that may lead to a
significant change to the benefit/risk profile or as the result of an important
(pharmacovigilance or risk minimisation) milestone being reached.</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Obligation to conduct post-authorisation
measures</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>The MAH shall complete, within the stated timeframe,
the below measures:</span></p>

<p class=MsoNormal style='margin-right:-.05pt;line-height:normal;page-break-after:
avoid'><span lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0 width="98%"
 style='width:98.0%;border-collapse:collapse;border:none'>
 <thead>
  <tr style='page-break-inside:avoid'>
   <td width="83%" valign=top style='width:83.62%;border:solid windowtext 1.0pt;
   padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-right:-.05pt;line-height:normal;page-break-after:
   avoid'><b><span lang=EN-GB>Description</span></b></p>
   </td>
   <td width="16%" valign=top style='width:16.38%;border:solid windowtext 1.0pt;
   border-left:none;padding:0in 5.4pt 0in 5.4pt'>
   <p class=MsoNormal style='margin-right:-.05pt;line-height:normal;page-break-after:
   avoid'><b><span lang=EN-GB>Due date</span></b></p>
   </td>
  </tr>
 </thead>
 <tr style='page-break-inside:avoid'>
  <td width="83%" valign=top style='width:83.62%;border:solid windowtext 1.0pt;
  border-top:none;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>In order to
  evaluate the recurrence of hepatocellular carcinoma associated with Epclusa,
  the MAH shall conduct and submit the results of a prospective safety study
  using data deriving from a cohort of a well-defined group of patients, based
  on an agreed protocol.&nbsp; The final study report shall be submitted by:</span></p>
  </td>
  <td width="16%" valign=top style='width:16.38%;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Q2 2021</span></p>
  </td>
 </tr>
</table>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:28.3pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>ANNEX III</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>&nbsp;</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>LABELLING AND PACKAGE LEAFLET</span></b></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>A. LABELLING</span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE
PACKAGING</span></b></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN-GB>BOTTLE AND CARTON LABELLING</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAME
OF THE MEDICINAL PRODUCT</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Epclusa 400&nbsp;mg/100&nbsp;mg film&#8209;coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>sofosbuvir/</span><span
lang=EN-GB>velpatasvir</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STATEMENT
OF ACTIVE SUBSTANCE(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Each film&#8209;coated
tablet contains 400&nbsp;mg sofosbuvir and 100&nbsp;mg </span><span lang=EN-GB>velpatasvir</span><span
lang=EN-GB>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; LIST
OF EXCIPIENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PHARMACEUTICAL
FORM AND CONTENTS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>28&nbsp;film&#8209;coated
tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; METHOD
AND ROUTE(S) OF ADMINISTRATION</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Read the package leaflet before use.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Oral use.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;text-autospace:none'><span
lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF
CHILDREN</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep out of the
sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTHER
SPECIAL WARNING(S), IF NECESSARY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EXPIRY
DATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EXP</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
STORAGE CONDITIONS</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>10.&nbsp;&nbsp;&nbsp;&nbsp; SPECIAL
PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS
DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>11.&nbsp;&nbsp;&nbsp;&nbsp; NAME
AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Gilead Sciences Ireland UC</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Carrigtohill</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>County Cork, T45 DP77</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ireland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>12.&nbsp;&nbsp;&nbsp;&nbsp; MARKETING
AUTHORISATION NUMBER(S)</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>EU/1/16/1116/001</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>13.&nbsp;&nbsp;&nbsp;&nbsp; BATCH
NUMBER</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Lot</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>14.&nbsp;&nbsp;&nbsp;&nbsp; GENERAL
CLASSIFICATION FOR SUPPLY</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>15.&nbsp;&nbsp;&nbsp;&nbsp; INSTRUCTIONS
ON USE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>16.&nbsp;&nbsp;&nbsp;&nbsp; INFORMATION
IN BRAILLE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Epclusa <span
style='color:black;background:#BFBFBF'>[Outer packaging only]</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>17.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER &#8211; 2D BARCODE</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='color:black;background:#BFBFBF'>2D barcode carrying the unique
identifier included.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB
style='background:#CCCCCC'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<div style='border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt'>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;border:none;padding:0in'><b><span lang=EN-GB>18.&nbsp;&nbsp;&nbsp;&nbsp; UNIQUE
IDENTIFIER - HUMAN READABLE DATA</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>PC: </span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>SN: </span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>NN: </span></p>

<span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=TitleA><span lang=EN-GB>B. PACKAGE LEAFLET</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<b><span lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span></b>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Package leaflet: Information for the user</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><b><span
lang=EN-GB>Epclusa</span></b><b><span lang=EN-GB> 400&nbsp;mg/100&nbsp;mg film&#8209;coated
tablets</span></b></p>

<p class=MsoNormal align=center style='text-align:center;line-height:normal'><span
lang=EN-GB>sofosbuvir/velpatasvir</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB><img border=0 width=21 height=17 id="Picture 2"
src="Epclusa-h-4210-e_files/image001.gif"></span><span lang=EN-GB>This medicine
is subject to additional monitoring.&nbsp; This will allow quick identification
of new safety information.&nbsp; You can help by reporting any side effects you
may get.&nbsp; See the end of section&nbsp;4 for how to report side effects.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Read all of this leaflet carefully before you start taking this
medicine because it contains important information for you.</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this
leaflet.&nbsp; You may need to read it again.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you
have any further questions, ask your doctor or pharmacist.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This
medicine has been prescribed for you only.&nbsp; Do not pass it on to
others.&nbsp; It may harm them, even if their signs of illness are the same as
yours.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you get
any side effects talk to your doctor or pharmacist.&nbsp; This includes any
possible side effects not listed in this leaflet.&nbsp; See section&nbsp;4.</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What is in this leaflet</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Epclusa is
and what it is used for</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need
to know before you take Epclusa</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to take Epclusa</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side
effects</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to store Epclusa</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents of the
pack and other information</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
Epclusa is and what it is used for</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Epclusa </span><span
lang=EN-GB>is a medicine that contains the active substances sofosbuvir and
velpatasvir in a single tablet.&nbsp; It is given to treat a chronic
(long-term) viral infection of the liver called hepatitis&nbsp;C in adults of
18&nbsp;years and older.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The active
substances in this medicine work together by blocking two different proteins
that the virus needs to grow and reproduce itself, allowing the infection to be
permanently eliminated from the body.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Epclusa </span><span
lang=EN-GB>is sometimes taken with another medicine, ribavirin.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is very
important that you also read the leaflets for the other medicines that you will
be taking with </span><span lang=EN-GB>Epclusa</span><span lang=EN-GB>.&nbsp;
If you have any questions about your medicines, please ask your doctor or
pharmacist.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What
you need to know before you take Epclusa</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Do not take Epclusa</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><a name="OLE_LINK2"></a><a name="OLE_LINK3"><span
lang=EN-GB style='font-family:Symbol'>&middot;<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>If you are allergic</span></b><span
lang=EN-GB> to sofosbuvir, velpatasvir or any of the other ingredients of this
medicine (listed in section&nbsp;6 of this leaflet).</span></a></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
normal'><b><span lang=EN-GB style='font-family:Wingdings'>&agrave;</span><span
lang=EN-GB> </span></b><span lang=EN-GB>If this applies to you, <b>do not take Epclusa
and tell your doctor immediately.</b></span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>If you are currently taking any of the
following medicines:</span></b></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>rifampicin</span></b><span lang=EN-GB> and <b>rifabutin</b>
(antibiotics used to treat infections, including tuberculosis);</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>St.&nbsp;John&#8217;s wort</span></b><span
lang=EN-GB> (<i>Hypericum perforatum</i> &#8211; herbal medicine used to treat
depression);</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>carbamazepine, phenobarbital</span></b><span
lang=EN-GB> and <b>phenytoin</b> (medicines used to treat epilepsy and prevent
seizures);</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Warnings and precautions</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Talk to your doctor if you:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>have liver problems</span></b><span
lang=EN-GB> other than from hepatitis&nbsp;C, for instance</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>if you have</span></b><span lang=EN-GB> a
current or previous infection with the <b>hepatitis&nbsp;B</b> virus</span><span
lang=EN-GB>, since your doctor may want to monitor you more closely;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>if you have had a liver transplant</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>have kidney problems,</span></b><span
lang=EN-GB> since </span><span lang=EN-GB>Epclusa </span><span lang=EN-GB>has
not been fully tested in patients with some severe kidney problems;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>are taking treatment for human
immunodeficiency virus (HIV) infection,</span></b><span lang=EN-GB> since your
doctor may want to monitor you more closely.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Talk to your doctor or pharmacist before taking </span><span
lang=EN-GB>Epclusa </span><span lang=EN-GB>if:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you currently take, or have taken in the last
few months, the medicine amiodarone to treat irregular heartbeats (your doctor
may consider alternative treatments if you have taken this medicine).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>you have diabetes. You may need closer
monitoring of your blood glucose levels and/or adjustment of your diabetes
medication after starting Epclusa. Some diabetic patients have experienced low
sugar levels in the blood (hypoglycaemia) after starting treatment with
medicines like Epclusa.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Tell your doctor immediately</span></b><span lang=EN-GB> if you are
taking any medicines for heart problems and during treatment you experience:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>shortness of breath</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>light-headedness</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>palpitations</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>fainting</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Blood tests</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Your doctor will test your blood before, during and after your
treatment with </span><span lang=EN-GB>Epclusa</span><span lang=EN-GB>.&nbsp;
This is so that:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Your doctor can decide if you should take Epclusa
and for how long;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>Your doctor can confirm that your treatment has
worked and you are free of the hepatitis&nbsp;C virus.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Children and adolescents</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not give this
medicine to children and adolescents under 18&nbsp;years of age.&nbsp; The use
of Epclusa in children and adolescents has not yet been studied.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Other medicines and Epclusa</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Tell your
doctor or pharmacist</span></b><span lang=EN-GB> if you are taking, have
recently taken or might take any other medicines.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Warfarin and
other similar medicines called vitamin&nbsp;K antagonists used to thin the
blood.&nbsp; Your doctor may need to increase the frequency of your blood tests
to check how well your blood can clot.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you are not sure
talk to your doctor or pharmacist.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Some medicines should not be taken with Epclusa.</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Do not take any other medicine that contains
sofosbuvir, one of the active substances in Epclusa.</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Tell your doctor or pharmacist</span></b><span lang=EN-GB> if you
are taking any of the medicines below:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>amiodarone</span></b><span lang=EN-GB> used
to treat irregular heartbeats;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>rifapentine</span></b><span lang=EN-GB>
(antibiotic used to treat infections, including tuberculosis);</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>oxcarbazepine</span></b><span lang=EN-GB>
(medicine used to treat epilepsy and prevent seizures)</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>tenofovir disoproxil fumarate</span></b><span
lang=EN-GB> or any medicine containing tenofovir disoproxil fumarate, used to
treat HIV infection;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>efavirenz</span></b><span lang=EN-GB> used to
treat HIV infection;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>digoxin</span></b><span lang=EN-GB> used to
treat heart conditions;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>dabigatran</span></b><span lang=EN-GB> used
to thin the blood;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;text-autospace:none'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>modafinil</span></b><span lang=EN-GB> used to
treat sleep disorders;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>rosuvastatin</span></b><span lang=EN-GB> or <b>other
statins</b> used to treat high cholesterol.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Taking Epclusa with
any of these may stop your medicines from working properly, or make any side
effects worse.&nbsp; Your doctor may need to give you a different medicine or
adjust the dose of medicine you are taking.&nbsp; This change could be to
Epclusa or another medicine you are taking.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>Get advice from a doctor or pharmacist</span></b><span
lang=EN-GB> if you take medicines used to treat <b>stomach ulcers, heartburn or
acid reflux</b> as they </span><span lang=EN-GB>can decrease the amount of
velpatasvir in your blood.&nbsp; These medicines include:</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>antacids (such as aluminium/magnesium hydroxide
or calcium carbonate).&nbsp; These should be taken at least 4&nbsp;hours before
or 4&nbsp;hours after Epclusa;</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>proton pump inhibitors (such as omeprazole,
lansoprazole, rabeprazole, pantoprazole and esomeprazole).&nbsp; Epclusa should
be taken with food 4&nbsp;hours before using a proton pump inhibitor.</span></p>

<p class=MsoNormal style='margin-left:56.7pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>H<sub>2</sub>&#8209;receptor antagonists (such
as famotidine, cimetidine, nizatidine or ranitidine).&nbsp; If you need high
doses of these medicines your doctor may give you a different medicine instead
or adjust the dose of the medicine you are taking.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>These medicines
can decrease the amount of velpatasvir in your blood.&nbsp; If you are taking
one of these medicines your doctor will either give you a different medicine
for stomach ulcers, heartburn or acid reflux, or recommend how and when you
take that medicine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Pregnancy and contraception</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The effects of Epclusa
during pregnancy are not known.&nbsp; If you are pregnant, think you may be
pregnant or are planning to have a baby, ask your doctor for advice before taking
this medicine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Epclusa is
sometimes used together with ribavirin.&nbsp; Ribavirin can harm your unborn
baby.&nbsp; It is therefore very important that you (or your partner) do not
become pregnant during this treatment or for a period of time after completing
treatment.&nbsp; You must read the &#8220;Pregnancy&#8221; section in the
ribavirin package leaflet very carefully. &nbsp;Ask your doctor for effective
contraception method suitable for you and your partner.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Breast&#8209;feeding</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Do not breast&#8209;feed
during treatment with Epclusa.</span></b><span lang=EN-GB>&nbsp; It is not
known whether sofosbuvir or velpatasvir, the two active substances of Epclusa,
pass into human breast milk.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Driving and using machines</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Epclusa should
not affect your ability to drive or use any tools or machinery.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid;text-autospace:none'><b><span lang=EN-GB>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to take Epclusa</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-right:-.1pt;line-height:normal'><span
lang=EN-GB>Always take this medicine exactly as your doctor has told you.&nbsp;
Check with your doctor or pharmacist if you are not sure.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Recommended dose</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The recommended
dose is <b>one&nbsp;tablet once&nbsp;a&nbsp;day for 12&nbsp;weeks.</b></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Swallow the
tablet whole with or without food.&nbsp; Do not chew, crush or split the tablet
as it has a very bitter taste.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>If you are
taking an antacid,</span></b><span lang=EN-GB> take it at least 4&nbsp;hours
before or at least 4&nbsp;hours after Epclusa.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>If you are
taking a proton pump inhibitor,</span></b><span lang=EN-GB> take Epclusa with
food 4&nbsp;hours before using a proton pump inhibitor.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If you are sick (vomit) after taking Epclusa</span></b><span
lang=EN-GB> it may affect the amount of Epclusa in your blood.&nbsp; This may
make Epclusa work less well.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you are sick (vomit) <b>less than 3&nbsp;hours
after</b> taking Epclusa, take another tablet.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>If you are sick (vomit) <b>more than 3&nbsp;hours
after</b> taking Epclusa, you do not need to take another tablet until your
next scheduled tablet.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If you take more Epclusa than you should</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you
accidentally take more than the recommended dose you should contact your doctor
or nearest emergency department immediately for advice.&nbsp; Keep the tablet
bottle with you so that you can easily describe what you have taken.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>If you forget to take Epclusa</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>It is important
not to miss a dose of this medicine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>If you do miss a dose, work out how long it is since you last took
your Epclusa:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>If you notice within 18&nbsp;hours</span></b><span
lang=EN-GB> of the time you usually take Epclusa, you must take the tablet as
soon as possible.&nbsp; Then take the next dose at your usual time.</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>If it&#8217;s 18&nbsp;hours or more</span></b><span
lang=EN-GB> after the time you usually take Epclusa, wait and take the next
dose at your usual time.&nbsp; Do not take a double dose (two doses close
together).</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Do not stop taking Epclusa</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not stop
taking this medicine unless your doctor tells you to.&nbsp; It is very
important that you complete the full course of treatment to give the medicine
the best chance to treat your hepatitis&nbsp;C virus infection.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>If you have any
further questions on the use of this medicine, ask your doctor or pharmacist.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible
side effects</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Like all medicines, this medicine may cause side effects, although
not everybody gets them.</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Other effects that may be seen during treatment with sofosbuvir:</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The frequency of the following side effects is not known (frequency
cannot be estimated from the available data).</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a wide
spread severe rash with peeling skin which may be accompanied by fever, flu
like symptoms, blisters in the mouth, eyes, and/or genitals (Stevens Johnson
syndrome).</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:14.2pt;text-indent:-14.2pt;line-height:
normal'><b><span lang=EN-GB style='font-family:Wingdings'>&agrave;</span></b><b><span
lang=EN-GB> </span><span lang=EN-GB>If you get any side effects tell your
doctor.</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Reporting of side effects</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>If you get
any side effects, talk to your doctor or pharmacist.</span></b><span
lang=EN-GB>&nbsp; This includes any possible side effects not listed in this
leaflet.&nbsp; You can also report side effects directly via </span><span
lang=EN-GB style='color:black;background:#BFBFBF'>the national reporting system
listed in </span><span lang=EN-GB><a
href="http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc"><span
style='color:black;background:#BFBFBF;text-decoration:none'>Appendix&nbsp;V</span></a></span><span
lang=EN-GB style='color:black;background:#BFBFBF'>.</span><span lang=EN-GB>&nbsp;
By reporting side effects you can help provide more information on the safety
of this medicine.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How
to store Epclusa</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Keep this
medicine out of the sight and reach of children.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not use this
medicine after the expiry date which is stated on the bottle and carton after
&#8220;EXP&#8221;.&nbsp; The expiry date refers to the last day of that month.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>This medicine
does not require any special storage conditions.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Do not throw
away any medicines via wastewater or household waste.&nbsp; Ask your pharmacist
how to throw away medicines you no longer use.&nbsp; These measures will help
protect the environment.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><b><span lang=EN-GB>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contents
of the pack and other information</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Epclusa contains</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>The active substances are</span></b><span
lang=EN-GB> sofosbuvir and velpatasvir.&nbsp; Each film&#8209;coated tablet
contains 400&nbsp;mg sofosbuvir and 100&nbsp;mg velpatasvir.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal;page-break-after:avoid'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><b><span lang=EN-GB>The other ingredients are</span></b></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
avoid'><i><span lang=EN-GB>Tablet core:</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
lang=EN-GB>Copovidone, microcrystalline cellulose, croscarmellose sodium,
magnesium stearate</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal;page-break-after:
avoid'><i><span lang=EN-GB>Film&#8209;coating:</span></i></p>

<p class=MsoNormal style='margin-left:28.35pt;line-height:normal'><span
lang=EN-GB>Polyvinyl alcohol, titanium dioxide, p</span><span lang=EN-GB>olyethylene
glycol, talc, iron oxide red</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>What Epclusa looks like and contents of the pack</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>The film&#8209;coated
tablets are pink, diamond&#8209;shaped tablets debossed with &#8220;GSI&#8221;
on one side and &#8220;7916&#8221; on the other side.&nbsp; The tablet is 20&nbsp;mm
long and 10&nbsp;mm wide.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>The following pack sizes are available:</span></p>

<p class=MsoNormal style='margin-left:28.35pt;text-indent:-28.35pt;line-height:
normal'><span lang=EN-GB style='font-family:Symbol'>&middot;<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-GB>outer cartons containing 1&nbsp;bottle of
28&nbsp;film&#8209;coated tablets</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Marketing Authorisation Holder</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Gilead Sciences Ireland UC</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Carrigtohill</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>County Cork, T45 DP77</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ireland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>Manufacturer</span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Gilead Sciences Ireland UC</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>IDA Business &amp; Technology Park</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>Carrigtohill</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>County Cork</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Ireland</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>For any information about this medicine, please contact the local
representative of the Marketing Authorisation Holder:</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=624
 style='margin-left:-1.7pt;border-collapse:collapse'>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Belgi&euml;/Belgique/Belgien</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Belgium SPRL-BVBA</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>T&eacute;l/Tel:
  + 32 (0) 24 01 35 50</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Lietuva</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Poland Sp. z o.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 48 22
  262 8702</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#1041;&#1098;&#1083;&#1075;&#1072;&#1088;&#1080;&#1103;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Ireland UC</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&#1058;&#1077;&#1083;.:
  + 353 (0) 1 686 1888</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Luxembourg/Luxemburg</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Belgium SPRL-BVBA</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>T&eacute;l/Tel:
  + 32 (0) 24 01 35 50</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#268;esk&aacute;
  republika</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 420 910
  871 986</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Magyarorsz&aacute;g</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Ireland UC</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 353 (0)
  1 686 1888</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Danmark</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Sweden AB</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tlf: + 46 (0)
  8 5057 1849</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Malta</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Ireland UC</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 353 (0)
  1 686 1888</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Deutschland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences GmbH</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 49 (0)
  89 899890-0</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Nederland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Netherlands B.V.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 31 (0)
  20 718 36 98</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Eesti</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Poland Sp. z o.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 48 22
  262 8702</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Norge</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Sweden AB</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tlf: + 46 (0)
  8 5057 1849</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#917;&#955;&#955;&#940;&#948;&#945;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences &#917;&#955;&#955;&#940;&#962; &#924;.&#917;&#928;&#917;.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&#932;&#951;&#955;:
  + 30 210 8930 100</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&Ouml;sterreich</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences GesmbH</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 43 1
  260 830</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Espa&ntilde;a</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences, S.L.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 34 91
  378 98 30</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Polska</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Poland Sp. z o.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 48 22
  262 8702</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>France</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>T&eacute;l: +
  33 (0) 1 46 09 41 00</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Portugal</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences, Lda.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 351 21
  7928790</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Hrvatska</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Ireland UC</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 353 (0)
  1 686 1888</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Rom&acirc;nia</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Ireland UC</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 353 (0)
  1 686 1888</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Ireland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Ireland UC</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 353 (0)
  214 825 999</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Slovenija</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Ireland UC</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 353 (0)
  1 686 1888</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&Iacute;sland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Sweden AB</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>S&iacute;mi: +
  46 (0) 8 5057 1849</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Slovensk&aacute;
  republika</span></b></p>
  <p class=MsoNormal style='line-height:normal;text-autospace:none'><span
  lang=EN-GB>Gilead Sciences Slovakia s.r.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 421 232
  121 210</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Italia</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences S.r.l.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 39 02
  439201</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Suomi/Finland</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Sweden AB</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Puh/Tel: + 46
  (0) 8 5057 1849</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&#922;&#973;&#960;&#961;&#959;&#962;</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences &#917;&#955;&#955;&#940;&#962; &#924;.&#917;&#928;&#917;.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&#932;&#951;&#955;:
  + 30 210 8930 100</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Sverige</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Sweden AB</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 46 (0)
  8 5057 1849</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
 <tr style='page-break-inside:avoid'>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>Latvija</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Poland Sp. z o.o.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 48 22
  262 8702</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
  <td width=312 valign=top style='width:233.9pt;padding:0in 5.4pt 0in 5.4pt'>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>United
  Kingdom</span></b></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Gilead
  Sciences Ltd.</span></p>
  <p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Tel: + 44 (0)
  8000 113700</span></p>
  <p class=MsoNormal style='line-height:normal'><b><span lang=EN-GB>&nbsp;</span></b></p>
  </td>
 </tr>
</table>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><b><span
lang=EN-GB>This leaflet was last revised in </span></b></p>

<p class=MsoNormal style='line-height:normal;page-break-after:avoid'><span
lang=EN-GB>&nbsp;</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN-GB>Detailed
information on this medicine is available on the European Medicines Agency web
site: <a href="http://www.ema.europa.eu/"><span style='color:windowtext;
text-decoration:none'>http://www.ema.europa.eu</span></a>.</span></p>

</div>

</body>

</html>
